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Summary 
The mitochondrial permeability transition (PT) is a sudden increase in the permeability of 
the inner mitochondrial membrane (IMM) to solutes with molecular masses up to 1,500 Da. 
This process is due to opening of a voltage- and Ca2+-dependent, cyclosporin (Cs) A-
sensitive, high-conductance channel called the permeability transition pore (PTP). Its 
involvement in pathological states and in the loss of cell viability is widely recognized, but 
its molecular identity remains elusive. The long standing idea that the PTP may form at 
inner-outer membrane contact sites and that it may be constituted by the adenine 
nucleotide translocator (ANT) in the IMM and voltage dependent anion channel (VDAC) in 
the outer mitochondrial membrane (OMM) has not been confirmed by genetic ablation of 
these proteins. Yet, the PT can be regulated by proteins that interact with the OMM such as 
hexokinase, and by ligands of the OMM translocator protein of 18 kDa (TSPO, formerly 
known as peripheral benzodiazepine receptor). TSPO is highly conserved throughout 
evolution and was first identified as a binding site for benzodiazepines in tissues that lack 
GABA receptors, the clinical target of benzodiazepines in the central nervous system. 
Moreover, TSPO together with VDAC and ANT was included in the early models of PTP and 
as of today remains the only putative PTP component whose role has not been addressed by 
genetic inactivation. Thus, we first investigated the role of OMM in PTP regulation; and then 
created mice where Tspo gene could be inactivated.  
We demonstrate that (i) PT is exclusively an IMM event, as it occurs in mitoplasts 
(mitochondria stripped of outer membranes); (ii) in the presence of specific, high affinity 
TSPO-ligands, such as PK11195, Ro5-4864, FGIN1-27 and protoporphyrin (PP) IX the PT is 
observed in rat  liver mitochondria, but not in mitoplasts; and (iii) upon photooxidative 
stress (achieved by photoirradiation after treatment with PP IX-like dicarboxylic 
porphyrins), low doses of light inactivate the PT both in mitochondria and in mitoplasts 
while high light doses activate the pore in mitochondria only. Conditional elimination of 
TSPO in mouse livers abolished high affinity binding of the TSPO ligand PK11195, but it did 
not prevent: (i) CsA-sensitive PTP formation; (ii) PT induction by TSPO ligands PK11195, 
Ro5-4864 and PP IX; (iii) PT induction by photooxidative stress. The latter findings are 
unequivocal demonstration that the ability of ‘specific’ TSPO ligands to regulate PTP is due 
to off-target effects, possibly at the FoF1 ATP synthase. 
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Riassunto 
La transizione della permeabilità mitocondriale (PT) è un aumento della permeabilità della 
membrana mitocondriale interna (IMM) a soluti con massa molecolare fino a 1.500 Da. 
Questo processo è causato dall’apertura di un canale ad alta conduttanza, voltaggio e Ca2+ 
dipendente, sensibile alla ciclosporina (Cs) A, chiamato poro di transizione della 
permeabilità (PTP). Il suo coinvolgimento in varie patologie e nella perdita della vitalità 
cellulare è ampiamente riconosciuto, ma la sua identità molecolare rimane ancora da 
stabilire. L’ipotesi che il PTP possa essere costituito dal traslocatore ANT della IMM e da 
VDAC della membrana mitocondriale esterna (OMM), e che si formi nei siti di contatto tra le 
due membrane, è stata confutata da esperimenti di inattivazione genetica di queste 
proteine. Tuttavia, la PT può essere modulata da proteine che interagiscono con la OMM 
come le esochinasi e ligandi del traslocatore TSPO (noto in precedenza come recetore 
periferico delle benzodiazepine). TSPO è una proteina altamente conservata nel corso 
dell’evoluzione ed è stata identificata come recettore per le benzodiazepine in tessuti privi 
dei recettori GABA. Inoltre, fin dai primi modelli del PTP, TSPO è stato considerato come uno 
dei suoi componenti assieme a VDAC e ANT, anche se il suo ruolo non è ancora stato 
confermato. In questo progetto ci siamo focalizzati prima sullo studio del ruolo della OMM 
nella regolazione del PT, e poi abbiamo creato topicon ablezione genetica di  Tspo (KO) per 
meglio caratterizzare il suo ruolo nella PT. 
Abbiamo dimostrato che: (i) la PT interessa esclusivamente la IMM, dato che avviene nei 
mitopasti (mitocondri privi di OMM); (ii) i ligandi di TSPO ad alta affinità come PK11195, 
Ro5-4864 e protoporfirina (PP) IX inducono la PT in mitocondri di fegato di ratto ma non in 
mitoplasti; (iii) in condizioni di stress foto-ossidativo la PT è inattivata a basse dosi di luce 
sia in mitocondri che in mitoplasti, mentre è attivata con alte dosi di luce solo nei 
mitocondri. Il KO condizionale di Tspo in fegato di topo previene il legame ad alta affinità tra 
TSPO e il suo ligando PK11195, ma non impedisce: (i) la formazione di PTP sensibile alla 
CsA; (ii) l’induzione della PT da ligandi di TSPO (PK11195, Ro5-4864 e PP IX); (iii) 
l’induzione della PT da stress fotoossidativo. Questi risultati sono la dimostrazione 
inequivocabile che i ligandi specifici di TSPO regolano il PTP agendo in un altro bersaglio, 
che potrebbe essere la FoF1 ATP sintetasi.  
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1. Introduction 
1.1. Mitochondria 
Situated in the cytoplasm of eukaryotic cells, mitochondria are essential for normal cell 
function. Originally studied mainly as the ‘powerhouses’ of the cell due to their ability to 
produce adenosine triphosphate (ATP, the key cellular fuel) nowadays they draw attention 
also for their role in Ca2+ homeostasis, inter-organelle communication, cell proliferation and 
senescence, and orchestration of various signaling pathways some of which determine cell 
commitment to death or survival [1]. Alterations in mitochondrial physiology are often 
synonyms of disease.  
The earliest records of intracellular structures that probably were mitochondria date back 
to the 1840s, but their identification was the achievement of R. Altmann, who in 1890 
observed cytoplasmic structures of ubiquitous occurrence resembling bacteria and 
functioning as “elementary organisms”, and called them bioblasts. The term 
“mitochondrion” was introduced eight years later by C. Benda and originates from the Greek 
“mitos” (thread) and “chondros” (granule) [2, 3]. Indeed, mitochondria not only look similar 
to bacteria in size (0.5-1µm), they also replicate by fission and have their own genetic 
material, a circular DNA molecule that in Homo Sapiens codes for 22 tRNAs, 2 rRNAs and 13 
respiratory chain proteins.  
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Figure 1. The morphology of mitochondrion.  
IMM – inner mitochondrial membrane, OMM – outer mitochondrial membrane, IMS – intermembrane 
space. Left: modified from [4] 
 
From a structural point of view, mitochondria possess two membranes (inner and outer) 
that are quite distinct in appearance and in physico-chemical properties, which determine 
the biochemical function of each. The membranes separate two aqueous compartments, the 
mitochondrial matrix and the intermembrane space (IMS) (Figure 1). 
The outer mitochondrial membrane (OMM) is smooth and similar in composition to the 
plasma membrane. It is composed of phospholipids and proteins in similar proportion. The 
most abundant proteins in the OMM are membrane-spanning channels called voltage 
dependent anion channels (VDAC) or porins. They are 2-3 nm-wide in diameter and allow 
ions, metabolites and small proteins up to 5 kDa to freely diffuse from the cytosol to the IMS 
and vice versa. Higher molecular weight species (proteins) are transported by the OMM 
translocase complex TOM. Other proteins include enzymes involved in mitochondrial lipid 
synthesis and tryptophan degradation, transporters of cholesterol or heme precursors, 
receptors for apoptosis or mitochondrial fusion initiation.  
At variance from the OMM, the inner mitochondrial membrane (IMM) has a very high 
protein-to-phospholipid ratio (~ 3:1 by weight) and its main lipid is cardiolipin. As such, the 
membrane is almost impermeable to ions and substrates; the only species able to cross it 
freely are H2O, oxygen and carbon dioxide (CO2). The IMM is highly convoluted and forms 
infoldings called cristae, dynamic structures that greatly increase the membrane’s surface 
area allowing a wide range of proteins to be embedded in it [5]. The membrane contains 
proteins that perform redox reactions in the electron transport chain, the FoF1-ATP synthase 
and tightly controlled transport systems (translocase of inner membrane for protein import 
and various proteins that govern ion and metabolite transport from or to the matrix) [4]. 
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The IMS is one of the two aqueous compartments of a mitochondrion and is in osmotic 
equilibrium with the cytosol. It hosts several proteins including cytochrome c (cyt c) and 
second mitochondria-derived activator of caspases (Smac)/ direct IAP binding protein with 
low pI (Diablo) that if released in the cytosol may initiate the apoptotic cascade leading to 
cell death [6]. IMS is also pivotal in exchange of lipids and ions between the matrix and the 
cytosol, scavenging of reactive oxygen species (ROS) produced by respiratory chain and the 
control of mitochondrial morphogenesis [7]. 
Since the matrix is enclosed by the almost impermeable IMM, it contains only a highly 
selected set of molecular species. It is the most protein-rich mitochondrial compartment, 
hosting about 2/3 of the organelle’s protein contents including enzymes of the Krebs cycle, 
but also mitochondrial DNA, tRNAs and ribosomes [4].  
 
1.1.1. Bioenergetics of mitochondria 
The cellular energy currency, ATP, can be produced in 3 ways: (i) by anaerobic glycolysis 
(which takes place in the cytosol); when glucose is converted to pyruvate only a small 
fraction of total free energy potentially available for ATP synthesis is released with an 
overall net gain of 2 ATP molecules; (ii) by tricarboxylic acid (TCA), also known as citric acid 
or Krebs cycle, which takes place in mitochondrial matrix and yields one ATP molecule per 
cycle, (iii) by oxidative phosphorylation (OXPHOS), which takes place in the IMM and allows 
~15 times more ATP to be made than that produced by glycolysis. This is because 
mitochondria house the major enzymatic systems used to complete the oxidation of sugars, 
fats and proteins that enter the Krebs cycle after being converted to acetyl-CoA. Pyruvate 
produced by glycolysis enters mitochondria, where pyruvate dehydrogenase catalyzes its 
conversion to acetyl-CoA, also reducing NAD+ to NADH; fatty acids are converted to acetyl-
CoA by β oxidation; while various enzymes exist for the conversion of specific amino acids 
into pyruvate, acetyl-CoA or directly into specific citric acid cycle intermediates. Once in the 
TCA cycle, CoA causes the acetyl moiety to react with oxaloacetate to produce citrate. In a 
series of seven subsequent enzymatic steps, citrate is oxidized back to oxaloacetate while 
giving off two molecules of carbon in the form of CO2, three NADH and one of flavin adenine 
dinucleotide FADH2 [8]. The latter two carry the free energy liberated from the Krebs cycle 
to the mitochondrial electron transport chain made up of OXPHOS complexes I to V (Figure 
2). 
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Figure 2. Cellular respiration: the electron transport chain and ATP synthase.   
Complexes I-IV of electron transport chain (ETC) and the ATP synthase (Complex V) are embedded in 
the IMM. The ETC substrates coming from Krebs cycle feed the electrons to complexes I and II, 
electrons are then transferred along the chain due to the increasing redox potential of the OXPHOS 
enzymes. The flow of electrons is accompanied by proton pumping from the matrix to the 
intermembrane space creating the electrochemical proton gradient which then drives the synthesis 
of ATP. Complexes I to V can be inhibited by rotenone, thenoyltrifluoroacetone (TTFA), antimycin A, 
cyanide and oligomycin, respectively.  
Modified from http://www.education-africa.com/wiki/index_en.php?title=Self-efficacy_and_its_ 
practice 
 
NADH donates electrons to respiratory complex I, also called NADH dehydrogenase, an L-
shaped enzyme complex that contains a hydrophobic domain embedded in the IMM and a 
hydrophilic arm which protrudes into the mitochondrial matrix and contains the NADH 
binding site [9, 10]. The reduced cofactor donates two electrons to a flavin mononucleotide 
prosthetic group contained in the hydrophilic arm of complex I. These electrons are then 
passed down the arm via a series of iron–sulphur clusters to the lipid soluble redox carrier 
coenzyme Q (CoQ) [8]. The liberated energy is used to pump out four protons (H+) from the 
matrix to the IMS against their concentration gradient. The other cofactor formed in the 
citric acid cycle (FADH2) never leaves the complex, as the dehydrogenase itself is a part of 
the electron transport chain. The enzyme, also known as complex II, contains FAD as a 
prosthetic group alongside Fe–S clusters to catalyze of electron transfer to ubiquinone 
(CoQ) [11]. In contrast to complex I, no protons are pumped by this complex as the liberated 
energy is insufficient. The electrons coming either from complex I or II reduce CoQ; the 
ubiquinone diffuses through the IMM to complex III, also called cytochrome c reductase. 
This enzyme oxidizes CoQ and passes the liberated electrons to two molecules of cyt c. In 
total four protons are translocated to IMS – two coming from the oxidation of CoQ and two 
additional ones [12]. Finally electrons arrive to complex IV (cytochrome c oxidase) where 
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they are passed to oxygen to form water. Again, alongside this reaction, four protons are 
pumped from the mitochondrial matrix into the intermembrane space [13].  
Because the IMM is impermeable to H+ and charged species in general, the movement of 
protons across the inner mitochondrial membrane generates an electrochemical proton 
gradient or proton-motive force (Δ  H), which can be calculated with the Nernst equation: 
                    
      
       
 
It can be appreciated that the Δ  H results from the sum of the pH difference and the 
membrane potential difference (ΔΨm), which is negative inside [4]. ΔpH in mammalian cells 
is about 0.5-1 units, which corresponds to 30-60 mV; ΔΨm is in the order of 180-200 mV, 
which makes it the major component of the proton-motive force [14]. As suggested by Peter 
Mitchell in 1961 [15], Δ  H is coupled to phosphorylation of ADP, which occurs at OXPHOS 
complex V, or ATP synthase. The enzyme consists of a membrane-spanning Fo domain, made 
of a variable number of c subunits organized in a ring-like structure. This proton-conducting 
ring allows proton influx back to the matrix, which results in Fo rotation. This is transmitted 
through a shaft to the F1 portion, a matrix-exposed complex where conversion of ADP+Pi to 
ATP takes place. Of note, the ATP synthase can work in reverse, that is hydrolyze ATP and 
pump protons to intermembrane space when nΔ  H is lower than the phosphorylation 
potential (ΔGp), where n is the H+/ATP stoichiometry [14].  
The ΔΨm also provides the major driving force for the electrophoretic Ca2+ uptake into 
mitochondria through a selective channel, the Ca2+ uniporter (MCU) [16-18]. Indeed, an 
obvious outcome of the chemiosmotic theory is that Ca2+ uptake across the inner membrane 
is greatly favored: based on the Nernst equation (and considering a ΔΨm of –180 mV), the 
equilibrium would be reached only when Ca2+ in the matrix reaches a value 106 higher than 
that in the extramitochondrial space [19]. Hence, the rapid uptake of Ca2+ by energized 
mitochondria is observed.  
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1.1.2. Mitochondrial Ca2+: from uptake to signaling 
Three major functions for mitochondrial Ca2+ transport have been proposed. First, matrix 
Ca2+ affects a wide range of metabolic reactions, including stimulation and control of 
oxidative phosphorylation. Ca2+ uptake by mitochondria stimulates three key enzymes of the 
cycle: (i) pyruvate dehydrogenase, where Ca2+ activates a phosphatase associated with the 
enzyme complex; (ii) isocitrate dehydrogenase; and (iii) α-ketoglutarate dehydrogenase. 
Ca2+ directly binds to the latter two and increases their affinity for the substrates [20-22]. 
Several studies also implied Ca2+ as a direct regulator of ATP synthase [23, 24]. Since 
increased matrix [Ca2+] is matched by increased activity of OXPHOS, uptake could represent 
a mechanism to couple ATP demand with supply [25]. Second, mitochondria act as cytosolic 
Ca2+ ‘buffers’. This is achieved largely by the formation of Ca2+-Pi complexes in 
mitochondrial matrix, which are favored by alkaline pH, while the existence of specific Ca2+ 
binding proteins in the matrix is still unclear. Third, Ca2+ signaling is involved in cell death 
execution. It has long been recognized that mitochondrial Ca2+ overload can lead to a 
bioenergetic crisis associated with cell death by necrosis [26] as demonstrated by formation 
of Ca2+-Pi deposits, collapse of Δ  H, rapid drop of ATP and production of ROS. Instead the 
role of Ca2+ in apoptosis was recognized only when it was discovered that the classical anti-
apoptotic protein Bcl-2 was capable to affect mitochondrial Ca2+ signaling [27, 28]. Further, 
Ca2+ overload triggers the opening of the mitochondrial permeability transition pore (PTP), 
a phenomenon discussed more in detail in paragraph 1.2, which leads to ATP depletion and 
release of cyt c, apoptosis inducing factor (AIF) and Smac/Diablo.  
Ca2+ fluxes must be tightly controlled. Ca2+ entry into mitochondria is mediated by a 
selective IMM channel, the MCU, whose molecular identity only recently has been 
unravelled [16, 17]. Ca2+ moves along its electrochemical gradient. According to the Nernst 
equation the equilibrium between the cytosol (given the Ca2+ concentration of 10-7 M there) 
and matrix would be reached only when matrix [Ca2+] becomes as high as 0.1 M, which is 
incompatible with cell physiology [29]. This is prevented by the low affinity for Ca2+ of MCU, 
which slows Ca2+ influx rates into mitochondria; and by operation of Na+/Ca2+ and/or 
H+/Ca2+ exchangers that release Ca2+ preventing electrochemical equilibrium from being 
reached and keeping the Ca2+ level at a steady state [30]. However, it must be mentioned 
that any change in cytosolic Ca2+ concentration would results in an alteration of this steady 
state [29]. Thus, when intracellular Ca2+ concentrations rise, e.g. under pathological 
conditions or due to the proximity of mitochondria to the endoplasmic reticulum, a fast 
mitochondrial Ca2+ uptake occurs.  
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1.1.3. Mitochondria as mediators of cell death 
Cell death is an essential physiological process that it is required for the normal 
development of multicellular organisms [31]. However, if deregulated, it can contribute to 
diseases including cancer and degenerative diseases. Historically, cell death has been 
classified into two types: apoptosis (programmed cell death) and necrosis (accidental cell 
death). However, nowadays more and more evidence indicate that necrosis can be regulated 
as well (the new term necroptosis was introduced), and also that there are other forms of 
programmed cell death, such as autophagy, which otherwise is a process in which the cells 
recycle their own organelles and macromolecular components by engulfing them and then 
degrading by the lysosome. In general, it is an adaptive response of cells to sublethal 
stresses, like nutrient deprivation, meant to supply cells with metabolites for production of 
ATP [32]. Even if autophagy can serve as a protective mechanism against cell death by 
degrading organelles, both excessive and defective autophagy can be detrimental to the cell. 
The way in which the cell will die depends on the intensity of noxious signals, ATP 
concentration, cell type and other factors [33]. 
Necrosis is usually considered as accidental (that is, non-programmed) cell death and is 
characterized by the swelling of cytoplasm and its organelles and the rupture of cell 
membrane that causes release of cellular constituents followed by inflammation in the 
surrounding tissue. Necrosis usually results from metabolic failure that has coincided with 
rapid ATP depletion, e.g. it classically occurs in ischemia [34]. 
 
1.1.3.1. Apoptosis  
Apoptosis is a genetically controlled and evolutionarily conserved form of cell death that is 
important for normal embryonic development and for maintenance of tissues homeostasis 
in the adult organism. In contrast to the swelling of the cell that defines necrosis, apoptosis 
occurs in a well organized sequence of morphological events [35]. First, the cytoplasm 
shrinks and the chromatin condenses, yet the organelles retain their integrity. Then the 
plasma membrane blebs, but stays intact, preventing the release of cellular components into 
extracellular medium. Ultimately, apoptotic cells fragment into membrane-enclosed vesicles 
(apoptotic bodies), that are recognized and removed by phagocytes, thereby avoiding 
inflammation [36]. Apoptotic cell death is triggered by extrinsic, receptor-mediated, or 
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intrinsic, mitochondria-mediated, signaling pathways that induce death-associated 
proteolytic and/or nucleolytic activities (Figure 3).  
 
 
Figure 3. Intrinsic and extrinsic pathways of apoptosis.  
Two pathways of apoptotic cell death exist: one triggered by death receptor (extrinsic) which 
activates caspases 8, 3 and 7, culminating in apoptosis; and the mitochondrial (intrinsic) one. The 
intrinsic stimuli cause mitochondrial outer membrane permeabilization (MOMP) mediated either by 
interplay of the Bcl-2 family proteins or mitochondrial permeability transition, the release of 
proapoptotic proteins and activation of caspase 3 and caspase 7. The two pathways crosstalk through 
the ability of caspase 8 to cleave a Bcl-2 family member Bid, which then activates Bax and Bak and 
causes MOMP. From [37].   
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The extrinsic apoptotic pathway is activated when members of the tumor necrosis factor 
(TNF) superfamily (FasL, Trail, TNF) bind to cell surface “death receptors”, members of the 
TNF-receptor family [38-40]. Ligation of these receptors recruits adaptor molecules, such as 
Fas-associated death domain protein (FADD) and then initiator caspase, caspase 8, forming 
the multiprotein death-inducing signaling complex (DISC) [41-43]. This results in the 
dimerization and activation of caspase 8, which can then directly cleave and activate caspase 
3 and caspase 7 and lead to apoptosis [32, 37], Figure 3. 
The intrinsic pathway is activated by a variety of intrinsic stimuli, such as intracellular ROS, 
γ radiation, DNA damage, ER stress, which eventually target mitochondria and lead to loss in 
OMM integrity. This in turn results in the release of the proapoptotic proteins from the IMS, 
e.g. cyt c, AIF, Smac/Diablo, DNAse endonuclease G (Endo G), high temperature requirement 
factor A2 (HtrA2)/Omi. Cyt c binds apoptotic protease-activating factor 1 (APAF1), inducing 
its oligomerization and thereby forming a structure termed apoptosome that recruits and 
activates an ATP-dependent initiator caspase, caspase 9. Caspase 9 cleaves and activates 
executor caspases (such as caspase 3 and caspase 7) leading to apoptosis. The release of 
Smac/Diablo and Omi/HtrA2 results in antagonizing the X-linked inhibitor of apoptosis 
protein (XIAP) ability to inhibit caspases (Figure 3). After release in the cytosol, AIF and 
EndoG translocate to the nucleus, where AIF causes DNA fragmentation and chromatin 
condensation [44] and EndoG cleaves DNA into nucleosomal fragments [45]; these proteins 
thus are part of caspase-independent, intrinsic cell death pathways. Release of the above 
mentioned proteins occurs through the mitochondrial outer membrane permeabilization 
(MOMP). The main mechanisms causing this event are: (i) direct membrane 
permeabilization by Bax and Bak, members of the B cell lymphoma 2 (Bcl-2) family; and (ii) 
indirect MOMP due to opening of the mitochondrial PTP (discussed in paragraph 1.2).  
The pro-/anti- apoptotic function of Bcl-2 family proteins depends on the number of the Bcl-
2 homology (BH) domains (four in total, BH1, BH2, BH3 and BH4) they contain. Prosurvival 
members (such as Bcl-2 and Bcl-xL) have as much as four, while proapoptotic ones are 
subdivided into the effectors (Bax, Bak and Bok) that share three homology domains and 
BH3-only, such as Bid and Bak, that by definition possess only BH3 domain [37]. Upon 
apoptosis inducing signals BH3-only proteins are activated which in turn leads to activation 
of proapoptotic Bax (Bcl-2-associated X protein) and Bak (Bcl-2 antagonist or killer). Bax 
and Bak change their conformation, oligomerize and form channels in the OMM leading to 
MOMP and the release of cyt c [37]. Anti-apoptotic BcL-2 proteins prevent MOMP by binding 
BH3-only proteins and activated Bax or Bak. Although traditionally receptor mediated 
apoptosis pathway had been thought to be independent of mitochondrial one, the finding 
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that caspase 8 can trigger cyt c release has led to an integrated view where intrinsic and 
extrinsic pathways crosstalk through Bid. Caspase 8 is able to cleave the BH3-only protein 
Bid, leading to a smaller form of the protein, tBid, which now is able to translocate to OMM, 
where it inhibits the antiapoptotic members of Bcl-2 family and directly activates Bax and 
Bak, thus permeabilizing the OMM [2].  
It needs to be stressed, however, that the formation of the channel in the OMM might not be 
enough to induce apoptosis. Indeed, the Bax/Bak pore size appears to be barely sufficient to 
release cyt c, but not other proapoptotic proteins. Furthermore, only about 15 % of the total 
cyt c is found in the IMS, while most of it is within intracristal compartments that 
communicate with the IMS through narrow openings of the so-called cristae junctions [46]. 
Cristae morphology and diameter of cristae junctions is regulated by a large dynamin-
related protein, optic atrophy 1 (OPA1), and by presenilin-associated rhomboid like protein 
(PARL) [47]. The oligomers of OPA1 maintain the bottleneck configuration of cristae, thus 
keeping the cyt c compartimentalized [47, 48]. During apoptosis tBid causes cristae 
remodeling, which is favored by matrix swelling [46] and is inhibited by CsA [49], 
suggesting that opening of the CsA-sensitive PTP is an important step in cristae remodeling 
that can favor cyt c release though Bax/Bak channels [50]. 
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1.2. Permeability transition pore  
The mitochondrial permeability transition (PT) is a sudden increase of permeability of the 
otherwise impermeable IMM to ions and solutes with an exclusion size of about 1500 Da 
[51-54]. The prevailing view is that the PT is due to opening of a regulated high conductance 
protein channel, the PTP, which in the fully open state has an estimated diameter of about 3 
nm [53, 55]. PTP opening requires the presence of matrix [Ca2+], which is an essential 
permissive factor, and of additional agents or conditions that are collectively termed 
“inducers”. Under the conditions used in most in vitro studies, PT is accompanied by 
depolarization, Ca2+ efflux, depletion of matrix pyridine nucleotides (PN), matrix swelling, 
cristae unfolding, outer membrane rupture and release of intermembrane space proteins, 
including cyt c, Smac/Diablo and AIF [2,56,57].  
Apart from the long-lasting pore openings that can compromise cell viability, transient PTP 
openings occur both in isolated mitochondria [64] and in situ [65]. Besides cristae 
remodelling, our laboratory has proposed that PTP could also serve a physiological function 
as a mitochondrial Ca2+ release channel [66-68]. This hypothesis is consistent with early 
results on the effects of CsA in Ca2+ distribution in rat ventricular cardiomyocytes [69] and 
with recent findings in Ppif−/− mice (Ppif is the gene encoding for the CsA target Cyclophilin 
D) whose heart mitochondria display a 2.6-fold elevation in total Ca2+ levels, and are more 
susceptible to heart failure after diverse stimuli that cause progressive Ca2+ overload [70]. 
The idea that the PTP may serve as a physiological Ca2+ release channel is also supported by 
recent work in mouse primary adult neurons showing that PTP is activated in response to 
the combined action of more than one physiological stimulus affecting cytosolic [Ca2+], and 
that under these conditions PTP opening does not induce neuronal death but rather takes 
part in physiological Ca2+ dynamics [71].  
 
1.2.1. Regulation of the PTP 
In spite of the fact that the molecular nature of the PTP remains elusive, a great deal of 
information is known regarding its regulation. The pore open–closed transitions are highly 
regulated by multiple effectors the main of which are discussed below (for reviews, see Refs. 
1, 67, 61).  
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As already mentioned matrix Ca2+ plays a key role in the induction of the PTP through a 
still-undefined mechanism. The Ca2+ binding site in the matrix can be competitively 
inhibited by other Me2+ ions, such as Mg2+, Sr2+ and Mn2+; while all these Me2+ ions, including 
Ca2+ itself, decrease the probability of pore opening through an external binding site [72].  
The PT is strictly modulated by matrix pH. The optimum matrix pH for PT occurrence is 
about 7.3, and both an increase and decrease lead to decreased probability of PTP opening. 
An acidic pH locks the pore in the closed conformation through reversible protonation of His 
residues (that can be prevented by diethylpyrocarbonate, DEPC), whilst the mechanism of 
inhibition by pH > 7.4 is still unknown [73, 74].  
The PTP is voltage dependent in the sense that that inside-negative ΔΨm tends to stabilize 
the PTP in the closed conformation while the open state is favored by depolarization [75]. 
Our group has postulated the existence of a voltage sensor that decodes the changes of both 
the surface potential (through a set of charged residues) and of the trans-membrane voltage 
into changes of the PTP-open probability [1, 76]. Such a sensor would easily account for 
pore opening following depolarization as such, and for the effects of a large variety of 
membrane-perturbing agents that can either inhibit or promote the PT. 
The voltage-dependence in turn is modulated by redox events. Pore opening is strongly 
promoted by an oxidized state of PN (NADH/NAD+ and NADPH/NADP+) [77], and through a 
dithiol-disulfide interconversion at two distinct, matrix- and intermembrane space- exposed 
sites (Figure 4). These can be discriminated by the use of proper oxidants and reductants. 
The membrane permeant dithiol phenylarsine oxide (PhAsO) cross-links matrix-exposed 
internal cysteins (Cys) and this can be prevented by low concentrations of N-ethylmaleimide 
(NEM) [78] or monobromobimane [79]. A second redox-sensitive site whose oxidation 
increases the probability of PTP opening is affected by membrane-impermeant oxidant 
copper-o- phenantroline [Cu(OP)2]; oxidation of this site is inhibited by dithiotreitol and β-
mercaptoethanol but not by monobromobimane, unless the latter one is in a cationic form 
[80]. 
PTP open-closed transitions are affected by photooxidative stress, which can be triggered 
by the use of protoporphyrin (PP)-like dicarboxylic porphyrins, such as hematoporphyrin 
(HP) IX, deuteroporphyrin (DP) IX and PP IX itself, and light. Short irradiation time of 
mitochondria treated with porphyrins prevents PTP opening by photomodifying matrix 
histidine residues, which in turn lowers the reactivity of critical PTP regulating dithiols; 
longer irradiation times instead cause opening of the PTP by direct oxidation of external 
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pore-regulating Cys [81]. For a detailed description of the photodynamic action and its effects 
on PTP, see Paper 2. 
 
 
Figure 4. Schematic representation of PTP-regulating thiols. 
The two sites can be distinguished by the use of proper oxidants and reductants. Cu(OP)2 (copper-o- 
phenantroline) is a membrane-impermeant oxidant which selectively affects IMS–exposed (external) 
sulfhydryls. PhAsO (phenylarsine oxide) is a membrane permeant thiol cross-linker, also affecting 
matrix thiols. 
 
Opening of the PTP is affected by the immunosuppressant cyclosporin A (CsA), a high-
affinity inhibitor of cyclophilins (CyP) that desensitizes the pore to the inducing effects of 
Ca2+ and Pi through its binding to matrix CyPD [61,63,82,83]. The immunosuppressive effect 
of CsA is caused by a Ca2+-calmodulin-dependent inhibition of calcineurin due to complex 
formation of the drug with cytosolic CyPA. In turn, this prevents dephosphorylation and 
nuclear translocation of nuclear factor of activated T cells and other transcription factors 
that are essential for the activation of T cells [84]. Available evidence indicates that CsA 
affects the pore independently of calcineurin, as non immunosuppressive CsA derivatives 
(Debio 025 and NIM811), that do not inhibit calcineurin, were found to be powerful PTP 
desensitizers [85-91]. 
Phosphate is a classical inducer of the PTP, but our group recently demonstrated that CyPD 
inhibition or its genetic ablation sensitizes the pore to the inhibitory effects of Pi, which 
would be an inhibitor of the pore under these conditions [92, 93]. This result is particulary 
intriguing because Pi is an inhibitor rather than an inducer of the PT in yeast [94, 95] and in 
Drosophila melanogaster¸ where the PTP cannot be desensitized by CsA [96]. 
Quinones may act both as inhibitors (the most potent is Ubiquinone 0, Ub0) or inducers; 
their structure-activity relationship for PTP inhibition is complex and has not yet been fully 
elucidated [97]. 
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Provided that Pi is present, rotenone desensitizes the PTP by inhibiting complex I. The 
potency of the drug has been correlated with the CyPD expression levels, the less CyPD 
mitochondria express, the more potent rotenone is in inhibiting the PTP. In tissues that have 
high levels of CyPD expressed, rotenone is not effective; however, the inhibitory potency of 
it can be restored by CyPD ablation or treatment with CsA [98].  
PTP is regulated by two inhibitors of the adenine nucleotide translocator (ANT): 
bongkrekate, which is an inhibitor and atractylate, which is an inducer.  
The pore is also affected by amphipatic compounds. They modify surface membrane 
potential fitting well with the idea of PTP regulation by voltage. In general, amphipathic 
anions, such as fatty acids produced by phospholipase A2 (PLA2) (e.g. arachidonic acid) 
mimic a depolarization and favor the PT. Instead, polycations such as spermine, 
amphipathic cations such as sphingosine and trifluoroperazine, and positively charged 
peptides mimic a hyperpolarization and inhibit pore opening [1, 61].  
 
1.2.2. Molecular nature of the PTP 
The key features of the permeability transition were described almost fifty years ago by 
Crofts and Chappell, who reported that energized mitochondria exposed to high loads of 
Ca2+ can undergo a massive swelling, which can be partially reverted by Ca2+ chelation [99, 
100]. Ever since, identification of the basis for this phenomenon has been a challenge, and in 
spite of many efforts the molecular nature of the PTP remains elusive. The regulation of the 
PTP is so complex that no model has so far been able to account for the huge variety of pore 
inducers and inhibitors (more than 50 classes were already listed in 1990 [101]). 
Over the years several models to explain the PT have been proposed. Haworth and Hunter 
suggested that PT is caused by opening of a proteinaceous pore in the IMM, with inhibitors 
and activators of the transition binding to the pore at specific sites affecting the tendency to 
open or close in an allosteric fashion, and proposed that it may serve an undefined 
physiological role [51-54]. Unfortunately, at the time this proposal did not get much 
attention, in part at least as a consequence of the general acceptance of the chemiosmotic 
theory and of the prevailing view that mitochondria did not possess cation channels; 
existence of a large unspecific pore in the IMM seemed to contradict the basic tenets of 
chemiosmosis [61]. Pfeiffer and co-workers proposed that changes in membrane 
permeability can occur from accumulating PLA2 reaction products. In this view, a substrate 
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cycle of phospholipid deacylation-reacylation establishes the steady state of free fatty acid 
and lysophospholipids which, in turn, alters permeability; Ca2+ uptake activates PLA2, and 
inducing agents inhibit reacylation, either directly [102, 103] or indirectly by raising the 
matrix content of reduced glutathione [104]. The PLA2 reaction product levels would then 
rise leading to increased membrane permeability. However, the observation that CsA is a 
potent PT inhibitor, but has no affect on PLA2 activity led to conclude that PLA2 activation is 
not a primary cause of the PT [101]. The ‘modern’ model of the PTP was introduced by 
Brdiczka’s lab. It suggests that the pore forms at the contact sites between the IMM and 
OMM and itself spans both the membranes [107]. The basis for this hypothesis is the 
presence of ANT and VDAC (together with many other proteins, however) in detergent 
membrane extracts that possess hexokinase (HK) activity and display properties that 
resemble those of the PTP after reconstitution in liposomes [108, 109]. Similar preparations 
(which were, however, not even enriched in ANT and VDAC) had been previously shown to 
possess electrophysiological properties similar to those of the PTP, although atractylate 
caused channel closure [110] rather than the opening that would be expected based on 
studies in intact mitochondria [53]. The findings that the PT can be inhibited by low 
concentrations of CsA [63]; and that the translocator protein (TSPO; previously known as 
the peripheral benzodiazepine receptor, PBR) co-purify with VDAC and ANT [111] added 
CyPD and TSPO to the most widespread PTP model to date (Figure 5). Each of the putative 
components of this PTP model is discussed more in detail below. It must also be mentioned 
that both He & Lemasters and Vercesi and co-workers have suggested that the PTP might 
not consist of a specific protein. They rather hypothesized that the pore may be formed by 
aggregation of different misfolded integral membrane proteins that have been damaged by 
oxidant or by other stresses [105, 106]. In the model of He & Lemasters binding of CyPD 
blocks the conductance through these proteins, and upon the increase of matrix Ca2+ this 
binding is somehow perturbed, which favors the PTP ‘open’ conformation [105]. While 
interesting, the model fails to explain the PTP regulation by voltage and matrix pH.  
 
1.2.2.1. Voltage-dependent anion channel 
The earliest indication that the OMM is involved in the PT was the finding that swelling 
induced by high concentrations of sulfhydryl reagents (like NEM and other substituted 
maleimides) is not observed in mitoplasts, i.e. preparations where the OMM has been 
removed [112]. VDAC is the most abundant protein of the OMM, and in mammals is present 
in three isoforms (VDAC1, VDAC2 and VDAC3). It functions as a gatekeeper for the entry and 
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exit of mitochondrial metabolites and thus controls the cross-talk between mitochondria 
and the cytosol. Several lines of evidence suggested that the OMM component contributing 
to the PT is VDAC. Purified VDAC forms channels with a pore diameter of 2.5-3.0 nm and 
possesses electrophysiological properties similar to those of the PTP [113, 114]. VDAC is 
modulated by many factors that also affect the PTP, such as NADH, Ca2+, glutamate and 
hexokinase [115]. Moreover, Crompton et al reported that GST-CyPD pulled down both the 
ANT and VDAC, and that after reconstitution in liposomes these proteins formed a Ca2+-
activated, CsA-sensitive pore [116], although only ANT, but not VDAC was detected by 
others in similar experiments [117]. In spite of these results, mice lacking VDAC1, VDAC3 or 
VDAC1 and VDAC3 developed normally; and mitochondria isolated from Vdac1–/– mice 
underwent CsA-sensitive PT, which was also inhibited by Ub0 [118] and Ro 68-3400 [119], 
 
 
Figure 5. The most widespread model of the permeability transition pore.  
This model suggests that PTP is formed by matrix cyclophilin D (CyPD), adenine nucleotide 
translocator in the inner mitochondrial membrane (IMM), outer membrane voltage dependant anion 
channel (VDAC), translocator protein (TSPO) and membrane bound hexokinase (HK) II. Modified from 
[72]. 
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and retained all basic features of PTP modulation, including inhibition by CsA [120]. Since 
non-conditional ablation of Vdac2 led to embryonic death, this gene was silenced in 
Vdac1/Vdac3-null background mouse embryonic fibroblasts; again, no relevant differences 
on PTP formation were observed [121]. Thus, it appears that VDAC in not an essential 
component of the PTP. 
 
1.2.2.2. Adenine nucleotide translocator 
The ANT, as the name indicates, catalyses the selective exchange ADP for ATP. Under 
physiological conditions matrix ATP is swapped with cytosolic ADP, and the reaction is 
favoured by the membrane potential. However, if mitochondrial respiration is compromised 
(and thus unable to maintain ΔΨm), ATP synthase steps in by hydrolyzing glycolytic ATP 
taken up by ANT working in reverse, i.e. transporting cytosolic ATP in exchange for matrix 
ADP. The ANT is the most abundant protein in the IMM.  
Based on the finding that PT is modulated by atractylate and bongkrekate (inhibitors of 
ANT) it was suggested that this protein is a core component of the PTP complex. Atractylate 
inhibits the ANT and stabilizes it in the c (cytosol-facing) conformation, and favors PTP 
opening. On the other hand, bongkrekate inhibits the ANT, stabilizes it in m (matrix-facing) 
conformation and favors PTP closure [122]. The purified ANT reconstituted into liposomes 
formed a Ca2+-activated channel measured by patch clamp [123]. Although the data 
supporting ANT involvement in the pore formation seemed reasonable, unequivocal 
evidence that the ANT is not essential for the PT was obtained in a detailed study of liver 
mitochondria prepared from mice lacking both ANT1 and ANT2. The ANT-null mitochondria 
underwent a Ca2+- and CsA-sensitive PT with matrix swelling, the only difference being its 
lack of sensitivity to the ligands of ANT and the requirement of a higher Ca2+ load. Thus, the 
study revealed that ANT is not an obligatory binding partner of CyPD [124]. Consistent with 
these findings, recent work has shown that the polyclonal antibody used to identify a CyPD 
binding protein as ANT1 in fact labelled the Pi carrier, which has now been incorporated in 
the model of the PTP proposed by the Halestrap laboratory [125, 126]. 
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1.2.2.3. Phosphate carrier  
The physiological role of the phosphate carrier (PiC) is to mediate the co-transport of Pi and 
H+ to the mitochondrial matrix [127], where Pi is essential for the phosphorylation of ADP to 
ATP. Interestingly, Pi has long been known to be a PTP sensitizer, too. This fact and the 
findings that PiC (i) associates with ANT in the so called “ATP synthasome”[128]; (ii) upon 
reconstitution in liposomes it can yield a non specific pore under certain conditions [129]; 
(iii) is inhibited by the PTP inhibitors Ub0, Ro 68-3400 and NEM [126]; (iv) is found among 
the proteins that bind a PhAsO affinity matrix, and could be eluted with GST-CyPD in a CsA-
sensitive manner [126] led Halestrap to propose a PTP model in which the pore is formed 
by ANT, PiC and CyPD [130, 131]. However, these agents might affect other mitochondrial 
transporters; and Basso et al. demonstrated that the PTP can be desensitized to Ca2+ by Ub0 
and Ro 68-3400 even if the Pi is substituted by arsenate or vanadate [92]. We think that the 
genetic approach should be used to unequivocally establish the importance of the PiC in the 
PTP. This was partially addressed in Saccharomyces cerevisiae lacking PiC. Mersalyl, which 
inhibits PiC and triggers PT, induced opening of the decavanadate-sensitive Yeast 
Mitochondrial Unselective Channel (YMUC) in WT, but not the ΔPiC strain, although the 
latter could still undergo a decavanadate sensitive permeabilization through a pore of 
smaller size [132]. It is fair to say however, that there is an open debate as to whether YMUC 
can be considered a bona fide equivalent of the mammalian PTP.  
 
1.2.2.4. Hexokinase 
HK initiates intracellular glucose utilization by catalyzing its phosphorylation to glucose-6-
phosphate [133]. In mammals there are four important isozymes, type II (HK II) being the 
most represented. It is highly expressed in most cancer cells, where it localizes on the OMM. 
In highly glycolytic tumors HK II fosters cell growth in the hypoxic conditions of the primary 
tumor mass [134]. As already mentioned, it was found to form complexes with VDAC and 
ANT [108], and direct binding of HK I and II to VDAC was demonstrated [135]. The 
detachment of HK from mitochondria triggered PTP opening and cell death [136], and this 
was also observed in mitochondria devoid of VDAC [135]. 
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1.2.2.5. Cyclophilin D 
CyPD (which in the mouse is encoded by the Ppif gene) is the mitochondrial isoform of a 
large family of proteins endowed with peptidylprolyl cis-trans isomerase activity that is 
blocked by CsA. CyPD involvement in PTP regulation was suggested by the finding that 
similar amounts of CsA are needed both to desensitize the pore and to inhibit CyPD 
enzymatic activity [137, 140]. Several genetic studies revealed that the protein is a powerful 
PTP regulator rather than a pore component. Inactivation of the Ppif gene didn’t prevent 
PTP opening, although more Ca2+ was required to induce the PT, matching the Ca2+ load 
required in wild-type mitochondria treated with CsA [141, 144]. As expected, sensitivity to 
CsA was no longer present, while inhibitors acting at different sites (such as Ub0 and Ro 68-
3400) were still active [144].  
 
1.2.3. PTP involvement in pathology 
The role of the PTP as a mediator of cell death in paradigms relevant to human health is no 
longer questioned. A word of caution about an exclusive causative role of the pore is in order 
about early studies based on the effects of CsA alone because (i) inhibition of calcineurin 
prevents mitochondrial fission by inhibiting mitochondrial translocation of Drp1, a 
cytoprotective event that occurs independent of PTP inhibition [145]; and (ii) CyPD displays 
multiple regulatory interactions in mitochondria including CsA-sensitive binding to Hsp90 
and TRAP1 [146], modulation of the FOF1 ATP synthase [147] and binding to Bcl-2 [148, 
149]. Yet a role of the PTP is generally supported by studies of Ppif−/− mice and of their 
cross-breeding with several disease genotypes. 
Ppif−/− mice were protected from ischemia–reperfusion injury of the heart [141, 142] and 
brain [143, 150], infarct size being reduced in CyPD-null adults compared to wild-type or 
littermate controls. These studies do corroborate the conclusions of previous studies based 
on the use of CsA in ischemic isolated hearts [151] and in infarcted patients [152], in brain 
damage by hypoglycemia [153], hyperglycemia [154], middle cerebral artery occlusion 
[155,156], and traumatic injury [157,158]. Ppif−/− mice also display resistance to 
development of axonopathy in autoimmune encephalomyelitis [159] and to disease 
progression after crossing with superoxide dismutase 1 mutant mice [160], suggesting that 
CyPD-dependent (and possibly PTP-dependent) mechanisms are critical in the 
neurodegenerative aspects of demyelinating and motor neuron diseases. Ablation of CyPD 
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substantially improved learning, memory and synaptic function, and alleviated decreased 
long-term potentiation by the amyloid β peptide in a mouse model of Alzheimer's disease 
[161]. 
Perhaps the best case involving CyPD in pathology in vivo is represented by collagen VI 
diseases [162], a set of genetically heterogenous conditions that cause Bethlem myopathy 
[163], Ullrich congenital muscular dystrophy [164] and myosclerosis myopathy [165]. The 
rodent model of the disease (Col6a1−/− mice lacking collagen VI [166]) displays 
mitochondrial alterations in affected muscles that could be cured with CsA [167] or with the 
CyP inhibitor Debio 025 [87]; and Ppif−/− Col6a1−/− mice lacking both CyPD and collagen VI 
became indistinguishable from syngenic wild type mice [168], a clear indication that CyPD is 
involved in the development of the disease downstream of the lack of collagen VI in a 
process that is amplified by defective autophagy [169]. These results match those obtained 
in patient cultures [170] and in a pilot clinical trial with CsA [171], and in Ppif−/− Scgd−/− and 
Ppif−/− Lama2−/− mice modeling sarcoglycan deficiency and congenital muscular dystrophy 
due to lack of laminin, respectively [172]. 
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1.3. Translocator protein (TSPO)  
The Translocator protein (TSPO), previously known as peripheral benzodiazepine receptor 
(PBR), is an 18 kDa, nuclear-encoded, highly hydrophobic protein located in the OMM [173], 
although minute amounts were also found in plasma membrane and nucleus [174–176]. 
TSPO is highly conserved throughout evolution from bacteria to humans [174, 175]. 
Although it is ubiquitously expressed, protein levels differ in different tissues; the highest 
levels are found in steroid-synthesizing ones [177]. Hydropathy profile analysis of the 169-
amino-acid TSPO sequence suggested a putative five transmembrane helix structure, N-
terminus and C-terminus facing IMS and cytosol respectively, a model that is supported by 
experiments [177–181].  
TSPO was first identified in 1977 by Braestrup and Squires in binding studies of the 
benzodiazepine diazepam in the central nervous system (CNS). While looking for a control 
tissue, they observed that the drug also binds rat kidney membranes [182, 183]. 
Benzodiazepine binding was also observed in other peripheral tissues and led to the 
denomination ‘peripheral benzodiazepine receptor – PBR’, to stress its expression in the 
periphery as opposed to the ‘central’ benzodiazepine receptor expressed in CNS [174, 176, 
184, 185]. 
In 2006 the Human Genome Organization Gene Nomenclature Committee renamed the PBR 
to translocator protein of 18 kDa (TSPO) [184]. The rationale for this was: 
i) ‘peripheral’ does not reflect the tissue distribution of the protein, as it is also 
expressed in glial and ependymal cells, located in the CNS; 
ii) the protein does bind other structures, such as the isoquinoline carboxamide 
PK11195, cholesterol and PP IX, but not all benzodiazepines;  
iii) the protein is not a receptor in the traditional sense; its primary location is the 
OMM, where it does not only bind but also facilitates transport molecules of such 
as cholesterol and PP IX.  
 
1.3.1. Biological roles 
Although TSPO was suggested to play a role in a wide variety of biological processes (such 
as regulation of mitochondrial membrane potential and respiration, cell proliferation, Ca2+ 
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signaling, apoptosis, control of immune response [174-176, 184-188]), its best 
characterized features are cholesterol and porphyrin transport [184]. 
Perhaps the most studied function of TSPO is cholesterol transport from the outer to inner 
mitochondrial membranes, a rate-limiting step in steroidogenesis [174, 176, 184, 189]. 
Steroids are formed from cholesterol by several sequential enzymatic steps. The first takes 
place in the IMM and is the conversion of cholesterol to pregnenolone by cholesterol side 
chain cleavage catalyzed by cytochrome P450. Then pregnenolone leaves the mitochondrion 
to enter the endoplasmic reticulum, where it undergoes further enzymatic transformations 
that give rise to the final steroids [176]. Evidence exists to show that TSPO may function as a 
channel, accommodating a cholesterol molecule in the space delimited by the five 
transmembrane helices [178]. A cholesterol recognition amino acid consensus (CRAC) 
domain in the cytosolic C-terminus of the TSPO was identified [190]. 
TSPO also binds and transports porphyrins involved in mammalian tetrapyrrole 
metabolism, and thus participates in heme biosynthesis [184, 191, 192]. In most eukaryotes 
heme synthesis is initiated in the mitochondrion where -aminolevulinic acid (ALA) is 
produced from succinyl-CoA and glycine. ALA is exported to the cytosol, where it is 
converted to coproporphyrinogen III. This molecule crosses the OMM, presumably at least 
in part through TSPO [191, 193], is oxidized in the IMS and imported into the mitochondrial 
matrix where it is further oxidized to PP IX. Heme synthesis is completed by the 
incorporation of iron into PP IX [193]. A bacterial homolog of TSPO, a tryptophan-rich 
sensory transducer of oxygen (TspO), regulates photosynthetic membrane complex 
formation in Rhodobacter sphaeroides and is involved in Rhodobacter transport of porphyrin 
intermediates [195]. 
 
1.3.2. TSPO ligands 
Ligands of TSPO have been extensively used to characterize TSPO function and to explore its 
role in cell pathophysiology; they are generally classified as endogenous and synthetic ones. 
The putative endogenous ligands include cholesterol, porphyrins (PP IX, mesoporphyrin 
IX, DP IX, hemin), which exhibit a nM affinity (Table 1) [196- 198], diazepin binding 
inhibitor (DBI), trikontatetraneuropeptide (TTN) and PLA2 [188].  
Porphyrins are a group of organic compounds. The core of the porphyrin molecule is a 
tetrapyrrolic macrocycle, while peripheral substituents control drug biodistribution and 
I n t r o d u c t i o n |  33 
 
pharmacokinetics. Tetrapyrroles are naturally occurring pigments and vital constituents of 
oxidation–reduction and oxygen transport–related proteins such as hemoglobins, 
cytochromes, apoferritin, catalase, ferrichrome and peroxidases. Free base porphyrins 
proved to be good photosensitizers, i.e. compounds which upon absorption of light transfer 
energy to a substrate rather than giving it away as heat or light. Due to the efficient 
formation of the triplet state (quantum yield ~ 0.7–0.9 in a monomeric state [199]) and the 
low energy gap between the triplet states of tetrapyrroles and molecular oxygen, a large 
fraction of triplets (0.7–1.0) leads to the generation of singlet oxygen (1O2), a highly reactive 
oxygen species whose diffusion distance in biological systems is only about 10-20 nm [200]. 
Consequently, photodamage occurs in close proximity to the porphyrin. For an extensive 
description of the photodynamic effect, of porphyrins and of their involvement in 
photosensitization see Paper 2.  
Table 1. Ligand-binding affinities for TSPO. 
Ligand Kd, nM 
PK11195 0.6-2.0* 
Ro5-4864 1.1-7.3* 
FGIN1-27 15.0* 
PP IX  14.5 ± 10.7$ 
DP IX 31.3 ± 2$  
Cholesterol 6.14# 
From: *[201], $[202], #[197]. 
 
The classical synthetic ligands of TSPO include 1-(2-chlorophenyl)-N-methyl-N-(1-
methylpropyl)isoquinoline-3-carboxamide (PK11195) and 4-chlorodiazepam (Ro5-4864). 
Although both of them exhibit nanomolar affinity for the protein, the former binds 
exclusively to TSPO across all species and shows high levels of stereoselectivity and 
specificity [203-204], whereas benzodiazepine Ro5-4864 binding differs between species 
[205-209] and may require additional mitochondrial proteins, such as VDAC, for full binding 
[185]. The distinctive properties the two compounds suggest that their binding sites are not 
identical. Based on the entropy- and enthalpy- driven nature of the ligand-receptor 
interactions, PK11195 was originally classified as an antagonist and Ro5-4864 as an agonist 
[204]. However, both ligands are able to induce similar effects under certain conditions. 
Moreover, additional TSPO ligands were developed, such as the indole derivative FGIN1-27 
(N,N-dihexyl-2-(4-fluorophenyl) indole-3-acetamide) [177, 210]. In contrast with 
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cholesterol, which binds to the C-terminus of TSPO, all other drug ligands (and presumably 
porphyrins) bind near the N-terminus [190, 208, 211]. 
 
1.3.3. TSPO and Permeability transition 
Involvement of TSPO in the ‘PTP’ complex was suggested by its co-purification with the 
putative pore components VDAC and ANT [111], and was tested by what are considered to 
be high affinity TSPO ligands. It was demonstrated that TSPO ligands, such as PK11195, 
Ro5-4864 and PP IX, cause PTP opening both in isolated mitochondria and in cells [212-
219], although the potency depended on the cell type and the concentration used, which 
varied from nM to µM. Further complexity was uncovered with the demonstration that the 
same compounds could instead inhibit PTP and/or protect cells from apoptosis in other 
models [220, 221]; and that individual TSPO ligands can have the opposite effect on the 
same cell. For example, Ro5-4864 and PK11195 can either stimulate or inhibit apoptosis, 
respectively, with addition of Ro5-4864 overcoming the antiapoptotic effect of PK11195 
[213, 222]. Furthermore, evidence exists that TSPO ligands can cause cellular responses that 
are independent of the TSPO [223-225], calling into question the specificity of TSPO ligands 
in general and the conclusions (such as the involvement of the TSPO in the PT) that were 
made based on the use of these drugs. Initial attempts to generate animals lacking 
expression of TSPO have indicated that non-conditional elimination of protein expression 
results in embryonic lethality [226], although details of the stage at which development 
arrests, and whether any specific phenotypes precede lethality have not been reported. We 
therefore generated mice in which the Tspo gene was conditionally eliminated. Our results 
are reported in paragraph 2.3.1.2. 
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2. Results  
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2.1. The mitochondrial permeability transition is an 
inner membrane event 
 
The long-standing idea that the PTP may form at inner-outer membrane contact sites and 
that it may be constituted by the ANT in the IMM and VDAC in the OMM has not been 
confirmed by genetic ablation of these proteins, yet the PT can be regulated by proteins that 
interact with the OMM such as hexokinase and by ligands of the OMM TSPO. As of today, 
however, it is not clear whether the OMM is necessary for the PT to occur and what 
regulatory properties, if any, it may contribute to the PTP. Intriguingly, apart from early 
studies of Lê-Quôc and Lê-Quôc demonstrating that the OMM is necessary to induce 
mitochondrial swelling upon treatment with maleimide derivatives [112], the question of 
whether a PT can occur in mitoplasts (mitochondria stripped of the OMM) has never been 
addressed.  
We thus studied the properties of the PTP in rat liver mitochondria and in mitoplasts 
retaining IMM ultrastructure and energy-linked functions. Like mitochondria, mitoplasts 
readily underwent a PT following Ca2+ uptake and upon treatment with classical PT inducers 
PhAsO and Cu(OP)2 (which affect two distinct PTP-regulatory sites) in a process that 
maintained sensitivity to CsA, demonstrating that PT is exclusively an IMM event. On the 
other hand, major differences between mitochondria and mitoplasts emerged in PTP 
regulation by ligands of the OMM TSPO. Indeed, mitoplasts became resistant (i) to the 
photodamage induced by the treatment with dicarboxylic porphyrins endowed with PP IX 
configuration (which bind TSPO in intact mitochondria) and irradiation (see also Ref. 81 and 
Papers 2 and 3); and (ii) to PTP-induction by the selective TSPO-ligands FGIN1-27, Ro5-
4864 and PK11195, suggesting that the OMM plays an important regulatory role through 
specific interactions with TSPO. 
 
Paper 1: 
Šileikytė J, Petronilli V, Zulian A, Dabbeni-Sala F, Tognon G, Nikolov P, Bernardi P, Ricchelli 
F. Regulation of the inner membrane mitochondrial permeability transition by the outer 
membrane translocator protein (peripheral.benzodiazepine receptor). J Biol Chem. 2011 Jan 
14; 286(2):1046-53. 
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We studied the properties of the permeability transition
pore (PTP) in rat liver mitochondria and in mitoplasts retain-
ing inner membrane ultrastructure and energy-linked func-
tions. Like mitochondria, mitoplasts readily underwent a per-
meability transition following Ca2 uptake in a process that
maintained sensitivity to cyclosporin A. On the other hand,
major differences between mitochondria and mitoplasts
emerged in PTP regulation by ligands of the outer membrane
translocator protein of 18 kDa, TSPO, formerly known as the
peripheral benzodiazepine receptor. Indeed, (i) in mitoplasts,
the PTP could not be activated by photo-oxidation after treat-
ment with dicarboxylic porphyrins endowed with protopor-
phyrin IX configuration, which bind TSPO in intact mitochon-
dria; and (ii) mitoplasts became resistant to the PTP-inducing
effects of N,N-dihexyl-2-(4-fluorophenyl)indole-3-acetamide
and of other selective ligands of TSPO. Thus, the permeability
transition is an inner membrane event that is regulated by the
outer membrane through specific interactions with TSPO.
The mitochondrial permeability transition (PT)4 is a sud-
den increase in the permeability of the inner mitochondrial
membrane to solutes with molecular masses of up to 1500 Da.
This process is due to opening of a voltage- and Ca2-depen-
dent, cyclosporin A (CsA)-sensitive, high conductance chan-
nel called the permeability transition pore (PTP). Its involve-
ment in pathological states and in the loss of cell viability is
widely recognized, but its molecular identity remains elusive
(1). The long-standing idea that the PTP may form at inner-
outer membrane contact sites and that it may be constituted
by the adenine nucleotide translocator (ANT) in the inner
mitochondrial membrane (IMM) and the voltage-dependent
anion channel (VDAC) in the outer mitochondrial membrane
(OMM) has not been confirmed by genetic ablation of these
proteins (2–4), yet the PT can be regulated by proteins that
interact with the OMM such as hexokinase (5, 6) and by li-
gands of the OMM translocator protein of 18 kDa, TSPO
(formerly known as the peripheral benzodiazepine receptor)
(7–17). As of today, however, it is not clear whether the
OMM is necessary for the PT to occur and what regulatory
properties, if any, it may contribute to the PTP.
Among the variety of effectors that regulate the PTP open-
closed transitions, oxidizing agents have received consider-
able attention, and changes in the redox state of pyridine nu-
cleotides, glutathione, and sulfhydryl groups have been shown
to play a prominent regulatory role (18–23). We have used
chemical modifiers, photosensitizing agents, and light to ex-
plore PTP regulation by redox events. As photodamage is re-
stricted to sites in close proximity to the photosensitizer, irra-
diation offered a unique opportunity to explore the role of
specific protein residues in PT regulation (24–26). One re-
markable finding was that hematoporphyrin IX (HP), which
produces mainly singlet oxygen (1O2) upon irradiation, results
in PT inhibition or activation depending on the light dose
(24–26). For low light doses, HP inhibits the PT through pho-
tomodification of matrix-exposed His residues (24), followed
by a drop in reactivity of critical matrix Cys residues (26). For
higher doses, HP instead causes PTP reactivation through
modification of distinct surface Cys residues (26). HP belongs
to the class of dicarboxylic porphyrins endowed with proto-
porphyrin IX (PP) configuration. These porphyrins bind mi-
tochondria with nanomolar affinity through TSPO (17, 27–
31), and intriguingly, PP is a potent inducer of PTP opening
(32). Given the long-standing proposals that the PTP is regu-
lated by the OMM and that it may include TSPO itself (7–9,
11, 32–34), we studied the properties of the PTP in rat liver
mitochondria and in digitonin-treated mitoplasts that retain
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IMM ultrastructure and energy-linked functions. Our results
indicate that mitoplasts undergo a Ca2-induced and CsA-
sensitive PT and that the OMM plays a regulatory role ex-
erted in part at least through TSPO.
EXPERIMENTAL PROCEDURES
Reagents—HP, PP, deuteroporphyrin IX (DP), and copro-
porphyrin III (CP) were obtained from Frontier Scientific (Lo-
gan, UT), and stock solutions were prepared in dimethyl
sulfoxide. FGIN1-27 (N,N-dihexyl-2-(4-fluorophenyl)indole-
3-acetamide) and PK11195 (1-(2-chlorophenyl)-N-methyl-N-
(1-methylpropyl)isoquinoline-3-carboxamide) were generous
gifts of Prof. Pietro Giusti (Department of Pharmacology and
Anesthesiology, University of Padova). Digitonin, phenylars-
ine oxide (PhAsO), and Ro 5-4864 (4-chlorodiazepam;
7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-
benzodiazepin-2-one) were from Sigma. Copper-o-phenan-
throline (Cu(OP)2) was prepared just before use by mixing
CuSO4 with o-phenanthroline at a molar ratio of 1:2 in bidis-
tilled water. All chemicals were of the highest purity commer-
cially available.
Preparation of Mitochondria—Liver mitochondria from
Wistar rats were prepared by standard differential centrifuga-
tion. The final pellet was suspended in isolation buffer (250
mM sucrose, 0.5 mM EGTA/Tris, and 10 mM Tris-HCl, pH
7.4) to give a protein concentration of 80–100 mg/ml as
measured by the biuret method. The quality of mitochondrial
preparations was established as described previously (26).
Preparation of Mitoplasts—The mitochondrial suspension
was added to solutions of varying digitonin concentrations in
isolation buffer at a final protein concentration of 20 mg/ml.
The resulting mixtures were then cooled in an ice-water bath
and gently stirred for 20 min. The suspensions were centri-
fuged at 10,000 g for 5 min, and the resulting pellets were
washed twice with isolation buffer and finally resuspended in
the same medium. The extent of OMM extraction was as-
sessed based on the activity of monoamine oxidase (MAO)
using benzylamine as a substrate (35). Extraction of MAO
activity was90% after treatment of mitochondria with
0.09–0.12 mg of digitonin/mg of mitochondrial protein (see
Fig. 2).
Western Blotting—Proteins were solubilized in Laemmli gel
sample buffer, separated by 15% SDS-PAGE, and transferred
electrophoretically to nitrocellulose membranes using a Mini
Trans-Blot system (Bio-Rad). Western blotting was per-
formed in phosphate-buffered saline containing 3% nonfat dry
milk with polyclonal antibodies prepared in rabbits against
purified bovine heart F1-ATPase, anti-GRIM19 monoclonal
antibody (Santa Cruz Biotechnology), anti-apoptosis-inducing
factor polyclonal antibody (Exalpha Biologicals, Inc.), anti-
Bcl-xL polyclonal antibody (Cell Signaling Technology), and
anti-VDAC1 monoclonal antibody (a generous gift of Dr. F.
Thinnes). Immunoreactive bands were detected by enhanced
chemiluminescence (Millipore).
Permeability Transition and Calcium Retention Capacity—
PT was induced at 25 °C in standard medium (250 mM su-
crose, 10 mM Tris/MOPS, 5 mM succinate, 1 mM Pi/Tris, 10
M EGTA/Tris, 0.5 g/ml oligomycin, and 2 M rotenone,
pH 7.4). Osmotic swelling was followed as the decrease in 90°
light scattering at 540 nm with a PerkinElmer Life Sciences
LS50 spectrofluorometer (36). The calcium retention capacity
of mitochondria and mitoplasts was measured in the same
medium supplemented with 0.5 M calcium green-5N (excita-
tion at 480 nm and emission at 530 nm).
Mitochondrial and Mitoplast Membrane Potential—
Changes in membrane potential difference (m) in mito-
chondria and mitoplasts were followed based on the accumu-
lation of pyronin G (3 M) as monitored by the changes in
emission fluorescence intensity at  580 nm (excitation,
 520 nm) (37).
Porphyrin Uptake and Photosensitization of Mitochondria
and Mitoplasts—Mitochondria and mitoplasts were sus-
pended in standard medium, and porphyrins were added un-
der gentle stirring at room temperature. After 2 min, the sus-
pensions were centrifuged at 4000 g for 2 min, and
porphyrin concentrations were determined fluorometrically
by calibration plots after extraction of supernatants and pel-
lets with 2% SDS. Porphyrin-mediated photosensitization of
mitochondria and mitoplasts was achieved as described previ-
ously (26). Briefly, preparations were incubated for 1–2 min in
the dark with the desired concentration of porphyrin and
then irradiated at 365 nm in a thermostatted glass reaction
vessel with a Philips HPW 125-watt lamp. The fluence rate at
the level of the preparations (40 watts (W)/m2) was measured
with a calibrated quantum photo radiometer (Delta OHMHD
9021). All irradiations were performed at 25 °C under mag-
netic stirring. Proper controls were carried out to verify that
neither incubation with the photosensitizer in the dark nor
illumination in the absence of porphyrin produced any appre-
ciable changes in the parameters under study. The structures
of the porphyrins studied in this work are shown in Fig. 1.
To compare the photoactivity of these different porphyrins
on the PTP, it was essential to establish first how much of
each was taken up by mitochondria and mitoplasts. Determi-
nations of porphyrin uptake revealed that HP, PP, and DP
exhibited higher incorporation yields in mitochondria (30–
40% of the total added) than in mitoplasts (20–30%) (see
Table 1; see also Ref. 38 for HP and PP). The membrane affin-
ity of the highly hydrophilic tetracarboxylic CP was much
lower and equal for mitochondria and mitoplasts (incorpora-
tion yield of10–13%). For each porphyrin, the concentra-
tion was adjusted in the range of 0.2–1.5 nmol of porphyrin
taken up per mg of protein to obtain comparable amounts of
membrane-bound compound, which was measured spec-
trofluorometrically. The rates of permeabilization were then
studied after irradiation times ranging from 10 to 240 s at 40
W/m2 (total light doses between 0.04 and 0.96 J/cm2). Under
these conditions, (i) porphyrins were bound to mitochondria
and mitoplasts as monomers, the only species that is appre-
ciably photoactive (39); (ii) no measurable effects were in-
duced in the dark (data not shown); and (iii) the molar ab-
sorption at the irradiation wavelength used (365 nm) was very
similar for all porphyrins (difference within 10%), which re-
flects an equivalent number of absorbed photons (data not
shown).
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Transmission Electron Microscopy—Mitochondria and mi-
toplasts were fixed for 30 min at 4 °C using glutaraldehyde at
a final concentration of 1.5% (v/v) in 0.1 M cacodylate buffer,
pH 7.2, and post-fixed with 1% OsO4. Thin sections (60–80
nm) were stained with uranyl acetate in alcohol (50%) and
lead citrate. Observations were made with an FEI Tecnai F12
transmission electron microscope.
RESULTS
We carried out a titration of mitochondria with increasing
concentrations of digitonin, and we assessed the release of
MAO and maintenance of the m by the resulting organelle
preparation. About 90% of MAO activity was solubilized be-
tween 0.09 and 0.12 mg of digitonin/mg of mitochondrial
protein, and a lower m was detected only with the highest
digitonin concentration (Fig. 2A).
Ultrastructural observation by transmission electron mi-
croscopy showed that treatment with 0.04 mg/mg digitonin
caused partial removal of the OMM (Fig. 2B, panel b, com-
pare with intact mitochondria in panel a), whereas with 0.09
mg/mg digitonin, the OMM was effectively removed. The
electron-dense matrix was preserved and delimited by a
highly convoluted, slightly unwound IMM (Fig. 2B, panel c).
At this concentration of digitonin, characteristic features of
mitoplasts were also foldings or finger-like protrusions of the
IMM and the absence of cristae and intracristal spaces pro-
jecting into the matrix typically found in mitochondria. A few
mitoplasts were round and swollen, and this population be-
came predominant after treatment with 0.12 mg/mg digito-
nin, which resulted in the formation of spherical vesicles (Fig.
2B, panel d).
We also studied the profile of marker proteins at increasing
digitonin concentrations. We found that 0.09 mg/mg digito-
nin extracted all of OMM Bcl-xL and nearly all VDAC, with a
marginal effect on the intermembrane apoptosis-inducing
factor, whereas it left an intact amount of IMM GRIM19 and
the -subunit of the ATP synthase complex, which resides
largely in the matrix space (Fig. 2C). We also tested an anti-
TSPO antibody (a generous gift of Dr. Vassilios Papadopou-
los), which unfortunately did not react with the rat protein.
However, similar digitonin titrations performed in mouse
liver mitochondria revealed an identical digestion pattern as
in rats and led to the complete disappearance of TSPO at 0.09
mg/mg digitonin (data not shown). On the basis of the ultra-
structural data and protein profiles, we therefore chose 0.09
mg of digitonin/mg of mitochondrial protein for subsequent
experiments.
We tested the ability of mitoplasts to undergo the PT with
the sensitive calcium retention capacity test, which measures
the threshold Ca2 load required to open the pore. Like mito-
chondria (Fig. 2D, trace a), mitoplasts readily took up a train
of Ca2 pulses (Fig. 2D, trace a) in a process that was fully
sensitive to ruthenium red, an inhibitor of the Ca2 uniporter
(data not shown). In mitoplasts, the threshold Ca2 required
for opening of the PTP, which is marked by a precipitous re-
lease of the previously accumulated Ca2, was about one-
third of that necessary to open the pore in intact mitochon-
dria. In both preparations, the Ca2 threshold was more than
doubled in the presence of 1 M CsA (data not shown). Mito-
plast Ca2 uptake could not be explained by residual intact
mitochondria after digitonin treatment. Indeed, a titration
with concentrations of mitochondria ranging between 0.1 and
1 mg/ml revealed that 0.4 mg/ml mitochondria was necessary
to match the calcium retention capacity of 1 mg/ml mito-
plasts (data not shown). This is well above the residual MAO
activity, which would account for a maximum of 0.10 mg/ml
intact mitochondria. Given that intact mitochondria were not
seen in EM images of preparations treated with 0.09 mg/mg
digitonin, we concluded that Ca2 uptake was entirely due to
mitoplasts (see also below).
A set of experiments was carried out to study PT regulation
in mitoplasts. Specifically, we checked whether the pore could
still be regulated by two distinct classes of matrix- and sur-
face-exposed sulfhydryl groups previously identified in intact
mitochondria (20, 22, 26). These thiols can be discriminated
based on their reactivity with the membrane-permeant dithiol
cross-linker PhAsO and the membrane-impermeant thiol
oxidant Cu(OP)2, respectively (20, 22, 26). Both mitochondria
(Fig. 3A) (22) and mitoplasts (Fig. 3A) underwent permeabili-
zation and swelling upon addition of PhAsO (traces a), in a
process that was prevented by CsA (traces b) or by 20 M N-
ethylmaleimide (traces c), indicating that the PhAsO-reactive
matrix thiols (19) maintained their PTP regulatory activity
after removal of the OMM. PTP-dependent permeabilization
of both mitochondria (Fig. 3B) and mitoplasts (Fig. 3B) was
also seen after the addition of Cu(OP)2 (traces a) in a process
that maintained its sensitivity to CsA (traces b) but was not
FIGURE 1. Structure of porphyrins. The chemical structures of HP, PP, DP,
and CP are shown.
Modulation of theMitochondrial Permeability Transition by TSPO
1048 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 2•JANUARY 14, 2011
 by PAO
LO
 BERNARDI, on January 7, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
inhibited by 20 M N-ethylmaleimide (traces c), as also de-
scribed in detail previously for intact mitochondria (22, 26).
These results prove that the Cu(OP)2-reactive external thiols
are located in the outer face of the IMM rather than in the
OMM.
In intact mitochondria, the PT can be either inhibited or
activated by photo-oxidative stress mediated by HP depend-
ing on whether low or high doses of light are applied, respec-
tively (26). We tested whether these peculiar photosensitizing
properties of HP are maintained in mitoplasts. Mitochondria
or mitoplasts (Fig. 4, closed and open squares, respectively)
were incubated with 2 M HP and irradiated for times ranging
between 30 and 240 s at 40 W/m2, corresponding to light
doses between 0.12 and 0.96 J/cm2. PTP opening was then
triggered by Ca2. These experiments showed that irradiation
for up to 100 s inactivated the PTP in both mitochondria (26)
FIGURE 2. Properties of mitochondria and digitonin-treatedmitoplasts. A, mitochondria (20 mg/ml) were incubated for 20 min with the indicated
amounts of digitonin. The suspensions were then diluted and pelleted by centrifugation as described under “Experimental Procedures.” For each prepara-
tion, MAO activity (f) and m () were determined. The activity was calculated as percent of the starting untreated mitochondria. Error bars represent
meansS.D. of four experiments. B, transmission electron microscopy of mitochondrial preparations without treatment with digitonin (panel a) and after
treatment with 0.04 (panel b), 0.09 (panel c), and 0.12 mg (panel d) of digitonin/mg of protein. Scale bars 1 m in themain panels and 0.2 m in the insets.
C, Western blot analysis of untreated mitochondria (lane 1) and of preparations obtained after treatment of mitochondria with the indicated amounts of
digitonin (lanes 2–4). AIF, apoptosis-inducing factor;mit., mitochondrial; sub., subunit. D, the incubation medium contained 250 mM sucrose, 10 mM Tris/
MOPS, 5 mM succinate, 1 mM Pi, 10 M EGTA/Tris, 0.5 M calcium green-5N, 0.5 g/ml oligomycin, and 2 M rotenone, pH 7.4, at 25 °C. The calcium retention
capacity was measured in mitochondria (1 mg/ml; trace a) or mitoplasts prepared with 0.09 mg of digitonin/mg of protein (1 mg/ml; trace a) by the se-
quential addition of a train of 10 M Ca2 pulses at 1-min intervals (arrows).
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and mitoplasts, although the latter were significantly more
resistant (Fig. 4). In both preparations, inactivation occurred
through photomodification of His residues, as indicated by
the counteracting effect of diethyl pyrocarbonate, which pre-
vents the addition of 1O2 to the His imidazole ring and its
irreversible degradation (data not shown, but see Ref. 26). On
the other hand, mitoplasts were strikingly resistant to the ac-
tivation of the PTP that in mitochondria follows irradiation
for times longer than 100 s (Fig. 4). It must be stressed that
the mitoplast preparations (i) maintained the ability to take
up Ca2 in the full range of light doses investigated, indicat-
ing that they retained energy coupling and a membrane po-
tential, and (ii) readily underwent large amplitude swelling
upon addition of alamethicin, indicating that they maintained
their structural integrity (data not shown). We deduce that in
intact mitochondria HP interferes with PTP-regulating OMM
sites that are lost in mitoplasts.
HP binds TSPO with nanomolar affinity (27). To test
whether this OMM protein mediates HP-dependent PTP
photoactivation, we extended our investigation to DP and PP,
dicarboxylic porphyrins that display even higher affinity than
HP in binding TSPO (27). We also tested CP (Table 1; see
“Experimental Procedures” for details), a tetracarboxylic por-
phyrin whose binding to TSPO is very weak (27).
Like HP, photoactivated PP and DP caused a concentra-
tion-dependent PT inhibition in both mitochondria and mito-
plasts (Fig. 5, A and A, respectively). PP and DP were more
effective than HP, whereas CP was totally inactive. As the effi-
ciency of 1O2 production is very similar for all porphyrins in
the monomeric state (0.7) (39), the resulting effects (or lack
thereof) must depend on the different localization of specific
porphyrins in the mitochondrial and mitoplast membranes. It
should be noted that the PTP-active porphyrins were more
effective in mitochondria than in mitoplasts (Fig. 5, compare
A and A), suggesting the TSPO facilitates their diffusion to
the “internal” PTP regulatory sites.
We next investigated the effects of these porphyrins on
PTP after prolonged irradiation. Mitochondria and mitoplasts
were allowed to accumulate a very small Ca2 load (10
nmol/mg of protein) that was not sufficient for spontaneous
PTP opening yet was permissive for the subsequent effect of
irradiation. In mitochondria, PTP opening was readily de-
tected with PP, DP, and HP (Fig. 6, closed symbols); of note,
the relative potency of porphyrins in eliciting photosensitiza-
tion of the PTP closely correlated with their relative affinities
for TSPO binding (27). Strikingly, in these protocols, all por-
phyrins were instead totally inactive in mitoplasts (Fig. 6, open
symbols).
Several TSPO ligands have been reported to cause PTP
opening (7–9, 11, 13, 16). We tested the effects of PP,
PK11195, Ro 5-4864, and FGIN1-27 (40) on Ca2 release in
Ca2-loaded mitochondria treated with ruthenium red, a sen-
sitive measure of pore opening (41). In these protocols, the
uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydra-
zone caused Ca2 release in both mitochondria and mito-
plasts (Fig. 7, A and A, respectively, traces b) through a fully
CsA-sensitive process (traces a). Strikingly, the addition of 40
FIGURE 3. Effect of PhAsO and Cu(OP)2 on light scattering in mitochon-
dria andmitoplasts. The experimental conditions were as described for
Fig. 2C, except that calcium green-5N was omitted. Light scattering was
measured at 540 nm in mitochondria (1 mg/ml; A and B) or mitoplasts (1
mg/ml; A and B). A and A, 5 M Ca2 and 5 M PhAsO were added where
indicated (traces a); 1 M CsA was added before (traces b); and 20 M N-eth-
ylmaleimide (NEM) was added where indicated (traces c). B and B, 5 M
Ca2 and 3 M Cu(OP)2 were added where indicated (traces a); 1 M CsA
was added before the organelles (traces b); and 20 M N-ethylmaleimide
was added where indicated (traces c).
FIGURE 4. Effect of the irradiation time inmitochondria andmitoplasts
loaded with HP.Mitochondria (f) and mitoplasts () at 0.5 mg/ml were
loaded with 2 M HP for 1 min at 25 °C in standard medium before irradia-
tion at 40 W/m2 for the indicated times; permeabilization was then studied
as the light scattering change at 540 nm following the addition of 60 M
(mitochondria) or 30 M (mitoplasts) Ca2. The permeabilization rates were
normalized to that of the control (non-irradiated organelles). Error bars rep-
resent the mean S.D. of four experiments.
TABLE 1
Porphyrin incorporation in mitochondria andmitoplasts
Mitochondria and mitoplasts (1 mg/ml protein) were incubated for 2 min in
standard medium in the presence of HP, PP, DP, and CP ranging from 1 to 6 nmol
of porphyrin/mg of protein. After 2 min, the suspensions were centrifuged at
4000 g for 2 min, and porphyrin concentrations were determined fluoro-
metrically by calibration plots after extraction of supernatants and pellets with 2%
SDS. All data are the average of at least three independent experiments and are
expressed as percent of the total amount of porphyrin added.
Mitochondria Mitoplasts
HP 30 4 20 2
PP 37 5 25 4
DP 40 5 30 5
CP 13 3 10 3
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M FGIN1-27 caused CsA-sensitive PTP opening in mito-
chondria but not in mitoplasts (Fig. 7, A and A, respectively,
traces c). A full titration was carried out with FGIN1-27, Ro
5-4864, and PK11195, which confirmed the striking resistance
of digitonin-treated mitoplasts to the PTP-inducing effects of
TSPO ligands (Fig. 8). Similar results were obtained for con-
centrations of PP above6 M (data not shown).
DISCUSSION
An important result of this work is the demonstration that
a CsA-sensitive PT can occur in digitonin-treated mitoplasts,
i.e. in the absence of an intact OMM. The PT of mitoplasts
maintains most of the basic features of the PT observed in
mitochondria (Ca2 dependence, desensitization by CsA, ac-
tivation by oxidants, inactivation by HP at low irradiation
times), thus indicating that the PT is fundamentally an IMM
event that can occur in the absence of an intact OMM. These
findings heavily bear on our understanding of the nature and
location of the PTP and call into question the widespread
conviction that the pore forms at contact sites between the
IMM and OMM and that the pore itself spans both mem-
branes (42).
The basis for this model of the PTP is the presence of ANT
and VDAC (together with many other proteins) in detergent
membrane extracts that possess hexokinase activity and dis-
play transport properties that resemble those of the PTP after
reconstitution in liposomes (43). Similar preparations (which
were, however, not even enriched in ANT and VDAC) had
been previously shown to possess electrophysiological proper-
ties similar to those of the PTP, although atractylate caused
channel closure (44) rather than the opening that would be
expected based on studies in intact mitochondria (45). We
believe that this model should be abandoned because (i) a
Ca2-dependent and CsA-sensitive PT can occur in mice in
which both isoforms of ANT have been genetically ablated
(2); (ii) the PTP of VDAC1-null mice is indistinguishable from
that of wild-type animals (3); (iii) a PT can occur in mitochon-
dria of cells in which the genes for all three VDAC isoforms
have been deleted or silenced (4); (iv) the 32-kDa protein
binding to the PTP modulator cyclophilin D under conditions
that favor pore opening is not ANT (46); and (v) the PT can
occur in the absence of an intact OMM (this study). Although
trace amounts of VDAC could be detected in our mitoplasts
(Fig. 2C), we would like to stress that the absence of an intact
OMM was documented by electron microscopy (Fig. 2B) and,
most importantly, by the lack of effects of TSPO ligands (see
below).
These results should not be taken to imply that the OMM
is not relevant for PTP modulation. On the contrary, another
important result of this work is the demonstration that the
OMM plays a prominent regulatory role and that this is in
part at least exerted through TSPO. Our data are consistent
with a dual role of TSPO (i) as a regulatory protein for PTP
modulation when it binds its selective ligands such as FGIN1-
27, PK11195, Ro 5-4864, and PP and (ii) as a transport protein
for PTP-active compounds that are then transferred to their
PTP regulatory site(s) in the IMM or in the matrix.
FIGURE 5. Effect of DP, HP, PP, and CP on light-dependent inactivation of the permeability transition.Mitochondria (A) and mitoplasts (A) at 0.5
mg/ml were incubated for 1 min with concentrations of each porphyrin giving a loading of 0.2–1.5 nmol of porphyrin/mg of protein at 25 °C (for details, see
Table 1 and “Experimental Procedures”). Preparations were irradiated for 45 s at a fluence rate of 40 W/m2 and then supplemented with 60 M (A) or 30 M
(A) Ca2 to trigger the PT, which was followed as the changes in 90° light scattering at 540 nm. The permeabilization rate was normalized to that of the
control (in the absence of porphyrins). Error bars represent the mean S.D. of three experiments.
FIGURE 6. Effect of DP, HP, and PP on light-dependent activation of the
permeability transition.Mitochondria (closed symbols) or mitoplasts (open
symbols) at 0.5 mg/ml were incubated for 1 min at 25 °C with concentra-
tions of each porphyrin (PP, circles; DP, squares; HP, triangles) giving a load-
ing of 1.2 nmol of porphyrin/mg of protein (for details, see Table 1 and “Ex-
perimental Procedures”). Preparations were then supplemented with 5 M
Ca2 (a concentration not sufficient to induce PTP opening per se) and irra-
diated for the indicated times at a fluence rate of 40 W/m2. The PT was fol-
lowed as the change in 90° light scattering at 540 nm. Error bars represent
the mean S.D. of three experiments.
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The first role is exemplified by the lack of pore reactivation
by light in mitoplasts treated with porphyrins that bind TSPO
in intact mitochondria (Figs. 4 and 6). This remarkable find-
ing demonstrates that high light doses in mitochondria
treated with HP, DP, and PP do not cause unspecific damage
to the IMM because damage should be more prominent,
rather than absent, in preparations that are not protected by
the OMM. Instead, our data show that porphyrin- and light-
dependent PTP reactivation is a specific event mediated by
the OMM and suggest that the PTP regulatory sites are con-
tributed by TSPO. In keeping with this hypothesis, in intact
mitochondria, PTP activation could be induced in the pres-
ence of porphyrins characterized by a PP-like configuration
that bind TSPO with nanomolar affinity (27, 28), whereas the
PP-unrelated CP was ineffective (data not shown). Further-
more, the photoactivity of dicarboxylic porphyrins (PP
DP HP) followed exactly their order of affinity for TSPO,
as calculated from the values of their inhibition constants for
[3H]PK11195 binding (27). Selectivity is the basis for the
physiological role of TSPO, which allows the transport of nat-
ural dicarboxylic porphyrins (such as PP), heme precursors,
heme itself, and cholesterol to mitochondria (28, 47–50).
Strong evidence in favor of a regulatory role of TSPO in inner
membrane permeability is provided by the observation that
FGIN1-27, PK11195, Ro 5-4864, and relatively high concen-
trations of PP (6 M or higher) cause PTP opening in mito-
chondria (7–16) but not in mitoplasts (Figs. 7 and 8). We be-
lieve that the liganded state of TSPO modulates the PTP
through protein-protein interactions that may be similar to
those described for dephosphorylated Bad and Bcl-xL (51).
The second role of TSPO is revealed by the effects of PP,
DP, and HP, which at low concentrations do not affect the
pore yet are able to induce PTP inhibition through photo-
oxidation of matrix His residues in both mitochondria and
mitoplasts (Fig. 5). Higher porphyrin concentrations are re-
quired in mitoplasts, indicating that transport through TSPO
facilitates diffusion of porphyrins to their relevant matrix or
IMM sites of action. In other words, these data demonstrate
that compounds whose PTP-dependent effects are facilitated
via transport through TSPO do not necessarily exert their
effects through TSPO itself.
TSPO is a member of an evolutionarily conserved family of
ubiquitous proteins able to bind small molecule drugs, choles-
terol, and porphyrins (17). TSPO has been conserved from
bacteria to mammals, and its inactivation induces an early
embryonic-lethal phenotype in mice (52). In mammals, TSPO
is highly expressed in the adrenal cortex (53), particularly in
the zona glomerulosa (54), which is consistent with its role in
steroid hormone synthesis. Its ubiquitous distribution sug-
gests, however, more general functions, including heme bio-
synthesis, apoptosis, cell proliferation, and PTP modulation
(49). A thorough study is under way to define which PTP li-
gands of pathophysiological relevance act through TSPO.
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2.2. PTP regulation by photooxidative stress: implication 
for the role of TSPO 
 
As already mentioned, PTP appears to be modulated by specific interactions with the OMM 
TSPO. Indeed, (i) TSPO ligands induce PTP opening in a CsA-sensitive manner in 
mitochondria, but not mitoplasts; (ii) PTP is modulated by photooxidative stress upon 
treatment with PP IX-like dicarboxylic porphyrins and irradiation with UV/visible light; 
indeed, the PT can be first inactivated at low irradiation times and then reactivated at longer 
times [81, Paper 1].  
Porphyrin photoactivity correlated with its affinity for TSPO: the higher the affinity, the 
lower light dose was needed for both PT inactivation and reactivation. In mitoplasts (that by 
definition should lack TSPO) the PTP could still be inactivated by porphyrins plus light. 
Strikingly, however, IMM preparations that should have became more fragile were instead 
completely resistant to PT reactivation by high light doses, suggesting that PTP occurred 
though the OMM, and was most likely mediated by TSPO.  
In Paper 2, which also includes original data, we review the basic principles of the 
photodynamic effect, the mechanisms of phototoxicity, and discuss the unique properties of 
1O2 generated by porphyrins in discrete mitochondrial domains. We also cover the 
characterization of the PTP by chemical modification of specific residues through 
photoirradiation of mitochondria after treatment with porphyrins. Finally, we propose a 
dual role of TSPO in PT: (i) as a transport protein for PTP-active compounds like porphyrins 
that are thus transferred to their PTP regulatory site(s) in the IMM or in the matrix; (ii) as a 
PTP regulatory protein when it binds its selective ligands like porphyrins. Moreover, results 
presented in Paper 3 provide additional evidence on a regulatory role of TSPO in PT. There 
we demonstrate that (i) PT activation by photodynamic events can be prevented by low µM 
concentrations of TSPO ligand FGIN1-27; and (ii) PP IX itself can induce the PT in 
mitochondria but not in mitoplasts. 
 
Paper 2: 
Ricchelli F, Šileikytė J, Bernardi P. Shedding light on the mitochondrial permeability 
transition. Biochim Biophys Acta. 2011 May; 1807(5):482-90. 
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Paper 3: 
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The mitochondrial permeability transition (PT) is an increase of
permeability of the inner mitochondrial membrane (IMM) to ions and
solutes with an exclusion size of about 1500 Da [1–4]. The prevailing
view is that the PT is due to opening of a regulated protein channel, the
PTpore (PTP),which in the fully open state has anestimateddiameter of
about 3 nm [3,5]. PTP opening requires the presence of matrix [Ca2+],which is an essential permissive factor, and of additional agents or
conditions that are collectively termed “inducers” [6–15]. In spite of
major efforts themolecular nature of the PTP remains undefined. Earlier
candidates such as the IMM adenine nucleotide translocator (ANT) and
the outer mitochondrial membrane (OMM) VDAC appear to be
regulators rather than constituents of the PTP, as their genetic ablation
did not prevent PTP opening [16–18] nor its sensitivity to cyclosporin A
(CsA) [19–22], a high-affinity inhibitor of cyclophilins (CyP) that
desensitizes the PTP to the inducing effects of Ca2+ and Pi through its
binding to matrix CyPD [23–25]. Consistent with these findings, recent
work has shown that the polyclonal antibody used to identify a CyPD-
binding protein as ANT1 in fact labeled the Pi carrier, which has now
been incorporated in the model of the PTP proposed by the Halestrap
laboratory [12,26].
Ablation of the Ppif gene encoding CyPD has similar effects as CsA,
in the sense that a higher of Ca2+ load and Pi is required for PTP
opening in isolated mitochondria [27–30]. Pi is a classical inducer of
the PTP, but we recently found that CyPD inhibition or its genetic
ablation sensitizes the pore to the inhibitory effects of Pi, which would
be the actual inhibitor of the pore under these conditions [31]. The
evolutionary implications of this finding and their importance in
reevaluating the yeast PTP (which is inhibited by Pi) as amodel for the
mammalian pore have been discussed in greater detail elsewhere [32].
1.1. The PTP as a fast Ca2+ release channel
Transient pore openings occur both in isolated mitochondria [33]
and in situ [34], and we have proposed that the PTP could serve a
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This hypothesis is consistent with early results on the effects of CsA in
Ca2+ distribution in rat ventricular cardiomyocytes [36] and with
recent findings in Ppif−/− mice whose heart mitochondria display a
2.6-fold elevation in total Ca2+ levels and consequent activation of
intramitochondrial Ca2+-dependent dehydrogenases resulting in
stimulation of glucose oxidation at the expense of fatty acids [37].
Strikingly, CyPD ablation resulted in increased propensity to heart
failure after transaortic constriction, overexpression of Ca2+/calmod-
ulin-dependent protein kinase IIδc and swimming exercise [37],
findings that suggest a progressive Ca2+ overload due to decreased
probability of PTP opening. That the PTP may serve as a physiological
Ca2+ release channel is also supported by recent work in mouse
primary adult neurons showing that PTP is activated in response to the
combined action of more than one physiological stimulus affecting
cytosolic [Ca2+] and that under these conditions PTP opening does not
induce neuronal death but rather takes part in physiological Ca2+
dynamics [38].
1.2. Role of the PTP in disease
The role of the PTP as a mediator of cell death in paradigms
relevant to human health is no longer questioned. A word of
caution about an exclusive causative role of the pore is in order
about early studies based on the effects of CsA alone because (i)
inhibition of calcineurin prevents mitochondrial fission by inhibiting
mitochondrial translocation of Drp1, a cytoprotective event that
occurs independent of PTP inhibition [39]; and (ii) CyPD displays
multiple regulatory interactions in mitochondria including CsA-
sensitive binding to Hsp90 and TRAP1 [40], modulation of the FOF1
ATP synthase [41] and binding to Bcl2 [42] (see Ref. [43] for a
review). Yet a role of the PTP is generally supported by studies of
Ppif−/− mice and of their cross-breeding with several disease
genotypes.
Ppif−/− mice were protected from ischemia–reperfusion injury
of the heart [27,29] and brain [30,44], infarct size being reduced in
CyPD-null adults compared to wild-type or littermate controls.
These studies do corroborate the conclusions of previous studies
based on the use of CsA in ischemic isolated hearts [45] and in
infarcted patients [46], in brain damage by hypoglycemia [47],
hyperglycemia [48], middle cerebral artery occlusion [49,50], and
traumatic injury [51,52]. Ppif−/− mice also display resistance to
development of axonopathy in autoimmune encephalomyelitis [53]
and to disease progression after crossing with superoxide dis-
mutase 1 mutant mice [54], suggesting that CyPD-dependent (and
possibly PTP-dependent) mechanisms are critical in the neurode-
generative aspects of demyelinating and motor neuron diseases.
Ablation of CyPD substantially improved learning, memory, and
synaptic function, and alleviated decreased long-term potentiation
by the amyloid β peptide in a mouse model of Alzheimer's disease
[55].
Perhaps the best case involving CyPD in pathology in vivo is
represented by collagen VI diseases [56], a set of genetically heterog-
enous conditions that cause Bethlemmyopathy [57], Ullrich congenital
muscular dystrophy [58,59] andmyosclerosis [60]. The rodentmodel of
the disease (Col6a1−/− mice lacking collagen VI [61]) displays
mitochondrial alterations in affected muscles that could be cured with
CsA [62] orwith theCyP inhibitor Debio 025 [63], and Ppif−/− Col6a1−/−
mice lacking both CyPD and collagen VI became indistinguishable from
syngenic wild typemice [64], a clear indication that CyPD is involved in
the development of the disease downstream of the lack of collagen VI in
a process that is amplified by defective autophagy [65]. These results
match those obtained in patient cultures [66] and in a pilot clinical trial
with CsA [67], and in Ppif−/− Scgd−/− and Ppif−/− Lama2−/− mice
modeling sarcoglycan deficiency and congenital muscular dystrophy
due to lack of laminin, respectively [68].1.3. Modulation of the PTP by specific amino acid residues
Asmentioned above, themolecular nature of the PTP is not known,
yet we understand in some detail how the pore is modulated by key
pathophysiological effectors like voltage, matrix pH and oxidative
stress through specific Cys and His residues [8,10]. The PTP is voltage-
dependent in the sense that the open conformation is favored by
depolarization [69] while an acidic matrix pH locks the pore in the
closed conformation through reversible protonation of His residues
even in depolarized mitochondria [70,71]. The voltage-dependence in
turn is modulated by redox events through a dithiol-disulfide
interconversion at a matrix site that can be prevented by N-
ethylmaleimide (NEM) [72] or monobromobimane [73]. A second
redox-sensitive site whose oxidation increases the probability of PTP
opening has been identified based on the effects of the IMM-
impermeant reagent copper-o-phenanthroline (Cu(OP)2) [74]. Oxi-
dation of this site promotes PTP opening that was inhibited by
dithiotreitol (DTT) and β-mercaptoethanol but not monobromobi-
mane [74]. Conclusive evidence that this site is located on the outer
surface of the IMM rather than in the OMM was recently obtained in
digitonin mitoplasts, which displayed an identical inducing effect of
Cu(OP)2 as intact mitochondria [75].
Characterization of the PTP by chemical modification of specific
residues has recently been pursued by a novel approach, i.e.
photoirradiation of mitochondria after treatment with porphyrins
[75–78]. The results of these experiments provided remarkable
information on the role and interactions of His and Cys residues in
PTP modulation, as well as on their topology, and suggested an
important role for the 18 kDa translocator protein (TSPO), formerly
known as the peripheral benzodiazepine receptor [79]. Before
covering in greater detail the picture emerging from these studies,
we will illustrate the basic principles of the photodynamic effect and
the mechanisms of phototoxicity and discuss the unique properties of
singlet oxygen (
1
O2) generated by specific porphyrins in discrete
mitochondrial domains.
2. The photodynamic effect
Photosensitization is a process induced by highly noxious
reactive species (free radicals and reactive oxygen species, ROS)
which are generated by molecules (called photosensitizers) after
they have adsorbed UV/visible light of appropriate wavelengths.
When oxygen is required for photosensitization to occur, the overall
process is defined as “photodynamic.” Photosensitization can lead to
severe cell damage or death [80]. Nearly all organisms contain
potential photosensitizers (e.g., bilirubin, chlorophylls and porphyr-
ins), but under physiological conditions the photodynamic effect
does not occur because the concentration of these compounds is
low or because they are sequestered in complexes that inhibit
photosensitization reactions. Photosensitization from these natural
substances is only observed under extreme conditions such as the
porphyrias, a group of diseases that causes severe skin lesions
through overproduction of porphyrins. In addition to endogeneous
sensitizers, a broad variety of exogenous photosensitizers (present
in food, cosmetics, plants or their juices, chemicals, drugs, etc.) can
enter the body through ingestion, inhalation, injection or direct
contact with the skin or exposed mucosa, causing photodamage in
the presence of light.
Early last century scientists realized that the harmful effects of
photosensitizers could be a tool for medicine [81,82]. Since then, the
photochemical approach has primarily been developed as a
treatment for cancer and for ophthalmologic and dermatologic
disorders [83–88]. Although the term photodynamic therapy (PDT)
was only defined at the beginning of the 20th century, this form of
therapy can be dated back over 3000 years. In one of India's sacred
books Atharava-Veda (1400 BC) a description is found of how
Fig. 1. Energy level diagram and photophysical and photobiological processes involving a photosensitizer. For explanation see text.
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ancient Egyptians cured with extracts of Ammi majus growing on the
banks of the Nile. The seeds of both plants contain psoralens, their
photoactive components [81,82]. The modern history of PDT started
with the observation that the combination of a chemical (acridine
red) and visible light had a lethal effect on the microorganism
Infusoria, a species of Paramecium [81,82]. The clinical potential of
this discovery was not explored for several decades also because of
the beginning of the antibiotic era. Today PDT (which inactivates
many classes of pathogens) is a promising tool to overcome the
problem of bacterial (multi-)drug resistance and to treat viral, fungal
and parasitic infections [87,89,90].Fig. 2. Simplified representation of the electronic configurations of molecular oxygen
lowest triplet and singlet states. The scheme depicts only π antibonding orbitals, for
further explanation see text.2.1. Mechanisms of phototoxicity
The physical processes involved in sensitizer phototoxicity are
illustrated in Fig. 1. The ground electronic state of the photosensitizer
is a singlet state (S0). On absorption of light of appropriate wavelength
(1) the photosensitizer is excited to one of its short-lived singlet
excited states, and rapid thermal relaxation leads to the lowest singlet
excited state (S1). The photosensitizer can then relax back to its
ground state by fluorescence emission (2) and internal conversion
(3), or can undergo intersystem crossing (4) to its lowest triplet
excited state (T1). This latter transition is spin-forbidden, but a good
photosensitizer has a high probability of triplet-state formation after
excitation. The T1-state is sufficiently long-lived to take part in
chemical reactions, and therefore the photosensitizing action is
mostly mediated by the T1-state. The T1-photosensitizer can also
return to the S0-state by emitting phosphorescence (5). Activated
photosensitizers in the excited triplet state can induce photochemical
changes in a neighboring molecule via two competing pathways
(Fig. 1). If oxygen is present in the environment, the photosensitizer
can transfer its energy to form the highly reactive
1
O2 in a reaction
defined as a type II mechanism [91]. The type I mechanism becomes
important at low oxygen concentration or in a more polar environ-
ment. In this process the photosensitizer reacts directly with organic
substrates, the solvent or another photosensitizer molecule via
electron or hydrogen transfer to yield free radicals. These species
are highly reactive and can easily interact with molecular oxygen to
generate intermediates such as the superoxide anion (O2−·), which
can convert to H2O2, the immediate precursor of the hydroxyl radical,
the most dangerous member of the ROS family [91–93]. Both type I
and type II reactions cause oxidation of cellular biomolecules.
Frequently they occur simultaneously, and the ratio depends onseveral parameters, the type of photosensitizer and the oxygen
concentration being the most important [91,93]. For most photo-
sensitizers employed in PDT, the type II photochemical reaction is the
dominant process [94,95].2.2. Singlet oxygen
In contrast to the vast majority of molecules, molecular oxygen in
its ground state has an electronic triplet configuration with two
unpaired electrons occupying two degenerate π antibonding orbitals
(Fig. 2). In the two forms of excited singlet states (
1∑gO2 and
1
ΔgO2)
these electrons have opposite spin. The
1
ΔgO2 form (noted for
simplicity as
1
O2) is involved in photosensitization, while
1∑gO2 is
too short-lived (10−11–10−9 s in solution) to be biologically relevant
[93,96]. Electrophilic
1
O2 is seeking electrons to fill its vacant
molecular orbital, and it thus reacts readily with electron-rich
molecules. Targets for oxidation are lipids (cholesterol and phospho-
lipids), amino acids (Trp, Tyr, His) and nucleic acid bases (guanine and
guanosine) that have double bonds, as well as sulfur-containing
amino acids (Cys, Met) [95,96]. In biological systems proteins are the
main intracellular targets for
1
O2 owing to their abundance and fast
rates of reaction, which are two orders of magnitude faster than those
displayed with unsaturated lipids [97,98]. The reaction of
1
O2 with
proteins can result in multiple effects including oxidation of side-
chains, backbone fragmentation, dimerization/aggregation, unfolding
Fig. 3. Effect of increasing irradiation times on the Ca2+ retention capacity of HP-loaded
mouse liver mitochondria. CD1 mouse liver mitochondria (0.5 mg/ml) were incubated
for 2 min at 25 °C in a medium containing 250 mM sucrose, 10 mM Tris–Mops pH 7.4,
5 mM succinate–Tris, 1 mM Pi–Tris, 10 μM EGTA–Tris, 3 μM HP, 2 μM rotenone, 0.5 μg/
ml oligomycin, 0.5 μM Calcium Green-5N. After irradiation for the indicated periods of
time at a fluence rate of 40 W/m2,mitochondriawere loadedwith a series of 10 μMCa2+
pulses at 1 min intervals. PTP opening was determined as the Ca2+ retention capacity
(CRC, expressed as the % of the CRC of non-irradiated organelles) measured at excitation
480 nm and emission 530 nm. The CRC decrease at high doses of light was prevented by
1 μM CsA (data not shown, see also Ref. [75]). Error bars refer to the mean±S.D. of four
experiments.
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tions in cellular handling and turnover [97].
1
O2 has unique features compared to other ROS. Being an
electronically excited state it is generally produced when exogenous
or endogenous photosensitizers absorb the appropriate wavelength of
visible or UV–radiation; in contrast, other ROS such as H2O2 and O2−·
are produced in cells during normal physiological processes or are
formed by activated neutrophils and macrophages. These “physio-
logical” ROS can readily interconvert, making it difficult to discern
which ROS is responsible for a particular cellular response, while
1
O2
does not interconvert to other ROS. Finally, the lifetime of
1
O2 has an
inherent upper value (i.e. how long
1
O2 exists in the absence of
reactive molecules) which poses an upper limit to its mobility from
the site of generation. Based on the
1
O2 lifetime of~4 μs a maximal
diffusion radius of a mere~220 nm in water has been calculated [98].
After this period of time
1
O2 returns to the ground state and loses
reactivity by transferring its energy to the solvent. In contrast, other
cellular ROS retain their activity until they hit a target or are destroyed
by enzymes [98].
The lifetime of
1
O2 in homogeneous solutions is between 10−6 and
10−3 s [99]. This value is considerably shorter in cellular systems,
ranging from 100 ns in the lipid regions of membranes to 250 ns in
the cytoplasm. The shorter intracellular lifetime of
1
O2 indicates
efficient quenching of this species by reaction with susceptible
intracellular targets (for a review see Ref. [93]). Due to the abundance
of these reactive molecules, the diffusion distance of
1
O2 in cells and
tissues has been estimated to be in the order of 0.01–0.02 μm [100–
102]. Given a cell diameter of 10–30 μm, it can be reasonably
assumed that the primary site of photodamage is also the site where
1
O2 has been generated. Thus, the intracellular localization of the
photosensitizer is the major determinant in dictating which
subcellular structures will be reached and attacked. Generally,
mitochondrial photosensitizers are able to induce apoptosis very
rapidly, lysosomal photosensitizers can elicit either a necrotic or an
apoptotic response, and plasmamembrane photosensitizers can lead
to cell rescue or initiate apoptosis and/or necrosis (for a review, see
Ref. [103]).
2.3. Porphyrins as photosensitizers
Porphyrins were identified in the mid-19th century, but it was
not until the early 20th century that they were used in Medicine.
Between 1908 and 1913 a number of photobiological experiments
were carried out with hematoporphyrin (HP), demonstrating how it
sensitized paramecia, erythrocytes, mice, and guinea pigs to light
[81,82]. The pioneering report of human photosensitization by
porphyrins was published in 1913 by Friedrich Meyer-Betz, who
injected himself with 200 mg of HP and reported swelling and
prolonged pain in light-exposed areas [82,104]. The subsequent
discovery of the tumor-localizing properties of porphyrins and of
the phototoxic effects on tumor tissues led to the development of
modern clinical PDT [105–110].
The “photoactive core” of porphyrin-based compounds is the
tetrapyrrolic macrocycle (porphine), while peripheral substituents
control drug biodistribution and pharmacokinetics. Tetrapyrroles
are naturally occurring pigments and vital constituents of oxida-
tion–reduction and oxygen transport-related proteins such as
hemoglobins, cytochromes, apoferritin, catalase, ferrichrome and
peroxidases. Within these proteins tetrapyrroles are not able to
induce photochemical reactions due to the presence of metal ions
(Fe3+, Al3+, Mg2+) which increase the probability of non-radiative
decay of the triplet state. Indeed, the most efficient porphyrin-
based photosensitizers (free base porphyrins) lack coordinated
metal ions.
In the monomeric state free base porphyrins are potent photo-
sensitizers with long lifetimes and high quantum yields of tripletformation (ΦT~0.7–0.9) while aggregation decreases the probability
of photoexcitation. Because of the low energy gap between the triplet
states of tetrapyrroles and molecular oxygen, a large fraction of
triplets (0.7–1.0) leads to
1
O2 generation by energy transfer. Thus,
1
O2
is the predominant phototoxic species involved in porphyrin-
photosensitized processes with a quantum yield of
1
O2 production
(ΦΔ) between about 0.7 and 0.9 for carboxylic porphyrins [111].
Alternative pathways for oxygen activation by photoexcited porphyr-
ins (e.g. generation of O2−· by electron transfer) usually have an
efficiency lower than 0.1 [112].
Under the same experimental conditions, monomeric porphyrins
exhibit quite similar photophysical properties and photosensitizing
efficiency, independent of their chemical structure and the nature of
the surrounding environment [111,113]. In particular, the yield of
1
O2
is similar for monomeric porphyrins with various degrees of
hydrophobicity [111]. In spite of their similar basic structure and
photophysical characteristics, however, porphyrins in cells display a
wide range of activities even when they target the same organelle;
and small differences (e.g. of peripheral substituents) result in
different physicochemical properties that modulate the affinity for
binding sites dictating uptake, subcellular distribution and therefore
the final target of the photoprocess [111,114]. For these reasons a
clever use of porphyrins can yield a wealth of information on
biological processes.2.4. Mitochondria as targets of porphyrin photodynamic activity
Studies with porphyrin-loaded cells indicate that hydrophobic
porphyrins tend to concentrate in mitochondria, especially after
prolonged incubation [115]. Mitochondrial damage is a major determi-
nant of porphyrin phototoxicity [116–118] to which cells with few
mitochondria are refractory [119]. Several mitochondrial components
are affected by photoirradiation [115,116,119–121]. Light- and dose-
dependence studies using dicarboxylic porphyrins (mainly HP) indicate
that ATP synthesis is the first function to be lost because the F0F1 ATP
synthase [115] and the adenine nucleotide translocator (ANT) [120] are
themost vulnerable
1
O2 targetswhereas respiration, Ca2+uptake,OMM,
matrix and intermembrane enzyme activities are more resistant in this
order.
Fig. 4. Effect of PP-like (DP, HP, PP) and PP-unrelated (CP, EP, UP) porphyrins on light-
dependent activation of the permeability transition. Wistar rat liver mitochondria
(0.5 mg/ml) were incubated for 2 min at 25 °C in a medium containing 250 mM
sucrose, 10 mM Tris–Mops, 5 mM succinate, 1 mM Pi–Tris, 10 μM EGTA–Tris, 0.5 μg/ml
oligomycin, 2 μM rotenone, pH 7.4 plus concentrations of each porphyrin giving a
loading of 1.2 nmol of porphyrin/mg of protein (see also Ref. [75]). Preparations were
then supplemented with 5 μM Ca2+ (a concentration not sufficient to induce PTP
opening per se) and irradiated for the indicated times at a fluence rate of 40 W/m2. The
PTwas followed as the change in 90° light scattering at 540 nm. Error bars represent the
mean±S.D. of three experiments. Ki values for porphyrins were taken from Ref. [123].
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at catalyzing cellular photodamage correlated closely with their
affinities for the TSPO. Among a wide variety of porphyrins and
porphyrin-like compounds the most photoactive were dicarboxylic
porphyrins endowed with PP-like configuration such as PP itself,Fig. 5. Photodynamic events mediated by porphyrins at PTP-regulating His and Cys residues.
TSPO. (B) Matrix-facing IMM porphyrin-binding sites are located in close proximity to cri
proximity to TSPO. In the dark, HP does not affect the structural properties of His- and Cys-co
Cys when PhAsO or Cu(OP)2 are added (omitted for clarity from the scheme, but see Refs. [75
generates
1
O2 in the proximity of critical His residues which undergo modification and c
oxidation, thus resulting in PTP inhibition. (D) Irradiation with high light doses causes TSP
surface thiols by
1
O2, resulting in PTP opening. For further explanation see text.mesoporphyrin IX, deuteroporphyrin (DP) and HP, which bind TSPO
with nanomolar affinities [123]. Such selectivity for PP-like porphyrins
has been ascribed to the major physiological role of TSPO to mediate
mitochondrial uptake of naturally occurring dicarboxylic porphyrins
such as PP, other hemeprecursors aswell as heme itself [123,124]. TSPO
is an 18 kDa OMM protein that may be located at junctional sites with
the IMM [124–126]. Such a localization could influence substrate
transfer between cytosolic and mitochondrial compartments, and
porphyrins with the highest affinity for TSPO would be expected to
accumulate best. The notion of TSPOmediating porphyrin phototoxicity
was confirmed by our recent results inmitoplasts [75] while it has been
challenged by other authors [127]. A key role of TSPO in controlling
mitochondrial internalization and photoactivity of porphyrins is
supported by the finding that high-affinity ligands of TSPO (such as 1-
(2-chlorophenyl)-N-methyl-N-(1-methyl-propyl)-3-isoquinolinecar-
boxamide, PK11195, and 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-
methyl-2H-1,4-benzodiazepin-2-one, Ro5-4864) as well as cholesterol,
prevent porphyrin-induced phototoxicity [128–131] probably by
inhibiting translocation of porphyrins into mitochondria [129,131]
(see also the following paragraphs).
3. Light on the PTP
In 1997 Salet et al. [76] and later Moreno et al. [77] exploited the
photodynamic effect to study the PT. This approach provided detailed
information on critical residues regulating the PT and helped to
understand the role of IMM and OMM in PTPmodulation [75–78]. The
first observation was that a short photoirradiation of mitochondria(A) Porphyrins with PP-like configuration are transported inside mitochondria through
tical His residues, and additional binding sites are adjacent to external thiols in close
ntaining domains, and PTP can open through selective oxidation of internal or external
,78]). (C) After mitochondrial irradiation with moderate light doses, photoactivated HP
ause a structural rearrangement of the internal dithiol which can no longer undergo
O-dependent photoactivation of porphyrins in the OMM leading to oxidation of IMM
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retained their ability to form a proton electrochemical gradient, and
accumulated Ca2+ and Pi at the same rate as non-irradiated
mitochondria. Strikingly, the oxidative effects of photodynamic action
prevented opening of the PTP, which is normally induced by Ca2+ plus
Pi, in the first example of pore inactivation by an oxidant [76], which is
at variance with what is generally observed under oxidizing
conditions [132–135]. The inactivating effect could be traced to
photomodification of matrix His residues (the direct target of
1
O2) by
vicinal porphyrin; this in turn lowered the reactivity of critical dithiols
whose oxidation (e.g. by diamide) causes opening of the PTP [72].
Irradiation of HP-loaded mitochondria thus represents an example of
site-selective inactivation of discrete pore functional domains
comprising critical His and Cys residues in close structural and
functional correlation [76].
The next finding was that irradiation with higher light doses
caused instead opening of the PTP, which was attributed to
photooxidation of IMM external thiols [75,78]. The effect of light
dose on the Ca2+ retention capacity (CRC) of mouse liver mitochon-
dria (a sensitive measure of the propensity of the PTP to open) is
illustrated in Fig. 3. The initial increase of CRC (i.e. pore desensitiza-
tion) was offset by a sharp decrease as the irradiation time increased.
Since at high light dose the previously identified His and Cys residues
have already been inactivated by matrix porphyrin, reactivation must
depend on a different porphyrin site, which is specifically contributed
by the OMM through TSPO [75]. The properties of this site are
illustrated in the experiments of Fig. 4, where irradiation times of
more than 60 s were applied to rat liver mitochondria preincubated
with concentrations of PP, DP, HP, coproporphyrin III (CP), uropor-
phyrin I (UP) and etioporphyrin (EP) yielding an identical loading of
1.2 nmol of porphyrin×mg−1 of protein. The relative potency of PP-
related porphyrins at sensitizing the PTP (measured here as the rate of
mitochondrial permeabilization to sucrose) matched their affinity for
TSPO, as based on the Ki displayed by each porphyrin for inhibition of
binding of PK11195, a classical ligand of TSPO (see also Ref. [136]). The
process of PTP activation was specific to porphyrins characterized by a
PP-like configuration that bind TSPO with nanomolar affinity (PP, DP
and HP), whereas PP-unrelated porphyrins such as tetracarboxylic CP,
octacarboxylic UP and EP, which lacks carboxylic groups, were
ineffective (Fig. 4 and Ref. [75]). It is also remarkable that
porphyrin-mediated PTP photoactivation is suppressed (results not
shown) by low concentrations of the high-affinity, porphyrin-
competitive TSPO ligand FGIN1-27 [136].
The regulatory role of the OMM and TSPO on the PTP was
confirmed by a study of mitoplasts prepared with digitonin
concentrations that allowed selective removal of the OMM without
interfering with mitochondrial energy-linked functions [75]. Like
mitochondria, mitoplasts readily underwent PTP opening following
Ca2+ uptake in a CsA-sensitive process, but major differences
emerged in PTP regulation by ligands of TSPO. In mitoplasts the PTP
could not be activated by photooxidation after treatment with
dicarboxylic porphyrins endowed with PP configuration, and mito-
plasts became resistant to the PTP-inducing effects of selective ligands
of TSPO [75].
4. Summary and conclusions
In photosensitization of biological materials by
1
O2 the photo-
damage is strictly limited to the immediate surroundings of the
sensitizer because of the short diffusion distance and high reactivity of
the photogenerated species. This peculiar oxidation mechanism
provided novel information on residues regulating the PTP. Studies
with this approach, whose results are summarized in Fig. 5, allowed to
characterize the PTP-modulating properties of sites which exhibit
different sensitivity towards oxidation by photoactivated porphyrins.
Under basal conditions (Fig. 5A) the PTP favors the closed conforma-tion. Porphyrins transported through TSPO are transferred to matrix,
IMM and OMM sites, but in the absence of photoirradiation they do
not affect the reactivity and pore-modulating properties of internal
(matrix-exposed) and external cysteines located on the outer surface
of the IMM [75] (Fig. 5B). Photoirradiation for short periods of time
hits the most vulnerable site, which comprises matrix-exposed His
and causes a secondary drop of reactivity of internal Cys, thus
stabilizing the PTP in the closed conformation (Fig. 5C). Inactivation of
internal Cys by His photodegradation allowed to establish the role of
(i) external regulatory Cys, which can still undergo oxidation and thus
increase the probability of PTP opening and (ii) of TSPO, which is
essential for reactivation of the PTP by high light doses, an effect
mediated in part at least by oxidation of regulatory thiols on the outer
surface of the IMM (Fig. 5D).
TSPO thus fulfills a dual role in PTP modulation (i) as a transport
protein for PTP-active compounds that are transferred to their PTP
regulatory site(s) in the IMM or in the matrix and (ii) as a PTP
regulatory protein when it binds its selective ligands like porphyrins.
TSPO belongs to a family of ubiquitous proteins conserved from
bacteria to mammals that bind small drugs, cholesterol, and
porphyrins [79]. Consistent with its role in steroid hormone synthesis,
in mammals TSPO is highly expressed in the adrenal cortex [137,138],
and its inactivation induces an early embryonic-lethal phenotype in
the mouse [139]. Establishing a role for TSPO in PTP modulation,
which was also made possible by the unique features of the
photodynamic effect, holds great promise for our continuing studies
on the nature of the PTP, and on the development of drugs that can
modulate its probability of opening.
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ABSTRACT: A prominent feature of successful photodynamic therapy (PDT) is the targeting of 
mitochondria, because these organelles are critical sites for initiating both necrotic and apoptotic cell 
death. Among the variety of structures identified as targets for PDT, the outer membrane (OMM)-
bound translocator protein, TSPO (formerly known as the peripheral benzodiazepine receptor), is of 
particular interest because it binds photosensitizers such as dicarboxylic porphyrins with nanomo-
lar affinity and it is present at elevated levels in cancer cells. TSPO has also been postulated to be 
a component of the mitochondrial permeability transition (PT) pore (PTP), a protein channel that 
opens in the inner membrane (IMM) under the action of various stimuli, mainly matrix Ca2+ over-
load and oxidative stress, leading the cell toward death. In this study, photooxidation experiments 
with porphyrins indicated a strict correlation between porphyrin affinity for TSPO and the extent 
of mitochondrial photosensitization; moreover, they revealed a dual role of TSPO: (1) as a transport 
protein that facilitates diffusion of porphyrins into IMM, and (2) as a PTP regulatory protein when 
it binds porphyrins at its selective sites. Only photoactivation of TSPO-bound porphyrins leads to the 
opening of the PTP and mitochondrial dysfunction, whereas photoactivation of IMM-bound porphyrins 
maintains the PTP in the closed state.
Key woRdS: mitochondria, mitoplasts, porphyrins, TSPO, photooxidative stress
ABBREVIATIONS
ANT: adenine nucleotide translocase; CP: coproporphyrin III; CyP-d: cyclophilin D; dP: deu-
teroporphyrin IX; eGTA: [ethylenebis(oxoethyleneni-trilo)] tetraacetic acid; eP: etioporphyrin; 
FGIN1-27: N,N-dihexyl-2-(4-fluorophenyl) indole-3-acetamide; HP: hematoporphyrin IX; IMM: 
inner mitochondrial membrane; MoPS: 4-morpholinepropanesulfonic acid; 1o2: singlet oxygen; 
oMM: outer mitochondrial membrane; PdT: photodynamic therapy; PK11195: 1-(2-chlorophenyl)-
N-methyl-N-(1-methyl-propyl)-3-isoquinolinecarboxamide; PP: protoporphyrin IX; PT: permeability 
transition; PTP: permeability transition pore; Ro5-4864: 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-
1-methyl-2H-1,4-benzodiazepin-2-one; RoS: reactive oxygen species; TSPo: 18 kDa translocator 
protein; UP: uroporphyrin I; VdAC: voltage-dependent anion channel
Šileikytė et al.216
Forum on Immunopathological Diseases and Therapeutics
I. INTRODUCTION
Mitochondria have a major role in various 
aspects of cell metabolism, particularly in 
energy production and maintenance of calcium 
homeostasis. The continuous growth of tumor 
cells is highly energy dependent, so disruption 
of mitochondrial function could be a significant 
therapeutic target.1 Many photosensitizers 
used in PDT can rapidly induce apoptosis. 
Works elucidating apoptotic mechanisms of 
various cytotoxic agents have revealed that 
many of the triggers converge on mitochon-
drial events that lead to downstream effector 
pathways, such as activation of the caspase 
cascade, culminating in apoptotic death.2 A 
major mechanism responsible for these events 
is the opening of the permeability transition 
(PT) pore (PTP) in the inner mitochondrial 
membrane (IMM). PTP opening causes a sud-
den increase in the permeability of the IMM 
to solutes with molecular mass less than 1.5 
kDa and is mainly induced by matrix calcium 
overload and oxidative stress. Under the con-
ditions used in most in vitro studies, PT is 
accompanied by depolarization, matrix swell-
ing, Ca2+ efflux, depletion of matrix pyridine 
nucleotides (PN), outer membrane (OMM) 
rupture, and release of intermembrane pro-
teins, including cytochrome c, Smac/DIABLO, 
and apoptosis inducing factor (AIF).3–7 
The molecular composition of the PTP 
remains elusive. In the classical view, the 
pore frame was thought to be formed by a 
complex comprising the adenine nucleotide 
translocase (ANT; a component of the IMM), 
the voltage dependent anion channel (VDAC; 
the most abundant protein in the OMM) , 
the cyclophilin D (CyP-D; a component of 
the matrix) and located at the contact sites 
between IMM and OMM (Figure 1A).8–10 The 
OMM translocator protein, TSPO (previously 
known as the peripheral benzodiazepine 
receptor-PBR),11,12 was also included in the 
PTP structure by some investigators.13,14 
This PTP model was recently abandoned for 
two reasons: (1) the PT can still occur in the 
mitochondria of mice in which ANT, VDAC, 
and CyP-D have been genetically ablated or 
silenced,15–17 and (2) the PT can occur in the 
absence of an intact OMM (in mitoplasts).18 
In the current view, the PTP is considered an 
IMM event and the elements comprising its 
structure remain unidentified but are prob-
ably regulated by ANT, VDAC, and CyP-D 
(Figure 1B). The role of TSPO in the PT, as 
well as of other putative regulatory proteins, 
remains an open question. 
Involvement of TSPO in PTP function 
was initially suggested following the activ-
ity of TSPO-specific ligands, notably the 
benzodiazepine, Ro5-4864, the isoquinoline 
carboxamide, PK11195, the indole derivative 
FGIN1-27 and the endogeneous ligand proto-
porphyrin (PP), which were shown to promote 
the PT in isolated mitochondria and apoptosis 
in a variety of cells. Other studies, however, 
have shown that TSPO ligands, particularly in 
combination with other pathological stimuli, 
inhibit, rather than promote, the PT and apop-
tosis.5,13,14 To circumvent these contradictions, 
we explored the regulatory properties of TSPO 
on PTP function using a novel methodology. 
This approach takes advantage of the ability of 
some PP-like porphyrins, such as hematopor-
phyrin (HP), deuteroporphyrin (DP), as well as 
PP itself, to bind to TSPO with high affinity 
(nanomolar range) and to produce reactive 
oxygen species [ROSs, mainly singlet oxygen 
(1O2)] upon irradiation with UV/visible light. 
The 1O2 transient photogenerated in situ can 
easily oxidize electron-rich protein targets, 
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provided that the substrate and the sensitizer 
are situated in close proximity. Interestingly, 
two of the targets readily oxidized by 1O2, Cys, 
and His have been shown to have a critical 
role in regulation of the PT.19,20
In our studies, we also aimed to define 
whether and how TSPO regulates porphyrin-
induced mitochondrial phototoxicity. Actually, 
the affinity of several porphyrins for TSPO 
and the high amount of TSPO in tumor cells 
suggest that binding of sensitizers to this site 
may be important for cell killing. 
II. MATERIAL AND METHODS
II.A. Reagents 
Hematoporphyrin IX (HP), protoporphyrin 
IX (PP), deuteroporphyrin IX (DP), copropor-
phyrin III (CP) and uroporphyrin I (UP) were 
obtained from Frontier Scientific (Logan, UT), 
and stock solutions were prepared in dimeth-
ylsulfoxide. N,N-dihexyl-2-(4-fluorophenyl) 
indole-3-acetamide (FGIN1-27), digitonin and 
etioporphyrin I (EP) were from Sigma-Aldrich. 
Calcium Green-5N was from Invitrogen. All 
chemicals were of the highest purity com-
mercially available.
II.B. Preparation of Mitochondria and 
Mitoplasts 
Liver mitochondria from Wistar rats were 
prepared by standard differential centrifu-
gation. The final pellet was suspended in a 
medium containing 250 mM sucrose, 0.5 mM 
EGTA-Tris, and 10 mM Tris-HCl pH 7.4 (iso-
lation buffer), and the protein concentration 
FIGURE 1. Proposed PTP complex architecture. (A) Classical model. The pore structure 
is formed by the VDAC–ANT–CyP-D complex, which is located at the contact sites 
between IMM and OMM. TSPO is included as a putative regulatory component. Other 
putative regulators (hexokinase II, creatine kinase , and Bcl-2-family members -Bcl-2, 
Bcl-xL and Bax) are not shown. (B) Current model. ANT, VDAC and CyP-D are no 
longer seen as pore components based on recent genetic evidence and studies on 
mitoplasts. The elements comprising the PTP itself (exclusively located in the IMM) 
are presently unidentified, but they are probably regulated by the adjacent elements 
as indicated.
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was determined using the biuret method. 
Mitoplasts were prepared by treating mito-
chondrial suspensions with proper amounts 
of digitonin, as described by Šileikytė et al.18
II.C. Permeability Transition 
PT was induced at 25°C in a medium contain-
ing 250 mM sucrose, 10 mM Tris-Mops, 5 mM 
succinate, 1 mM Pi-Tris, 10 µM EGTA-Tris, 
0.5 µg/ml oligomycin, and 2 µM rotenone, pH 
7.4 (standard medium). PT-related osmotic 
swelling was measured by the decrease in 
90° light scattering at 540 nm, measured 
with a Perkin-Elmer LS50 spectrofluorometer. 
PT-related Ca2+ efflux was measured in the 
same medium supplemented with 0.5 μM of 
the fluorescent, membrane-impermeant Ca2+-
indicator, calcium green-5N (excitation 480 
nm and emission 530 nm). In all experimental 
conditions, occurrence of the PT was verified 
by the desensitizing effect of cyclosporin A.18
II.D. Porphyrin-Based Photosensitization 
of Mitochondria and Mitoplasts 
Porphyrin-mediated photosensitization of 
mitochondria and mitoplasts was achieved as 
described by Šileikytė et al.18 and Petronilli et 
al.21 Briefly, preparations were incubated for 
1–2 min in the dark with the desired concen-
tration of porphyrin and then irradiated at 
365 nm in a thermostated glass reaction ves-
sel with a Philips HPW 125W lamp (Philips, 
Eindhoven, The Netherlands). The fluence rate 
of the preparations (40 W/m2) was measured 
using a calibrated quantum-photo-radiometer 
(Delta OHM HD 9021). All irradiations were 
performed at 25°C under magnetic stirring. 
Proper controls were conducted to verify that 
neither incubation with the photosensitizer in 
the dark nor illumination in the absence of 
porphyrin produced any appreciable changes 
in the parameters under study. Photooxidation 
experiments were performed in a range of 
concentrations of 0.2–1.8 nmoles of porphyrin 
taken up per milligram protein. Under 
these conditions, porphyrins were bound to 
mitochondria and mitoplasts as monomers, 
the only species appreciably photoactive; 
moreover, they did not induce detrimental 
effects on the organelles in the dark. In 
addition, we determined that the molar 
absorptivities at the irradiation wavelength 
used (365 nm) were very similar (within 10%) 
for all porphyrins, which reflects an equivalent 
number of photons absorbed (data not 
shown). Thus, for comparative investigations 
the sensitizer concentrations were properly 
adjusted to obtain an equivalent amount of 
dyes effectively taken up by the organelles, 
which ensured a similar photosensitizing 
effectiveness upon irradiation. Determina-
tions of porphyrin uptake were performed as 
described previously.18
III. RESULTS AND DISCUSSION 
III.A. Photooxidation of PTP-Regulating His 
and Cys in Mitochondria
PTP opening is strongly promoted by an 
oxidized state of critical Cys at discrete sites 
of the IMM. So far, at least two sites have 
been identified as being involved in the PT 
process. The first site resides in internal, 
matrix-exposed regions of IMM (internal 
Cys) and is in close structural and functional 
correlation with critical His, whereas the 
second site is located on the outer surface 
of the IMM (external Cys) (see scheme in 
Figure 2).18 
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FIGURE 2. Distribution of critical His and Cys in the PTP. A group of Cys is located 
in matrix-exposed regions of the IMM (internal Cys), in close structural and functional 
correlation with critical His; another group of Cys is located on the outer surface 
of the IMM (external Cys). Opening of the PTP by oxidative stress is mainly due to 
modifications of one or both Cys sites.
In sharp contrast with other activated 
oxygen species such as H2O2 or superox-
ide, porphyrin-photogenerated 1O2 does not 
induce the PT, which follows Cys oxidation, 
when relatively low doses of light are used. 
Rather, photodynamic action leads to sup-
pression of the PT.19 As shown in Figure 3, 
photoactivation of HP at increasing irradia-
tion times induces a gradual decrease of the 
rate of Ca2+-triggered membrane permeabili-
zation until IMM becomes fully impermeable 
to external solutes. Irradiation for times 
longer than 45 s, however, counteracts the 
inhibitory effect and reactivates the PTP. 
The peculiar effects of porphyrin-based pho-
tooxidative stress on the PT can be easily 
explained by the fact that photodamage is 
restricted to sites that are in close proxim-
ity to the photosensitizer.20 Therefore, the 
properties of the region surrounding the 
photosensitizer binding site may be criti-
cal in determining the molecular events 
involved in the PT. The inactivating 
effect can be traced back to critical His 
(the most photovulnerable target), whose 
photomodification by vicinal HP causes 
a drop in reactivity of internal, PTP-
regulating Cys, thus stabilizing the pore 
in a closed conformation.21 On the other 
hand, photooxidation of external Cys (the 
most photoresistant target) promoted by 
vicinal HP reactivates the PTP after the 
block caused by His photodegradation 
(see Petronilli et akl.21). The processes of 
PTP inhibition and/or reactivation are 
specific to porphyrins characterized by 
a PP-like configuration that bind TSPO 
with nanomolar affinity such as HP, PP, 
and DP. Interestingly, their potencies 
in eliciting both PT-photoinhibition and 
PT-photoreactivation strictly match the 
affinities for the OMM-TSPO (Table 1).
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TABLE 1. Relationship Between Porphyrin Photosensitizing Effects and TSPO Affinity
 Porphyrin Light dose (J/cm2) Light dose (J/cm2) TSPO Ki 
  for PT inhibitiona  for PT reactivationb  (nM)c
 PP 0.05±0.01 0.12± 0.03 14.5 ± 10.7
 DP 0.07±0.005 0.15±0.02 31.3 ± 2
 HP 0.18±0.01 0.35±0.05 500.0 ±151
aMinimal dose of light required to obtain full PT inhibition and bminimal dose of light required to start PT reactiva-
tion for 1.8 nmol porphyrin taken up per milligram mitochondrial protein; cKi is the value of the constant displayed 
by each porphyrin for inhibition of binding of PK11195, a classical ligand of TSPO.28
FIGURE 3. Mitochondrial PT inhibition and reactivation at increasing irradiation times 
in HP-loaded mitochondria. Mitochondria (0.5 mg/ml) labelled with 3 μM HP (corre-
sponding to 1.8 nmol HP taken up/mg protein) (m+HP) were incubated for 2 min at 
25°C in the standard medium. Irradiation (hν) was performed for the indicated periods 
of time at a fluence rate of 40 W/m2. PT was triggered by 80 μM Ca2+. PT-induced 
matrix swelling was followed as the decrease of 90° light scattering at 540 nm.
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PP-unrelated porphyrins (such as the 
tetracarboxylic coproporphyrin III (CP), the 
octacarboxylic uroporphyrin I (UP) and etio-
porphyrin I (EP) that lacks carboxylic groups), 
which exhibit negligible affinity for TSPO, 
are ineffective on the PT (data not shown).
III.B. Photooxidation of PTP-Regulating 
His and Cys in Mitoplasts
The photodynamic events observed in mito-
chondria using PP-like porphyrins as sensitiz-
ers were only partly retained in mitoplasts, 
which lacked OMM-bound TSPO. Irradia-
tion of porphyrin-loaded mitoplasts with low 
doses of light caused inactivation of the PTP, 
although mitoplasts were significantly more 
resistant to photosensitization than mitochon-
dria. As shown in Figure 4, which shows the 
results obtained with HP, higher doses of light 
were required to inhibit the PT in mitoplasts, 
compared to mitochondria. Also DP and PP 
were more effective in mitochondria than in 
mitoplasts (data not shown), suggesting that 
TSPO facilitates the diffusion of PTP-active 
porphyrins to the “internal” PTP regulatory 
sites.
Unlike mitochondria, pore reactivation by 
high light doses in mitoplasts treated with 
PP-like porphyrins were not observed (data 
not shown). Therefore, PTP reactivation is 
a specific event mediated by the OMM, and 
importantly, PTP regulatory, porphyrin-
binding sites are contributed by TSPO.
III.C. Photooxidation of Mitochondria in 
the Presence of Porphyrin Competitive, 
TSPO-Ligands
To further prove the role of TSPO on the 
PTP-related photooxidative events, we tested 
whether the presence of other TSPO ligands 
could influence porphyrin photoactivity 
in mitochondria. As shown in Figure 5 B, 
porphyrin-mediated PTP photoactivation 
(at high light doses) was suppressed by low 
concentrations of the high affinity, porphyrin 
competitive, TSPO ligand FGIN1-27, indicat-
ing that FGIN1-27 protects external cysteines 
from being converted to cystines. Probably, 
competition with other ligands displaces 
porphyrins from their selective binding sites 
on TSPO. Specific involvement of TSPO in 
FGIN1-27 effects was demonstrated by the 
fact that this ligand did not partition into PTP 
sites; actually, it neither interfered with the 
process of PT inhibition (Figure 5A), which 
involves “internal” PTP domains, nor modified 
the reactivity of external Cys in mitoplasts 
(data not shown).
III.D. Effects of TSPO Ligands on the 
Mitochondrial and Mitoplast PT in the 
Dark
At the concentrations we used in our pho-
tooxidation experiments, TSPO ligands did 
not affect the PTP in the dark. At relatively 
high concentrations, however, several TSPO 
ligands were potent inducers of the PT per 
se.22–26 In the experiments shown in Figure 6, 
we tested the effect of PP on the PT-related 
Ca2+ release in Ca2+-loaded mitochondria 
and mitoplasts. Doses of PP higher than 
2 nmol/mg protein caused PTP opening in 
mitochondria but not in mitoplasts. A full 
titration conducted with other compounds 
that bind to TSPO with nanomolar affinity, 
including FGIN1-27, Ro-4864, and PK11195, 
confirmed the striking resistance of mito-
plasts to the PTP-inducing effects of TSPO 
ligands (see Šileikytė et al.18). In the absence 
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FIGURE 4. PT inhibition in mitochondria and mitoplasts loaded with HP. Mitochondria (Mc) 
and mitoplasts (Mp) at 0.5 mg/ml were incubated for 2 min with a concentration of HP 
(2 μM), giving a loading of 1.2 nmol/mg of protein at 25°C. Preparations were irradiated 
for the indicated times at a fluence rate of 40 W/m2 and then supplemented with 60 μM 
(Mc) or 30 μM (Mp) Ca2+ to trigger the PT, which was followed by the changes in 90° light 
scattering at 540 nm. The permeabilization rate was normalized to that of the control (in 
the absence of porphyrins). Error bars represent the mean ± S.D. of the three experiments.
of a clear PT inducer (such as the oxidant 
1O2) in the dark, we postulate that TSPO 
in its liganded state can regulate the PTP 
activity per se, likely through conformational 
changes of specific domains closely associ-
ated with the pore.
IV. CONCLUSIONS
TSPO is an 18-kDa OMM protein highly 
conserved throughout evolution, from bac-
teria to humans. It is involved in a variety 
of biological functions such as apoptosis, cell 
proliferation, mitochondrial respiration, isch-
emia, microglial activation, immune response, 
and steroidogenesis (transport of cholesterol). 
Consistent with this latter function, TSPO is 
particularly present (up to 20- to 50-fold) in 
tissues in which steroids are synthesized.11–13 
In addition, TSPO mediates mitochondrial 
uptake of naturally occurring dicarboxylic por-
phyrins such as protoporphyrin IX (PP), other 
heme precursors, as well as heme itself.26,27
Our results provide evidence for the 
involvement of TSPO in PTP opening as well. 
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TSPO plays a dual role in PTP modulation 
(1) as a transport protein for PTP-active 
compounds that are transferred to their PTP 
regulatory site(s) in the IMM or in the matrix 
and (2) as a PTP regulatory protein when it 
binds its selective ligands like porphyrins. 
These modes of action of TSPO result in 
modulation of porphyrin phototoxicity on 
PT-related mitochondrial dysfunction. Actu-
ally, porphyrin-based photodynamic effects 
can either inhibit (by porphyrin channeled 
to internal domains by TSPO) or, oppositely, 
open (by porphyrin bound to TSPO) the PTP. 
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FIGURE 5. Effects of FGIN1-27 on PT inhibition (A) and PT reactivation (B) in HP-loaded 
mitochondria. A. The experiments were performed as described in Figure 4, except that an 
HP loading of 1.8 nmol/mg of protein was used; FGIN1-27 was added after HP at 5 μM 
concentration; B. HP-labelled mitochondria were supplemented with 5 μM Ca2+ (a concen-
tration not sufficient to induce PTP opening per se), then irradiated for the indicates times 
at 40 W/m2 to activate the PT. The permeabilization rates are expressed as the changes 
of light scattering intensity at 540 nm (Δls) per min.
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2.3. Characterization of PTP in TSPO-null liver 
mitochondria 
 
As also mentioned before, TSPO was attributed a variety of biological functions including 
taking part (or at least regulating) the mitochondrial PTP. As the initial attempts to generate 
TSPO-null animals led to early embryonic death, the “golden standard” in the field has been 
the use of high affinity TSPO ligands, such as PP IX, PK11195 and Ro5-4864. On this basis 
the involvement of TSPO in PT was suggested by others [214, 216, 217] and was also 
supported by our own results (see Papers 1, 2 and 3). We have shown that all of these 
compounds can activate the PT in a CsA-sensitive manner in isolated rat liver mitochondria, 
but not mitoplasts.  
In order to investigate the role of TSPO in PTP regulation directly, in collaboration with Dr. 
M. Forte (Vollum Institute, Portland, Oregon) we created a mouse line in which the Tspo 
gene could be conditionally inactivated. We characterized TSPO-null mitochondria from 
these mice and showed that: (i) isolated TSPO-null liver mitochondria possess a CsA-
sensitive PTP, ruling out that TSPO is required for the PT to occur; (ii) TSPO ligands PP IX, 
PK11195 and Ro5-4864 induced the PT in isolated liver mitochondria lacking TSPO with the 
same concentration-dependence as they did in littermate controls; and (iii) upon 
photooxidative stress in mitochondria treated with PP IX (high light dose) PT was also 
induced in TSPO-null mitochondria. The latter findings are the first unequivocal 
demonstration that the ability of ‘specific’ TSPO ligands to regulate PTP is due to off-target 
effects.  
The details of this study, which is being submitted for publication (Šileikytė J et al.), are 
reported in the following sections.  
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2.3.1. Materials and methods  
2.3.1.1. Reagents 
PP IX, DP IX and HP IX were obtained from Frontier Scientific (Logan, UT) and stock 
solutions were prepared in dimethylsulfoxide. Cu(OP)2 was prepared just before use by 
mixing CuSO4 with o-phenanthroline at a molar ratio of 1:2 in bidistilled water. PK11195, 
Ro5-4864, PhAsO, oligonucleotides and all generic reagents were from Sigma-Aldrich. 
Calcium Green-5N was from Invitrogen. [3H]PK11195 (85.7 Ci/mmol) and Ultima Gold 
scintillation cocktail were from Perkin Elmer. Genomic mouse DNA was isolated with 
DNeasy Blood and Tissue Kit from QIAGEN, Finnzymes 2X Phusion HF master mix was used 
for PCR. Nitrocellulose membrane was from GE Healthcare, Enhanced chemiluminencence 
kit – from Millipore.  
All chemicals were of the highest purity commercially available. 
 
2.3.1.2. Generation of TSPO-null mouse livers 
In the mouse genome, the TSPO is encoded by the nuclear Tspo gene, located on 
Chromosome 15. Initial attempts to generate animals lacking expression of the TSPO have 
indicated that non-conditional elimination of TSPO expression results in embryonic 
lethality. Consequently, our group (led by Dr. M. Forte Vollum Institute, Portland, Oregon) 
used Cre/loxP site-specific recombination system to conditionally eliminate Tspo gene in the 
mouse liver. 
 
2.3.1.2.1. Cre-loxP recombination system 
Routinely, the Cre/loxP site-specific recombination has proven to be a powerful tool to 
achieve tissue-specific manipulations of genes in mice. It was discovered in P1 
bacteriophage as part of this organism's normal viral live cycle [227, 228]. The 
bacteriophage uses Cre/loxP recombination to circularize and facilitate replication of its 
genomic DNA when reproducing. The system requires only two components: 
1) Cre recombinase, a 38 kDa enzyme that catalyzes the recombination  between two 
its recognition sites, called loxP sites;  
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2) LoxP (locus of X-over P1) sites, which are bacteriophage specific 34 bp sequences. 
They consist of an 8 bp core sequence, where recombination takes place, and two 
flanking 13 bp inverted repeats [229]. (Figure 6 )  
 
 
Figure 6. The 34 bp loxP sequence. 
 
 
 
2.3.1.2.2. Modification of mouse Tspo locus 
In order to generate Tspo replacement gene for the use of the Cre/loxP conditional gene 
elimination strategies, bacterial artificial chromosome (BAC) clones containing the Tspo 
gene on Chrm-15 from C57Bl/6J mice (C57) were obtained from libraries maintained by the 
Children’s Hospital Oakland Research Institute (clone number RP23-121MC). 
The Tspo gene (Figure 7A) spans 4 exons (exon1 is a non-translated exon) and encompasses 
10.6 kB of genomic DNA. Subclones containing Tspo protein coding exons  were modified in 
two ways:  
1) the insertion of loxP sites in intronic sequence flanking exons 2 and 3, resulting in the 
elimination of residues encoding the translational start site through amino acid 124 on Cre-
mediated recombination and  
2) the addition of the neo gene (that renders cells resistant to antibiotic G418) between loxP 
sites and flanked by flippase recognition target (FRT) sites that are recognized by the FRT 
recombinase (FLP) from yeast [230-232] (Figure 7B, C).  
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Figure 7. Mouse Tspo locus and modifications. 
A, map of the mouse Tspo locus. E1-E4 indicate exons 1-4; E1 is a non-coding exon. 
B, modified Tspo DNA construct used to transfect ES cells. Neo is the neomycin resistance gene; FRT, 
FLP recombination sites; loxP, Cre recombination sites. 
C, mouse Tspo locus after recombination with construct B. 
D, Tspo locus as in C, but after recombination at FRT sites to remove the neo gene. 
 
 
2.3.1.2.3. Generation of mice in which the Tspo gene contains loxP sites  
To generate mice in which the expression of TSPO has been eliminated, C57 ES cells were 
cultured using standard conditions, transfected by electroporation with the targeting 
construct described in Figure 7B, transfectants selected with appropriate antibiotic (G418), 
and candidate ES cells screened for replacement of the endogenous Tspo gene with the 
targeting construct by PCR analysis and Southern blotting. Five candidate ES cell lines were 
identified, injected into C57 MF-1 blastocysts (an albino variant of black C57) and evaluated 
for the ability to generate chimeric offspring (black coat color on a normally white 
background). Of the five ES cell lines identified, two were able to successfully generate 
chimeric offspring (≥95% black). Male chimeras were subsequently mated with C57 female 
mice and all offspring evaluated for germ line transmission. Several of the males from two 
targeted ES cell lines were able to pass the modified Tspo gene to progeny. 
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F1 heterozygotes carrying the targeted allele were mated to mice expressing the FLP1 
recombinase from yeast driven by the Gt(ROSA)26Sor promoter. In this “deletor strain”, 
FLP1 recombinase is constitutively expressed from pre-implantation onward resulting in 
progeny in which the neo gene used for selection of ES cells containing modified Tspo genes 
has been eliminated. The progeny was tested for the elimination of the neo gene by PCR 
analysis of genomic DNA (final gene shown in Figure 7D) and homozygotes for the Tspo 
containing loxP sites were established.  
 
 
  
Figure 8. Generation of mice in which the Tspo gene was inactivated only in livers.  
Simplified version, for details see the text. 
Tspofl/fl – mouse lines homozygous for the Tspo gene containing loxP sites. 
Cre+/0 – mouse lines heterozygous for the Cre recombinase driven by Albumin promoter. 
KO – the progeny that acquired both of the above mentioned constructs, Floxed – the ones that 
express only Tspo gene containing loxP sites, but no Cre recombinase.  
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Finally, the above mentioned mice were mated to mice heterozygous for Cre recombinase 
driven by hepatocyte specific albumin (Alb) promoter. The offspring that were positive for 
Cre were then mated to each other to establish lines that were Cre positive and homozygous 
for a Tspo gene containing flanking loxP sites. Lastly, the latter were mated to each other or 
to homozygotes carrying only modified Tspo allele and the progeny that had an Alb-Cre 
recombinase expressed, had an inactivated Tspo in hepatocytes (thus generating TSPO-null 
liver) while retaining normal gene function in all other types of cells, and are called ‘KO’ 
throughout this Thesis, while their littermates that contain only the modified Tspo gene, but 
no Cre, are called ‘floxed’ (Figure 8). 
 
2.3.1.3. Mice genotyping 
In order to distinguish the TSPO KO mice from their littermate controls the mice were 
genotyped by the polymerase chain reaction (PCR).  
Briefly, the pups were numbered and tailed at weaning and their genomic DNA was 
extracted with DNeasy Blood and Tissue Kit from QIAGEN according to manufacturer’s 
instructions. Afterwards, the PCRs for the Tspo containing loxP sites (TSPO) and Cre 
recombinase (Cre) were performed. Each PCR reaction tube contained in Table 2 reported 
components. The sequences of the primers used are indicated in Table 3.  The PCR reaction 
mixtures were loaded into thermocycler (Bio-rad) and cycling programs denoted in Table 4 
were run. PCR products were analyzed by electrophoresis on a Syber Safe stained 1% 
agarose gel, followed by visualization under UV light with the ChemiDoc XRS System (Bio-
Rad).  
  
Table 2. Composition of the PCR reaction mixture.  
Component Volume (µl) Final concentration 
2X Phusion HF Master mix 12.5 1X 
Working Primer mix* 11.5 1 µM each  
DNA 11  
*Working Primer mix contained 2.17 µM of both Forward and Reverse primers. 
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Table 3. The list of primers used in PCR. Fwd – forward, Rev – reverse. 
Primer name Sequence (5’-3’) 
TSPO Fwd ACCCAGAGTTTGCCAATTGC 
TSPO Rev CTCTGGGCTGAAATCAAGAC 
Cre Fwd GCGTCTGGCAGTAAAAACTATC 
Cre Rev GTGAAACAGCATTGCTGTCACTT 
 
  
Table 4. Cycling programs used to amplify Tspo gene region containing loxP sites (TSPO) and a 
part of Cre recombinase DNA (Cre).  
 TSPO Cre 
Cycle step Temp °C Time Cycle Temp °C Time Cycle 
Denaturation  96 2 min - 94 3 min - 
Denaturation 96 1min  94 30 sec  
Annealing 55 45 sec 34 51.7 1 min 35 
Extention 72 1 min  72.1 1 min  
Final Anneling 72 2 min - 72 2 min - 
 
 
2.3.1.4. Isolation of mitochondria 
TSPO-null and floxed mouse liver mitochondria were prepared by standard differential 
centrifugation. Livers were removed and placed in a glass beaker containing ice-cold 0.25 M 
sucrose, 10 mM Tris-HCl pH 7.4, 0.1 mM EGTA-Tris buffer (Isolation buffer -IB-) 
supplemented with a small amount of Bovine serum albumin.  
Livers were then cut into small pieces with scissors, rinsed with ice-cold IB (to remove as 
much blood as possible) and passed through a pre-chilled Potter homogenizer with theflon 
pestle. The homogenate (~ 60 ml) per liver was transferred to 2 Beckman F0650 rotor 
centrifuge tubes. Unbroken cells and nuclei were removed by centrifugation at 2700 RPM 
(685 g) for 10 minutes in a refrigerated Beckman Allegra-64R centrifuge at 4°C. The 
supernatant containing mitochondria and other organelles was transferred to new tubes 
and centrifuged at 8000 RPM (6010 g) for 10 minutes at the same temperature. The 
resulting supernatant was discarded, mitochondrial pellet carefully suspended in ice-cold IB 
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buffer and spun at 10000 RPM (9390 g) for 5 minutes at 4°C. The mitochondrial pellet was 
suspended in IB to give a protein concentration of about 60-80 mg/ml and stored on ice.  
 
2.3.1.4.1. Protein determination by Biuret method 
Mitochondrial protein concentration was determined by Biuret method as follows: 20 µl of 
mitochondria (sample; omitted for the reference) were suspended in 1 ml of H2O + 0.5 ml of 
1% deoxycholic acid + 1.5 ml of Biuret reagent [233]. Both solutions were put in a 
thermostated bath (100 °C) for 1 minute and then cooled with cold water. Next, the 
absorbance of the sample solution was read at 540 nm and the total protein concentration 
was determined using standard calibration curve. 
 
2.3.1.5. Western blotting 
Mitochondrial proteins were solubilized in loading buffer (2 % SDS, 50 mM Tris-HCl, pH 6.8, 
10% glycerol, 2,5% β-mercaptoethanol, 0.002% bromphenol blue), boiled for 5 min and 
separated by 15% SDS-PAGE. The proteins were then electrophoretically transferred to 
nitrocellulose membrane (GE Healthcare) using a Mini Trans-Blot system (Bio-Rad). 
To minimize the non specific binding, the membrane was blocked with TBST (10 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 0.01% Tween 20) buffer containing 5% nonfat dry milk at room 
temperature for 1 h, followed by an overnight incubation with an anti-TSPO (a generous gift 
of Dr. V. Papadopoulos) or monoclonal anti-ANT (MitoSciences) antibody. The membrane 
was then washed in TBST and subjected to 1 h incubation with appropriate secondary 
antibody conjugated to horseradish peroxidase. The membrane was washed again in TBST 
buffer and immunoreactive bands were detected by enhanced chemiluminescence 
(Millipore). 
 
2.3.1.6. Radioligand binding assay  
The presence of the TSPO in mitochondrial membranes was assayed by the use of 
[3H]PK11195 (85.7 Ci/mmol), a specific TSPO ligand [203]. Liver mitochondria were 
isolated as described in paragraph 2.3.1.4 and mitochondrial protein was adjusted to 
0.1 mg/ml in Tris buffer (50 mM Tris-HCl, pH 7.4, 4°C) to a final assay volume of 200 µl. The 
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suspensions were incubated with 0.05-9.6 nM radioligand or 10 µM PK11195 (for 
background correction) for 60 min at 4°C. Assays were terminated by the rapid vacuum 
filtration though Whatman GF/C glass microfiber filters. The filters were immediately 
washed first with 1 ml of 10 µM PK11195 in Tris buffer (in order to wash-out filter bound 
radioligand), then with additional 15 ml of ice cold 50 mM Tris-HCl, pH 7.4. Subsequently 
the membranes were dried, placed in 5ml of liquid scintillation counting cocktail Ultima 
gold (Perkin Elmer), vortexed and assayed for 3H using Packard Tri-Carb 1500 Liquid 
Scintillation Analyzer.  
 
2.3.1.7. Measurement of mitochondrial respiration 
Experiments were initiated by the addition of 2 ml of Assay buffer (250 mM sucrose, 10 mM 
MOPS-Tris, 10 µM EGTA-Tris, 5 mM succinate-Tris, 1 mM Pi-Tris and 1 µM rotenone, pH7.4) 
to the chamber. When the recorded trace was stable, an aliquot of mitochondrial suspension 
to give a final concentration of 1.0 mg/ml was added. The chamber was then sealed with a 
frosted glass stopper and further additions were made through a small syringe port in the 
stopper. Basal mitochondrial respiration (analogous to respiratory state 4, as described by 
Chance and Williams [234]) was measured, followed by the addition of 0.3 mM ADP, which 
allowed to measure state 3 [234] respiration, and finally oligomycin (0.5 µg/ml) and 
carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP; 0.1 µM). The respiratory 
control ratio (RCR) was calculated as the ratio between ADP-stimulated and basal 
respiratory rates. All experiments were performed at 25 °C under magnetic stirring.  
 
2.3.1.8. Estimation of mitochondrial membrane potential 
Mitochondrial inner membrane potential (ΔΨ) was assessed with the potentiometric 
fluorescent probe Rhodamine 123 (Rh123, Figure 9) [235], a lipophilic cation, which readily 
equilibrates across the IMM and accumulates in the matrix of energized mitochondria 
because of the inside negative ΔΨ. The accumulation was shown to follow Nernst equation 
[236], and can be monitored because the probe concentrates in the matrix forming 
aggregates that cause a process of fluorescence quenching. 
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Figure 9. Structure of Rhodamine 123.  
 
Rh123 (λexcitation=503 nm, λemission=523 nm) fluorescence intensity changes were monitored 
with a PerkinElmer Life Sciences LS50 spectrofluorimeter: 2 ml of assay buffer (250 mM 
sucrose, 10 mM MOPS-Tris, 10 µM EGTA-Tris, 1 mM Pi-Tris and 1 µM rotenone) was 
supplemented with 0.3 µM Rh123, followed by the addition 0.5 mg/ml mitochondria, 5 mM 
succinate and 0.5 µM FCCP. All experiments were performed at 25 °C under magnetic 
stirring. 
 
2.3.1.9. Ca2+ retention capacity (CRC) test 
The Ca2+ retention capacity (CRC) is one of the most sensitive assays to assess the 
propensity of the PTP to open [58]. The test measures the amount of Ca2+ that mitochondria 
can accumulate and retain before the precipitous release that marks PTP opening.  
 
 
Figure 10. Structure of Calcium Green-5N. 
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Extramitochondrial Ca2+ fluxes were measured fluorimetrically using Calcium Green-5N 
(excitation-emission λ: 505-535 nm) (Figure 10), a low affinity membrane-impermeant 
probe which increases its fluorescence emission upon Ca2+ binding. Mitochondria (0.5 
mg/ml) were suspended in 2 ml of Assay buffer that also contained 0.5 µM Calcium Green-
5N and the suspension was subjected to train of Ca2+ pulses (typically 40 µM each). 
 
2.3.1.10. Permeability transition assessed on the osmotic swelling of 
mitochondria 
A classical approach to detect occurrence of the PT is to follow osmotic swelling of isolated 
mitochondria as measured by the decrease of light scattering at 540 nm. Indeed, the amount 
of light scattering (LS) by mitochondrial suspension depends on matrix volume [237], which 
increases during PT lowering the refraction index of the suspension. This results in a large 
decrease in LS, as measured at 90° a using Perkin Elmer Life Sciences LS50 
spectrofluorimeter equipped with magnetic stirring and thermostatic control. The 
experiments were performed at 25 °C in Assay buffer (see paragraph 2.3.1.7) supplemented 
with 0.5 mg/ml mitochondria. Permeabilization rates were calculated as the rate of change 
of LS immediately after addition of Ca2+. 
 
2.3.1.11. Photosensitization of mitochondria 
Mitochondria were suspended in Assay buffer, and porphyrins were added under gentle 
stirring at room temperature. After 5 min, the suspensions were centrifuged at 10,000 g for 
1 min. Supernatant was diluted 1:1 ratio with 2% SDS, pellet was suspended in 2% SDS and 
the OD of the suspensions at Soret band was registered. Porphyrin concentrations were 
determined by Lambert-Beer law based of the extinction coefficient of the porphyrins. 
Porphyrin-mediated photosensitization of mitochondria achieved as described previously 
[81]. Briefly, preparations were incubated for 1–2 min in the dark with the desired 
concentration of porphyrin and then irradiated at 365 nm with a Philips HPW 125-watt 
lamp. The fluence rate at the level of the preparations (56 W/m2) was measured with a 
calibrated quantum photo radiometer (Delta OHM HD9021). All irradiations were 
performed at 25 °C under magnetic stirring. 
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2.3.2. Results and Discussion 
 
As already mentioned, most studies on TSPO have been performed using high-affinity 
ligands, and only few of them were complemented by manipulation of TSPO expression. 
Many conclusions in the field of cell death have been undermined by the demonstration that 
similar effects of ‘TSPO ligands’ can be observed in cells where expression of TSPO has been 
suppressed [184, 225]. Thus, there is emerging evidence of TSPO-independent effects of 
‘TSPO ligands’. To directly investigate the role of TSPO in PTP, we created mice in which the 
protein was eliminated specifically in the livers. The mice were viable, developed normally 
and had no apparent phenotype, Figure 11A.  
PCR analysis of genomic DNA from Tspo+/+ (WT), Tspofl/fl (floxed) and Tspofl/fl Cre+/0 (KO) 
mice confirmed that: (i) neither loxP nor Cre is expressed in WT mice; (ii) only loxP is 
expressed in floxed mice; (iii) both of the constructs are expressed in KO mice (Figure 11B, 
upper panel). The TSPO protein levels were assessed by SDS-PAGE and subsequent western 
blotting. TSPO expression in Tspofl/fl animal liver mitochondria was not altered by the 
insertion of loxP sites, while TSPO was undetectable in Tspofl/fl Cre+/0 mice liver 
mitochondria; on the other hand, expression of ANT was identical in the three genotypes 
(Figure 11B, lower panel). Transmission electron microscopy (TEM) analysis revealed no 
obvious ultrastructural difference between floxed and KO mouse liver mitochondria. Both of 
them possessed a well defined OMM, finger-like cristae infoldings and an electron dense 
matrix (Figure 11C, D). 
TSPO ligands were demonstrated to increase state 4 and decrease state 3 respiration rates 
resulting in a decrease in respiratory control ratio (RCR) [240]. Thus, we wondered if the 
absence of TSPO had any effect on oxygen consumption rates. Mitochondria were isolated 
from floxed and KO mouse livers and assayed in sucrose-based medium (250 mM sucrose, 
10 mM MOPS-Tris, 10 µM EGTA-Tris, 1 mM Pi-Tris, pH7.4) supplemented with complex II 
substrate succinate-Tris (5 mM) and complex I inhibitor rotenone (1 µM). The KO 
mitochondria most often displayed slightly lower rates of basal, ADP- and uncoupler-
stimulated respiration compared with mitochondria isolated from floxed animal livers 
(results not shown); however, the difference in the RCRs were not significant (Figure 12A). 
Further, we measured mitochondrial membrane potential based on the changes in 
fluorescence quenching of Rh123. Both mitochondrial preparations readily developed ΔΨ 
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(~ -180 mV) upon addition of succinate; and ΔΨ could be abolished by the uncoupler FCCP 
(Figure 12). 
 
Figure 11. TSPO-null mice have no obvious phenotype. 
A, Tspofl/fl (Floxed) and Tspofl/fl Cre+/0 (KO) animals. B, upper panel: agarose gel electrophoresis of PCR 
amplification products of mice genomic DNA; T – primer set for Tspofl/fl, C – for Cre recombinase; 
lower panel: western blot analysis of mitochondria isolated from Tspo+/+ (WT), Floxed and KO mice 
livers. ANT antibody was used as a loading control. C and D, transmission electron microscopy of 
floxed and KO mice livers, bars: 500 nm. Panel D represents the 3X magnification of the areas boxed in 
panel C. 
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Figure 12. The absence of TSPO does not affect mitochondrial respiration and development of 
ΔΨ.  
A, respiratory control ratios, i.e. ratios between ADP-stimulated and basal oxygen consumption rates 
(OCR), of Tspofl/fl (Floxed) and Tspofl/fl Cre+/0 (KO) mitochondria. Error bars represent the mean ± S.D. 
of at least three independent experiments. B, typical traces of ΔΨ measurement of floxed and KO liver 
mitochondria. Additions were made as indicated in the graph.  
The OCR and ΔΨ were measured as described in Materials and Methods.  
 
 
We next tested the ability of TSPO-null mitochondria to undergo PT with the sensitive CRC 
test. KO mitochondria readily took up a train of Ca2+ pulses (Figure 13B, trace a) in a process 
that was sensitive to CsA (Figure 13B, trace b). The Ca2+ load required to trigger PTP 
opening, as well as the desensitizing effect of CsA, was indistinguishable from that of floxed 
mitochondria (Figure 13A) ruling out that TSPO is required for the PTP to occur.  
In order to investigate whether TSPO plays a regulatory role in the PT, we challenged floxed 
and KO mouse liver mitochondria with TSPO-ligands PK11195 (100 µM), Ro5-4864 (100 
µM) and PP IX (8 µM) (Figure 14 traces b, c and d, respectively) and tested their effect on the 
CRC. As expected, all of the compounds lowered the CRC of floxed liver mitochondria (Figure 
14A). Surprisingly, however, we observed exactly the same response of TSPO-null 
mitochondria to the inducing effects of PK11195, Ro5-4864 and PP IX (Figure 14B traces b, c 
and d, respectively), which could be prevented by 1 µM CsA (data not shown). 
 
R e s u l t s  a n d  d i s c u s s i o n | 85 
 
 
Figure 13. CRC of floxed and KO mouse liver mitochondria. 
Floxed (A) and KO (B) mouse liver mitochondria (0.5 mg/ml) were suspended in Assay buffer 
supplemented with 0.5 µM Calcium Green-5N, and loaded with a train of Ca2+ pulses, traces a. In 
traces b medium was supplemented with 1 µM CsA. Representative traces of at least five independent 
experiments.  
 
 
 
Figure 14. Effect of PK11195, Ro5-4864 and PP IX on floxed and KO mouse liver mitochondria 
CRC.  
Floxed (A) and KO (B) mouse liver mitochondria (0.5 mg/ml) were suspended in Assay buffer 
containing 0.5 µM Calcium Green-5N and loaded with a train of Ca2+ pulses, traces a. In traces b, c and 
d 100 µM PK11195, 100 µM Ro5-4864 and 8 µM PP IX, respectively, were added immediately prior to 
mitochondria. Representative traces of three independent experiments. 
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In isolated mitochondria PT can be modulated by photooxidative stress mediated by PP IX-
like dicarboxylic porphyrins. Low doses of light inactivate the PTP, while higher light doses 
activate it [81]. As already mentioned, pore activation occurs through the OMM, since 
(unlike PTP inactivation) in mitoplasts the PT cannot be triggered after prolonged 
irradiation. Since porphyrins are ligands of TSPO, we proposed that PT photoactivation 
occurs through TSPO [238]. To test this hypothesis, we assessed the PT (measured as a 
decrease of light scattered at 540 nm) in floxed and KO mouse liver mitochondria upon 
photooxidative stress. Liver mitochondria 
 
 
 
 
Figure 15. Effect of irradiation time in PP IX-treated floxed and KO mouse liver mitochondria.  
A, B, 0.5 mg/ml of PP IX-treated (0.5 µM) floxed (A) or KO (B) liver mitochondria were challenged 
with 220 µM Ca2+ (traces a); in traces b and c mitochondria were irradiated for the indicated time 
prior to Ca2+ addition. C, experiments were performed as in A and B, and permeabilization rates were 
normalized to those of non-irradiated mitochondria. A, B, represent typical traces, C, error bars mean 
± S.D. of three independent experiments.   
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from floxed (Figure 15A) or KO (Figure 15B) mice were incubated with 0.5 µM PP IX in 
Assay buffer in the dark; and PT was triggered with 220 µM Ca2+ (Figure 15A and B, traces 
a). Irradiation for short times expectedly [81, 238, 239] inhibited the PT in both genotypes 
(Figure 15A and B, traces b). The totally unexpected finding was that irradiation for longer 
times activated the PTP irrespective of the presence of TSPO (Figure 15A, B, traces c). When 
a full range of irradiation times was investigated, both inactivation and activation were 
somewhat shifted to the right, yet at striking variance from mitoplasts [238], activation did 
occur in TSPO-null mitochondria (Figure 15C). Since TSPO was implicated in porphyrin 
transport from OMM to IMM, we suspected that the difference might be explained by 
different amounts of porphyrin accumulated by the two types of mitochondria. This was not 
the case, as identical amounts of porphyrin were found in KO and in floxed mouse liver 
mitochondria. Furthermore, in both genotypes uptake was completed in less than 30 s 
(results not shown). We suspected that KO mice could express other TSPO isoforms [241]. 
We therefore studied binding profiles of [3H]PK11195 in TSPO floxed and KO mitochondria 
(Figure 16). [3H]PK11195 labelled floxed, but not KO liver mitochondria (Figure 16A), and 
Scatchard plots confirmed the existence of high affinity binding sites (Kd = 1.2 nM) only in 
TSPO floxed mitochondria (Figure 16B). 
 
 
Figure 16. [3H]PK11195 binding to TSPO floxed and KO mitochondria.  
A, [3H]PK11195 binding to floxed (full squares) and KO (open squares) liver mitochondria was 
assessed as described in Materials and Methods. B, Scatchard plots of experiments described in A. 
Error bars represent the mean ± S.D. of three independent experiments performed in duplicate. 
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3. Conclusions 
The results of the work presented in this Thesis are remarkable in many respects, and open 
a set of new questions both on the nature and function of the PTP and on the physiological 
role(s) of TSPO. 
The first point is the demonstration that a PT can take place in the absence of an intact 
OMM. This finding in turn bears on the nature of the PTP, and on the mechanism(s) through 
which its opening affects mitochondrial pathophysiology. Indeed, we can predict that the 
pore will turn out to be an IMM protein or protein complex, whose opening causes 
membrane depolarization, Ca2+ release, changes of matrix volume, cristae junction 
rearrangement and mobilization of cyt c. Damage/rupture of the OMM leading to release of 
IMS proteins would be a secondary consequence of matrix expansion, and would occur only 
for extreme degrees of swelling. Thus, the PTP does not span the OMM and IMM, a physical 
arrangement that would be expected to release matrix solutes but certainly not cyt c, which 
would be in fact sealed off in the IMS [61]. Swelling must not necessarily take place in all 
mitochondria in the cell, resulting in a graded response. Indeed, affected mitochondria may 
release proapoptotic factors and intact mitochondria provide the ATP required for 
execution of apoptosis, while the involvement of the majority or of all mitochondria may 
switch the process toward necrosis, in keeping with earlier results demonstrating the key 
role of mitochondrial function in dictating the shape of cell death [244]. 
The second issue concerns the regulatory role of the OMM on PTP function, and how is this 
exerted. Our group as well as others have demonstrated that interactions of HK with the 
OMM decrease the probability of PTP opening [135, 136, 245] suggesting that OMM-IMM 
protein-protein interactions influence the propensity of the pore to open. As remarkably, 
our results demonstrate that the OMM can also sensitize the PTP to opening, since 
mitoplasts are protected from the pore-inducing effects of photosensitization by TSPO-
binding porphyrins seen in intact mitochondria [238, 246]. In spite of our own predictions, 
the sensitizing effect cannot be due to the TSPO because it is observed in TSPO-null 
mitochondria which demonstrably lack high affinity binding sites for [3H]PK11195. These 
results are very puzzling, and indicate that the inducing effects of FGIN1-27, PK11195, Ro5-
4864, and PP IX on the PTP must be mediated by a different target. Data from the Glick 
laboratory show that many ligands of TSPO (such as the benzodiazepine Bz-423 and 
PK11195 analogs) bind to and inhibit the mitochondrial FOF1 ATP synthase [247, 248]. 
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While the affinity displayed toward TSPO is in the nanomolar range, i.e. about 4 orders of 
magnitude lower than that required to sensitize the PTP, the concentrations required for the 
inhibitory effect on the ATP synthase match those on the PTP [238, 246]. Consistent with 
these findings, our laboratory has strong data supporting the idea that the PTP forms from 
dimers of the mitochondrial ATP synthase (Giorgio et al., submitted). While these results 
would explain the effects of ‘TSPO ligands’ on the PTP, what protein(s) mediate pore 
activation through the protoporphyrin-dependent photodynamic effect remains an open 
question. 
The third issue concerns the lack of phenotypic effects of TSPO ablation. It must be stressed 
that gene inactivation was specific for the liver, i.e. an organ that is actively involved in 
steroid catabolism rather than production. Given the fact that TSPO is important in 
steroidogenesis but also in heme biosynthesis [249], we were surprised that no phenotypic 
alteration was detectable at the macroscopic, functional or ultrastructural level. It may well 
be that subtle differences exist that escaped our attention, or that other proteins may play a 
compensatory role. These issues, as well as the production of adrenal cortex TSPO-null mice, 
can now be addressed starting from our floxed strains. 
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PhotooxidationWe have studied the mitochondrial permeability transition pore (PTP) under oxidizing conditions with
mitochondria-bound hematoporphyrin, which generates reactive oxygen species (mainly singlet oxygen,
1O2) upon UV/visible light-irradiation and promotes the photooxidative modification of vicinal targets. We
have characterized the PTP-modulating properties of two major critical sites endowed with different degrees
of photosensitivity: (i) the most photovulnerable site comprises critical histidines, whose photomodification
by vicinal hematoporphyrin causes a drop in reactivity of matrix-exposed (internal), PTP-regulating cysteines
thus stabilizing the pore in a closed conformation; (ii) the most photoresistant site coincides with the
binding domains of (external) cysteines sensitive to membrane-impermeant reagents, which are easily
unmasked when oxidation of internal cysteines is prevented. Photooxidation of external cysteines promoted
by vicinal hematoporphyrin reactivates the PTP after the block caused by histidine photodegradation. Thus,
hematoporphyrin-mediated photooxidative stress can either inhibit or activate the mitochondrial
permeability transition depending on the site of hematoporphyrin localization and on the nature of the
substrate; and selective photomodification of different hematoporphyrin-containing pore domains can be
achieved by fine regulation of the sensitizer/light doses. These findings shed new light on PTP modulation by
oxidative stress.© 2009 Elsevier B.V. All rights reserved.1. IntroductionThe mitochondrial permeability transition (PT) features an abrupt
increase of mitochondrial inner membrane permeability to solutes
with molecular masses up to about 1500 Da. If long-lasting, this event
is followed bymembrane depolarization, matrix swelling, depletion of; CsA, cyclosporin A; Cyp-D,
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ll rights reserved.matrix pyridine nucleotides (PN), outer membrane rupture and
release of intermembrane proteins, including cytochrome c, thus
leading to cell death [1,2]. The PT is due to the opening of a protein
channel, the CsA-sensitive permeability transition pore (PTP), whose
structure has yet to be identified. The most studied candidates have
been the adenine nucleotide translocator (ANT), the voltage-depen-
dent anion channel (VDAC), and cyclophilin D (CyP-D) [1–4].
However, recent studies on the response of mouse mitochondria
devoid of CyP-D [5–7], of ANT1 and ANT2 [8], and of the three VDAC
isoforms [9] have shown that a functional PTP can still be formed in
the absence of each of these proteins (see ref. [10] for a review). In
spite of these uncertainties on the molecular nature of the PTP, its role
as a mechanism for the execution of cell death is no longer questioned
(reviewed in refs. [4] and [11]).
The PT can be favoured by a variety of structurally unrelated
compounds and conditions. In spite of the inducer heterogeneity, a
large body of data indicates that the PT is a regulated process, and
that inducers converge on one or more discrete regulatory step(s)
[12]. A key feature of the system is the regulation by both ΔpH and
ΔΨm components of the mitochondrial protonmotive force. Critical
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membrane make the pore responsive to pH (matrix acidification
favoring pore closure through His protonation) [13]. A voltage sensor
which is influenced by various effectors is proposed to make the pore
opening sensitive toΔΨm (depolarization favoring pore opening) [14].
Amajor role in tuning the voltage sensor of the PTP is played by the
oxidation-reduction state of vicinal thiols in cysteinyl (Cys) residues.
Disulfide formation (as well as dithiol cross-linking) at a critical site
(dubbed the “S-site”) located in the matrix is associated with a higher
probability of PTactivation through a shift of the threshold potential at
which pore opening occurs [15,16]. In addition, a class of pore-
regulating thiols, which are sensitive to membrane-impermeant
reagents (external thiols) has been also described. External thiols
could be either located on the outer surface of the inner membrane, or
on intermembrane/outermembrane regulatory protein(s), possibly at
contact sites [17].
In 1997, Salet et al. [18] used a novel methodological approach to
explore the regulatory properties of PTP-critical sites. Their method
took advantage of the ability of porphyrins to bind to mitochondria
and produce reactive oxygen species [ROS, mainly singlet oxygen
(1O2)] upon irradiation with UV/visible light [19]. The 1O2 transient
photogenerated in situ can easily oxidize electron-rich protein targets,
including Cys and His, provided that the substrate and the sensitizer
are situated in close proximity [20,21]. Using the porphyrin photo-
sensitizing properties, Salet et al. [18] demonstrated that hematopor-
phyrin (HP) localizes to strategic matrix sites containing PTP-
regulating His. In the first example of PTP desensitization by ROS,
His degradation by 1O2 generated by vicinal photoactivated HP
maintained the pore in a closed conformation, in sharp contrast
with what is generally observed with oxidizing agents (see also refs.
[22,23]).
Herein we find that pore inhibition following His photodegrada-
tion can be ascribed to a drop of reactivity of the internal PTP-
activating thiols (the “S” site), which are no longer reactivewith cross-
linkers and oxidants.We have exploited this inactivation of the “S” site
to study the contribution to PTP regulation of an additional class of
sulfhydryls, which can also trigger the PT after oxidation or reaction
with cross-linkers. Based on the PT-desensitizing effect of membrane-
impermeant, thiol-protective reagents and on the PT-activating effect
of copper-o-phenanthroline, we conclude that this group of thiols is
located on the external side of the inner membrane.
2. Materials and methods
2.1. Reagents
Hematoporphyrin IX (HP) was obtained from Frontier Scientific
(Logan, UT, USA). Stock solutions were prepared in dimethylsulfoxide
(DMSO). Trimethylammonium monobromobimane (MBM+) was a
product of Calbiochem, UK. Copper-o-phenanthroline [Cu(OP)2] was
prepared just before use by mixing CuSO4 with o-phenanthroline in a
molar ratio of 1:2 in bidistilled water. All chemicals were of the
highest purity commercially available.
2.2. Preparation of mitochondria
Liver mitochondria from Wistar rats were prepared by standard
differential centrifugation. The final pellet was suspended in 0.25 M
sucrose to give a protein concentration of 80–100mg/ml, as measured
by the biuret method. The functionality of mitochondria was
established by measuring the respiratory control ratio (RCR) between
the rate of oxygen consumption in state 3 (in the presence of 0.3 mM
ADP) and in state 4 (in the absence of ADP) in a thermostatted
(T=25 °C), water-jacketed vessel, using a Clark electrode connected
to a recorder. The incubation buffer contained 100 mM sucrose,
50 mM KCl, 10 mM Tris–Mops, 10 mM KH2P04, 2 mM MgCl2, 1 mMEDTA, 2 μM rotenone, pH 7.4. Succinate (5 mM) was used as the
energizing substrate. Onlymitochondrial suspensionswith a RCR≥3.0
were used.
2.3. Mitochondrial permeability transition
Mitochondrial PT was induced at 25 °C in a medium containing
200 mM sucrose, 10 mM Tris–Mops, 5 mM succinate, 1 mM Pi, 10 μM
EGTA–Tris, 0.5 μg/ml oligomycin, 2 μM rotenone, pH 7.4 (standard
medium) [14]. Ca2+, phenylarsine oxide (PhAsO) and copper-o-
phenanthroline [Cu(OP)2] were used as PT inducers.
PT-induced osmotic swelling of mitochondrial suspensions was
followed as the decrease in 90° light scattering at 540 nm, measured
with a Perkin-Elmer LS 50 spectrophotofluorimeter [22].
The calcium retention capacity (CRC), i.e., the amount of Ca2+
accumulated and retained by mitochondria before the occurrence of
the PT [24], was measured with a Ca2+-selective electrode (Elektrode
ISE Calcium, Crison Instruments, Barcelona, Spain).
2.4. Photosensitization of HP-labelled mitochondria
Mitochondria (0.5 mg/ml) were incubated for 1–2 min in the dark
with the desired concentration of HP and then irradiated at 365 nm in
a thermostated glass reaction vessel with a Philips HPW 125-W lamp
(Philips, Eindhoven, The Netherlands). The fluence rate at the level of
the preparations (40 W/m2) was measured with a calibrated
quantum-photo-radiometer (Delta OHM HD 9021). All irradiations
were performed at 25 °C under magnetic stirring. Proper controls
were carried out indicating that neither incubation with the
photosensitizer in the dark nor illumination under identical experi-
mental conditions but in the absence of porphyrin produced any
appreciable changes in the parameters under study.
2.5. Transmission electron microscopy (TEM) of mitochondria
Mitochondria in the various experimental conditions were fixed
for 30 min at 4 °C using glutaraldehyde at a final concentration of 1.5%
(V/V) in 0.1 M cacodilate buffer (pH 7.2), then post-fixed with 1%
OsO4. Thin sections (60–80 nm) were stained with uranyl acetate in
alcohol (50%) and lead citrate. Observations were made by using a FEI
Tecnai F12 transmission electron microscope.
3. Results and discussion
3.1. Inhibition of the mitochondrial PT by HP-mediated photooxidative
stress. Degradation of PTP-regulating His
We studied the effects of photoactivated HP on mitochondrial
Ca2+ uptake and membrane permeabilization to sucrose. Mitochon-
dria labelled with 3 μM HP were incubated for 2 min at 25 °C and
the PT was triggered by Ca2+ after irradiation for increasing times at
a fluence rate of 40 W/m2. Non-irradiated mitochondria did not
retain a 80 μM Ca2+ pulse, and a fast process of Ca2+ release readily
followed the initial phase of Ca2+ uptake (Fig. 1A, trace a). This fast
process of Ca2+ release was due to the opening of the PTP since it
was accompanied by swelling (Fig. 1B, trace a), and the Ca2+
threshold was more than doubled in the presence of 1 μM CsA (not
shown). After 20 s of irradiation (total light dose=0.08 J/cm2)
mitochondria readily accumulated the initial 80 μM Ca2+ pulse,
whereas Ca2+ efflux was triggered by a further 60 μM Ca2+ load
(Fig. 1A, trace b) and the rate of membrane permeabilization was
significantly decreased (Fig. 1B, trace b). After irradiation for 45 s
(total light dose=0.18 J/cm2), the ability of mitochondria to take up
and retain Ca2+ was further improved (Fig. 1A, trace c), and the
inner mitochondrial membrane became impermeable to sucrose
(Fig. 1B, trace c).
Fig. 1. Progressive mitochondrial PT inhibition at increasing irradiation times in HP-loaded mitochondria, as followed by the changes in PT-induced Ca2+ release (A) and matrix
swelling (B). Mitochondria (0.5 mg/ml) labelled with HP (3 μM) (m+HP) were incubated for 2 min at 25 °C in the standard medium. Irradiation (hν) was performed for the
indicated periods of time at a fluence rate of 40 W/m2. Where indicated (trace d) mitochondria were supplemented with DEPC (200 μM). Panel A: Ca2+ pulses were added to the
mitochondrial suspensions as indicated by arrows. Extramitochondrial Ca2+ was monitored by a Ca2+-selective electrode. Panel B: the PT was triggered by 80 μM Ca2+. Matrix
swelling was followed as the decrease of 90° light scattering at 540 nm.
Fig. 2. Activation of the PT by PhAsO in HP-loaded, irradiated mitochondria. Trace a: the
PT was induced by 80 μM Ca2+ in HP (3 μM)-labelled, non-irradiated mitochondria.
Trace b: the Ca2+-induced PT was inhibited by irradiation at 40 W/m2 for 45 s (total
light dose=0.18 J/cm2). Trace c: opening of the PTP was triggered in irradiated
mitochondria by addition of 10 μM PhAsO. Trace d; 1 μM CsA was present in the
incubation medium under the various experimental conditions. The PT trend was
followed by the changes in 90° light scattering intensity at 540 nm, due to the changes
of mitochondrial volume.
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irradiation in the presence of HP was previously attributed to
photodegradation of matrix-exposed, PTP-regulating His residues
[18,22,23]. Involvement of His as the photosensitive substrate is
demonstrated by the antagonizing effects of pretreatment of mito-
chondria with diethyl pyrocarbonate (DEPC), which prevented the
effects of photoirradiation (Fig. 1A and B, traces d). DEPC reacts with
His, thereby hindering the addition of 1O2 to the C2–C3 bond of the
imidazole ring and its irreversible degradation [23].
3.2. Functional state of PTP-regulating thiols after His photodegradation.
Unmasking external thiols
Under conditions leading to PT inhibition HP-mediated photo-
damage was selective to His, and PTP opening could still be triggered
through other critical sites of the pore. As an example, the
experiments reported in Fig. 2 show that non-irradiated mitochondria
were permeabilized to sucrose by 80 μM Ca2+ (trace a), whereas
irradiated mitochondria maintained their permeability barrier when
challenged with an identical Ca2+ load (trace b), yet underwent
permeabilization and swelling upon addition of the dithiol cross-
Fig. 3. Induction of the PT by PhAsO in HP-loaded, non-irradiated (A) and irradiated (B) mitochondria. Mitochondria (0.5 mg/ml) labelled with 3 μMHP, either in the dark (panel A)
or irradiated for 45 s at 40 W/m2 (total light dose=0.18 J/cm2) (panel B), were supplemented with a small Ca2+ pulse (5 μM), which was unable to induce PTP opening per se
(panels A and B, traces a), followed by addition of PhAsO at concentration: 5 μM (panels A and B, traces b), 20 μM (panel B, trace c) or 40 μM (panel B, trace d). The PT was followed by
the changes in 90° light scattering intensity at 540 nm.
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CsA (trace d). These findings indicate that the pore remained
competent for opening through critical thiols, which must have
maintained the reduced state during the His photooxidation process
(see also ref. [18]). Since photodamage is strictly localized to
substrates that are in close proximity to the sensitizer, it follows
that the PhAsO-reactive thiols and HP were beyond the critical
distance (less than 0.02 μm, according to Moan and Berg, [20])
required for an efficient oxidative photoprocess (otherwise cysteine
should be oxidized to cystine by 1O2).
The –SH groups insensitive to the photoprocess could belong to the
matrix-facing, critical cysteines (“S” site), as suggested by their
availability to cross-linking reactions by the membrane-permeant
PhAsO. Alternatively, His photodegradation could modify the pore-
regulatory activity of the “S” site and lead to unmasking an additional
class of thiols. The following set of experiments was aimed at
discriminating between these two possibilities.
HP-labelled mitochondria, either non-irradiated (Fig. 3A) or
exposed to a light dose of 0.18 J/cm2 (40 W/m2 for 45 s) (Fig. 3B),
were supplemented with a small Ca2+ pulse (5 μM) unable to induce
PTP opening per se (Fig. 3A, B, traces a), followed by PhAsO. In non-
irradiated mitochondria, 5 μM PhAsO was sufficient to trigger the PT
(Fig. 3A, trace b), a concentration that was instead ineffective in
irradiated mitochondria (Fig. 3B, trace b). Remarkably, much higher
PhAsO concentrations were necessary to induce swelling in irradiated
mitochondria (Fig. 3B, traces c, d). Similar results were obtained withFig. 4. Induction of the PT by PhAsO in HP-loaded, non-irradiated (A) and irradiated (B) mi
labelled mitochondria (0.5mg/ml), either non-irradiated (panel A) or irradiated for 45 s at 40
then 10 μMCa2+ (a concentration not sufficient to induce PTP opening per se) was added (pa
(10–200 μM in panel A and 10 μM in panel B, traces c) were also added. The PT was followthe membrane-permeant thiol oxidant diamide (DIA) (data not
shown). These results suggest that the accessibility of PhAsO-reactive
thiols was altered during irradiation, probably as a consequence of a
conformational change brought about by His photooxidation [18,23].
To identify the class of thiols involved in the photoirradiation-
dependent events we performed a set of experiments using DTT and
MBM+ as –SH protective agents. Monobromobimane (MBM) and the
cationic derivative MBM+ were introduced by Costantini et al. [25] as
PTP-thiol reagents which neither inhibit the phosphate carrier, nor
interfere with Ca2+ transport, energy coupling or ATP production and
transport.
The process of PT activation by PhAsO (Fig. 4A, B, traces a) was
prevented by treatment with 200 μM DTT in both non-irradiated (Fig.
4A, trace b) and irradiated (Fig. 4B, trace b) mitochondria. MBM+ (up
to 200 μM) was ineffective at blocking the DTT-sensitive site in non-
irradiated mitochondria (Fig. 4A, trace c). Since this cationic species is
impermeant to (or slowly permeating) cell membranes [26] we
conclude that PhAsO interacted with internal thiols that could not be
protected by MBM+. In striking contrast, 10 μM MBM+ significantly
delayed opening of the pore in irradiated mitochondria (Fig. 4B, trace
c). Protection of the PhAsO-reactive thiols byMBM+ strongly suggests
that in irradiated mitochondria PhAsO triggered the PT mainly via an
external site. In keeping with this interpretation, addition of up to
0.5 mMMBM+ to mitochondria did not cause any perturbation of the
membrane potential as measured through the fluorescence changes of
Pyronin G [22,23] (results not shown), in contrast to what observedtochondria in the absence and in the presence of thiol-protective reagents. HP (3 μM)-
W/m2 (total light dose=0.18 J/cm2) (panel B), were supplementedwith 10 μMPhAsO,
nels A and B, traces a). Where indicated, 200 μMDTT (panels A and B, traces b) orMBM+
ed by the changes in 90° light scattering intensity at 540 nm.
Fig. 5. Induction of the PT by Cu(OP)2 in HP-loaded, non-irradiated (A) and irradiated (B) mitochondria in the absence and in the presence of the thiol-protective reagent, MBM+. HP
(3 μM)-labelledmitochondria (0.5mg/ml), either non-irradiated (panel A) or irradiated for 45 s at 40W/m2 (total light dose=0.18 J/cm2) (panel B), were supplementedwith 10 μM
Ca2+ (a concentration not sufficient to induce PTP opening per se), then Cu(OP)2 (3 μM)was added (panels A and B, traces a). Where indicated, 10 μMMBM+ (panels A and B, traces
b) were also added. In traces c, the various experiments were carried out in the presence of 1 μM CsA. The PT was followed by the changes in 90° light scattering intensity at 540 nm.
Fig. 6. Effects of irradiation on the PT in HP-loaded mitochondria at different HP
concentrations and light doses. Mitochondria (0.5 mg/ml) were incubated for 2 min at
25 °C in the standard medium after labelling with: 1 μM (a), 3 μM (b), 4 μM (c), or 5 μM
(d) HP. After irradiation for the indicated periods of time at a fluence rate of 40 W/m2,
mitochondria were loaded with a series of 10 μM Ca2+ pulses at 1 min intervals. PTP
opening was determined as the CRC measured with a Ca2+-selective electrode.
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Thus, it appears that MBM+ is not transported across the inner
membrane; and that the MBM+-inhibitable sites unmasked by
irradiation are not located in the matrix, also based on the effects of
membrane-impermeant Cu(OP)2 (see below).
To further probe the involvement of external thiols in mitochon-
drial PT activation after His photooxidation, we used a PTP-triggering,
membrane-impermeant reagent. In the next set of experiments HP-
loaded mitochondria were assayed using the thiol oxidant Cu(OP)2 as
the PT inducer. It was previously shown that Cu(OP)2 stimulates the
PT by catalyzing the dithiol-disulfide interconversion of a class of
external thiols [17]. Both non-irradiated (Fig. 5A) and irradiated (Fig.
5B) mitochondria underwent matrix swelling after exposure to 3 μM
Cu(OP)2 (Fig. 5A, B, traces a), in a process sensitive to CsA (Fig. 5A, B,
traces c). In both cases, the effects of Cu(OP)2 could be prevented by
thiol reaction with MBM+ (Fig. 5A, B, traces b). These results clearly
indicate that PT induction and PT inhibition by MBM+ in irradiated
mitochondria was indeed due to the activation and protection of
external thiols, respectively. These groups were not affected by any
structural rearrangement after His photodegradation, because the
concentration of Cu(OP)2 required to induce the PT was identical in
irradiated and non-irradiated mitochondria.
Taken together, these findings suggest that: (i) in non-irradiated
mitochondria, pore opening via cross-linking of –SH groups by low
PhAsO concentrations is mainly regulated by the internal, matrix-
facing sites; (ii) His photodegradation causes a drop in reactivity of
internal but not of external thiols, thus allowing to study the specific
contribution of the latter to PT regulation. This class of thiols readily
reacts with membrane-impermeants reagents, such as Cu(OP)2,
whereas more drastic conditions are necessary for the interaction
withmembrane-permeant compounds, such as PhAsO and DIA, which
partition in both surface and internal mitochondrial membrane
domains.
3.3. HP-mediated photooxidation of external thiols
The next set of experiments was aimed at determining whether
HP-binding sites were also present near the external thiol domains,
and could modify their reactivity upon irradiation. Since under the
experimental conditions used thus far (3 μM HP, 45 s irradiation at
40W/m2) only HP-binding sites interfering with the critical His could
be detected, we explored the effects of different times of irradiation
and HP concentrations on the PT, as measured with the sensitive CRC
assay (Fig. 6). These experiments revealed that the effect of irradiation
was biphasic in all the experimental conditions used. Inhibition of the
PT increasedwith the irradiation time up to amaximum, followed by adecreased inhibition at longer irradiation times. In all cases, HP-
mediated photodamage causing PT inhibition could be ascribed to His
photodegradation, as indicated by the counteracting effect of DEPC
(results not shown). These findings suggest that the HP-binding sites
adjacent to the critical His are highly selective for the porphyrin, being
the most photovulnerable in the whole range of effective HP
concentrations.
The CRC values rapidly decreased upon increase of the light dose.
We found that the CRC decrease below control values could still be
largely counteracted by CsA. As an example, Fig. 7 shows that 0.5 mg/
ml of mitochondria incubated with 3 μM HP and supplemented with
40 μM Ca2+ (which does not affect the membrane permeability per
se), then irradiated for 100 s at 40W/m2 (total light dose=0.4 J/cm2)
underwent a large amplitude swelling (trace a) that was prevented by
CsA (trace b). Similarly to most PTP inducers, HP+light needed Ca2+
as a permissive factor for PTP opening (see in trace c the lack of effect
obtained in the absence of Ca2+). Thus, in these protocols, PTP
opening was due to a HP-dependent photooxidation process of a PTP-
regulating site that is less photosensitive than His. This site coincides
with the external critical thiols, as shown by the antagonizing effect of
the membrane-impermeant thiol reagent MBM+ (trace d). This result
Fig. 7. Induction of mitochondrial PT after 100 s irradiation of HP-loaded
mitochondria. HP (3 μM)-labelled mitochondria (0.5 mg/ml) after addition of 40 μM
Ca2+ (a concentration not sufficient to induce PTP opening per se), were irradiated for
100 s at 40W/m2 (total light dose=0.4 J/cm2) (trace a). In trace b,1 μMCsAwas present
in the incubation medium; in trace c, irradiationwas performed in the absence of added
Ca2+; in trace d, 10 μMMBM+was added before irradiation. The PT was followed by the
changes in 90° light scattering intensity at 540 nm.
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mediated by the same sensitizer (HP) can either inhibit (through His
degradation) or activate (through external thiol oxidation) the PT,
depending on the interplay between light and sensitizer dose.
3.4. Effects of HP and irradiation on mitochondrial ultrastructure
We studied the effects of photooxidative eventsmediated by HP on
mitochondrial ultrastructure, as analysed by TEM. Mitochondria
maintained their integrity after loading with HP in the dark, as
demonstrated by their regular shape with a well defined outer
membrane and rich inner membrane infolding to define the cristae
(Fig. 8A and B). Following PTP opening by 80 μM Ca2+, mitochondriaFig. 8. Effects of HP loading and different light doses on mitochondrial ultrastructure. Mitoch
(panel A) or with 3 μMHP (panels B–H). HP-loaded mitochondria were treated as follows: k
C); exposed to 0.18 J/cm2 light dose (40W/m2 for 45 s) before addition of 80 μMCa2+ (panel
cm2 light dose (40 W/m2 for 100 s) in the absence of added Ca2+ (panel F); supplemented w
40 μM Ca2+ plus 10 μM MBM+ before exposure to 0.4 J/cm2 light dose (panel H). Bars corrappeared swollen with decreased matrix electron density and
increased volume (Fig. 8C). The mitochondrial membranes were
well preserved when Ca2+ was added after exposure to 0.18 J/cm2
light dose (40 W/m2 for 45 s) (Fig. 8D), mitochondrial morphology
being closely comparable to that obtained by pretreatment with 1 μM
CsA (Fig. 8E).
HP-loaded mitochondria had normal morphology and folding of
the inner membrane after exposure to 0.4 J/cm2 light dose (40 W/m2
for 100 s) in the absence of added Ca2+ (Fig. 8F) (i.e. a condition
under which the PTP was in the closed state, Fig. 7). Addition of
40 μM Ca2+, which induced PTP opening (Fig. 7), caused matrix
swelling and expansion of the mitochondrial volume (Fig. 8G). These
effects were prevented by pretreatment with 10 μMMBM+ (Fig. 8H).
It should be noted that the outer membrane could not be clearly
detected after HP+light treatment when the PTP did not open (Fig.
8F and H); yet, the activity of monoaminooxidase was fully retained,
indicating that impermeability barrier to proteins was fully main-
tained (data not shown). It appears likely that the observed structural
reorganization is concomitant with the marked decrease of oxidative
phosphorylation efficiency after prolonged irradiation times [18]. This
would be consistent with the observations of Hackenbrock [28,29],
which indicate that the internal mitochondrial structure is rather
flexible, and linked to the metabolic state of the organelle.
4. Summary and conclusions
In photosensitization of biological materials by reactive oxygen
species (including 1O2) the photodamage is strictly limited to the
immediate surroundings of the sensitizer because of the short
diffusion distance and high reactivity of the photogenerated species.
On this basis, selective targeting of photosensitive substrates located
at or near the sensitizer binding sites is thus possible. This peculiar
oxidation mechanism has provided more detailed information on
residues regulating the PT than is possible to achieve with otherondria (0.5 mg/ml) were incubated for 2 min at 25 °C in the standard mediumwithout
ept in the dark (panel B); supplemented with 80 μM Ca2+ to induce PTP opening (panel
D); pretreated with 1 μMCsA before addition of 80 μMCa2+ (panel E); exposed to 0.4 J/
ith 40 μM Ca2+ before exposure to 0.4 J/cm2 light dose (panel G); supplemented with
espond to 1 μm (main figure) or 0.2 μm (insets).
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rized in Fig. 9, we were able to characterize the PTP-modulating
properties of two sites which exhibited different sensitivity towards
oxidation by vicinal, photoactivated HP.
Under basal conditions (step 1) the PTP favors the closed con-
formation, and the presence of HP does not affect the reactivity and
pore-modulating properties of internal (matrix-exposed) and exter-
nal cysteines (for clarity, the latter are represented as located on the
outer surface of the IMM); indeed, an increased probability of PTP
opening can be easily elicited by complex formation with PhAsO
(which reacts with both sites) or Cu(OP)2, a membrane-impermeant
reagent that only oxidizes the external site (step 2). Photoirradiation
for short periods of time hits the most photovulnerable site, which
comprises matrix-exposed His (see also ref. [18]), and causes a
secondary drop of reactivity of internal, pore-activating Cys, thus
stabilizing the PTP in the closed conformation (step 3); indeed, matrix
Cys can no longer react with PhAsO, probably because of a
conformational rearrangement of the “S” site which makes these
residues distant or poorly accessible to reagents. On this basis, the key
His residues appear to play a role in PT activation as modulators of the
conformation of internal thiol domains. In agreement, literature data
indicate that protonation of the key His is associated with less
extensive thiol oxidation [30] or cross-linking [23]. Thus, it appears
that any modification of the His site interferes with the activity of the
“S” site, suggesting that they are closely related both structurally and
functionally.
The functional inactivation of internal Cys by His photodegradation
in turn allows to study the role of external regulatory Cys, which can
still undergo oxidation by Cu(OP)2 (or complex formation by PhAsO,
omitted for clarity) and thus increase the probability of PTP opening
(step 4). Finally, photoirradiation for times longer than necessary toFig. 9. Summary of the photodynamic events mediated by HP at PTP-regulating His and Cys re
His residues. Additional HP-binding sites are adjacent to external, critical thiols. For clarity,
facing the intermembrane space (ims). In the dark, HP does not affect the structural properti
activation of internal or external Cyswhen lowconcentrations of PhAsO or Cu(OP)2 are used (
irradiation with moderate light doses, m-located photoactivated HP generates 1O2. The phot
thiol binding sites, which hinders the cross-linking reactionwith PhAsO leading to PT inhibiti
(step 4) or by cross-linking with PhAsO (not shown). Irradiation with high light doses ca
photogenerated in situ (step 5). For further explanation see text.oxidize His causes direct oxidation of the external Cys, which is
followed by PTP opening (step 5).
In conclusion, oxidative stress mediated by 1O2 photogenerated in
the presence of HP can either trigger or inhibit the mitochondrial PT
depending on porphyrin localization and nature of the photosubstrate.
The importance of the sensitizer binding site for the effects of 1O2 on the
PT was already demonstrated by comparative studies with two
structurally different photoactivated dyes, HP (PT inhibition) and
4,5′,8-trimethylpsoralen (PT induction) [21]. In addition, the present
data demonstrate that the photoprocess stimulated by the same
sensitizer can switch the mitochondrial PT from inhibition to activation
byafine tuningof light intensity/sensitizer concentration combinations.
The identity of the mitochondrial proteins which bind the two
PTP-regulating, photosensitive substrates remains undefined. Yet,
some indications could arise from previous studies of mitochondrial
function under irradiation. At increasing light doses, oxidative
phosphorylation was the first function to be lost, whereas respiration,
Ca2+ cycling, OMM-, matrix- and intermembrane-enzyme activities
were more resistant in this order. Among the identified 1O2-targets of
the IMM, ANT inactivation was largely responsible for the decline of
oxidative phosphorylation at short irradiation times [18,31]. Thus, it is
tempting to speculate that ANT domains exposed to the matrix side
might contain the highly photosensitive, critical His. Such His location
would also agree with the desensitizing effect caused by His
photodegradation on the oxidation of the vicinal, internal thiol
groups if these are exposed to the matrix side of the ANT as well, as
suggested by some authors [3,32–36]. This interpretation would be in
agreement with a PT-regulatory role of ANT, but of course PTP
photoinactivation may well involve other critical targets of the
phosphorylation cycle, including the Pi carrier, which was recently
postulated to contain PTP-critical thiol groups [37]. Work aimed atsidues. Matrix-facing (m) IMMHP-binding sites are located in close proximity to critical
external thiols are represented as located on the outer surface of the inner membrane
es of His- and Cys-containing domains (step 1) and PTP can be opened through selective
step 2; reaction of external Cyswith PhAsO is not shown for clarity). After mitochondrial
oprocess causes oxidation of the key His and a structural rearrangement of the internal
on (step 3). The PT can be reactivated through external thiols by oxidationwith Cu(OP)2
uses photoactivation of ims-located HP leading to oxidation of ims-facing Cys by 1O2
904 V. Petronilli et al. / Biochimica et Biophysica Acta 1787 (2009) 897–904identifying the relevant protein targets of HP-mediated photooxida-
tion is under way in our laboratories.
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Norbormide (NRB, 5-(α-hydroxy-α-2-pyridylbenzyl)-7-(α-2-
pyridylbenzylidene)-5-norbornene-2,3-dicarboximide) is a synthetic
compound introduced as a specific rat toxicant in 1964 [1]. It is
endowed with unique pharmacodynamic properties inducing
species-selective contraction of rat peripheral blood vessels, likelyby acting on a phospholipase C (PLC)-coupled receptor, which is
abundantly or exclusively expressed in the myocytes of these vessels
[2]. NRB instead elicits a relaxing action in rat aorta and non-vascular
smooth muscles, as well as in blood vessels of species other than the
rat, possibly because of reduced Ca2+ influx through voltage-
dependent L-type Ca2+ channels [1–7]. NRB is a mixture of eight
racemic stereoisomers, which differ in their vasoconstrictor activity
and toxicity [8–10]. Detailed studies of each individual stereoisomer
demonstrate that both drug-induced contractile activity and lethality
in rats are strongly stereospecific, with only the endo configurations
retaining the effects elicited by the mixture [8]. Moreover, investiga-
tions over a series of NRB fragments derived from the “deconstruc-
tion” of the parent molecule suggest that integrity of the molecule
must be retained, in order for NRB-type vasoconstriction to be con-
served [11].
Intriguingly, NRB also causes rat-selective mitochondrial dysfunc-
tion that can be traced to opening of the permeability transition (PT)
pore (PTP) [12,13]. The PTP is a high conductance channel of the inner
mitochondrial membrane (IMM), whose opening leads to an increase
of permeability to ions and solutes with an exclusion size of about
1500 Da. This potentially catastrophic event has long been known,
yet the molecular bases for its occurrence remain unsolved despite
its established importance in several in vivo models of pathology
[14–17]. The key structural feature responsible for PTP activation by
1601A. Zulian et al. / Biochimica et Biophysica Acta 1807 (2011) 1600–1605NRB is its 2-(1-phenylvinyl)pyridine fragment (DR166) [13]. The re-
lationship between lethal vasoconstriction and the PTP-inducing
effect is not obvious, because both lethal (endo-) and non lethal
(exo-) NRB isomers display comparable stimulatory effects on the
PT in isolated mitochondria [13].
In order to better understand the mode of action of NRB, and the
possible correlation between the various rat-selective effects, this
study examines the mechanisms causing species-specificity for PTP
activation. It has already been shown that rat selectivity of NRB toward
the PT is not due to a different PTP structure/target in the various animal
species, but rather involves a transport system allowing selective
penetration of the drug in the IMM/matrix of rat mitochondria
[12,13]. Indeed, the cationic NRB derivative 5-(α-hydroxy-α-2-pyridyl-
benzyl)-7-(N-pivaloyloxymethyl-α-2-pyridylbenzylydene)-5-norbor-
nene-2,3-dicarboximide (OL14), which permeates through the IMM
driven by the inside negative membrane potential, is as effective in
mouse and guinea pig as it is in rat mitochondria [13]. The present
paper reports on whether the putative NRB carrier is located in the
outer mitochondrial membrane (OMM) by comparing the PTP-
regulatory properties of the drug in mitochondria and in digitonin-
treated mitoplasts. Our data demonstrate that an intact OMM is neces-
sary for the PTP-inducing effects of NRB, and strongly suggest that the
drug permeates through domains of the 18 kDa translocator protein
(TSPO, formerly known as peripheral benzodiazepine receptor, [18]),
or of TSPO-associated protein(s), that are unique to the rat.
2. Materials and methods
NRB was purchased from I.N.D.I.A. Industria Chimica, Padova while
its cationic derivative OL14 was synthesized and purified by Drs.
David Rennison and Olivia Laita, Department of Chemistry,
University of Auckland (New Zealand). The structure of these com-
pounds is depicted in Fig. 1. Hematoporhyrin IX, protoporphyrin IX,
deuteroporphyrin IX, and coproporphyrin III were obtained from Fron-
tier Scientific (Logan, UT, U.S.A.) and stock solutions were prepared in
dimethylsulfoxide. N,N-dihexyl-2-(4-fluorophenyl)indole-3-acetamide
(FGIN1-27), (4′-chlorodiazepam;7-chloro-5-(4-chlorophenyl)-1,3-
dihydro-1-methyl-2H-1,4-benzodiazepin-2-one) (Ro5-4864), digito-
nin, phenylarsine oxide (PhAsO) and etioporphyrin I were purchased
from Sigma. Copper-o-phenanthroline (Cu(OP)2) was prepared just be-
fore use by mixing CuSO4 with o-phenanthroline in a molar ratio of 1:2
in bidistilled water. All chemicals were of the highest purity commer-
cially available.
Liver mitochondria from Albino Wistar rats, CD1 mice and Albino
guinea pigs (from Charles River, Italy) were prepared by standard dif-
ferential centrifugation. The final pellet was suspended in 0.25 M
sucrose to give a protein concentration of 80-100 mg/ml, as measured
by the biuret method. The quality of mitochondrial preparations was
established by the value of the respiratory control ratio (RCR), as
described previously [13].
Mitoplasts were prepared by treatment of mitochondria with
0.09 mg of digitonin/mg of mitochondrial protein, and purity of theFig. 1. Chemical structures of NRB and OL14.preparations was checked by enzymatic and electron microscopy as-
says, as described in detail in Ref. [19].
Mitochondrial PT was induced at 25 °C in a standard medium
(250 mM sucrose, 10 mM Tris-Mops pH 7.4, 5 mM succinate-Tris,
1 mM Pi-Tris, 10 μM EGTA-Tris, 1 μM rotenone, 0.5 μg/ml oligomycin).
Ca2+, phenylarsine oxide (PhAsO) and Cu(OP)2 were used as PT in-
ducers. PT-induced osmotic swelling of mitochondrial suspensions
was followed as the decrease in 90° light scattering at 540 nm,
measured with a Perkin-Elmer LS 50 spectrophotofluorimeter [12].
Permeabilization rates were calculated as the rate of change of light
scattering immediately after addition of inducer. The calcium
retention capacity (CRC), i.e., the amount of Ca2+ accumulated and
retained by mitochondria before the occurrence of the PT [20] was
measured with 0.5 μM Calcium Green-5N as an indicator of the Ca2+
concentration in the external medium (excitation at 480 nm and
emission at 530 nm) [13].
3. Results
3.1. Effects of NRB and OL14 on the mitochondrial and mitoplast PT
We compared the effects of NRB and its cationic derivative, OL14,
on mitochondria and mitoplasts prepared by extraction with 0.09 mg
digitonin×mg−1 of protein, i.e. a condition yielding mitoplasts that
maintain a high IMM integrity as assessed by development of a mem-
brane potential, ability to take up Ca2+, and maintenance of a perme-
ability barrier to solutes [19]. We tested the ability of both organelles
to undergo the PT with the sensitive calcium retention capacity (CRC)
test, which measures the threshold Ca2+ load required to open the
pore. Incubation of mitochondria with 40 nmol/mg protein of NRB
for 5 min decreased the Ca2+ load required for PTP opening without
affecting the rate of Ca2+ uptake (Fig. 2A trace b, compare with
trace a), an effect that was also seen with OL14 (Fig. 2A, trace c). In
striking contrast, NRB did not affect the CRC in mitoplasts (Fig. 2A′,
trace b, compare with trace a) while OL14 was as effective as it was
in mitochondria. The concentration-dependence of the effects of
NRB and OL14 in mitochondria and mitoplasts is presented in Fig. 3.
These findings indicate that NRB requires an intact OMM to be effec-
tive; yet its site of action must be at the IMM or matrix, because its
PTP-inducing effects in mitochondria are retained by the permeant
cationic OL14 (see also Refs. [12,13]). The higher doses necessary to
induce PT activation in mitoplasts suggest that access of OL14 to the
mitochondrial matrix is also facilitated by the OMM.
We next tested if the differential effects of NRB on PTP in mito-
chondria and mitoplasts could also be detected by modifying two
classes of IMM (matrix- and surface-exposed) PT-regulating sulfhy-
dryls, which can be discriminated based on their reactivity with the
membrane-permeant dithiol cross-linker phenylarsine oxide
(PhAsO) and the membrane-impermeant thiol oxidant copper-o-
phenanthroline (Cu(OP)2), respectively [21–23]. We first assessed
the response to PhAsO. In these protocols, a permissive Ca2+ load
that does not cause PTP opening per se was allowed to accumulate
first (Fig. 4A, A′, trace a); ruthenium red (RR) was then added to pre-
vent Ca2+ redistribution, and finally PTP opening was triggered by
PhAsO and the process was monitored as the ensuing Ca2+ release
(Fig. 4A, A′, trace b), which was indeed fully inhibited by CsA
(Fig. 4A, A′, trace c). Treatment with NRB caused an earlier onset of
PTP opening in mitochondria (Fig. 4A, trace d) but not in mitoplasts,
where the release rate was indistinguishable from that of PhAsO
alone (Fig. 4A′, trace d). Consistent with what was observed with
Ca2+-dependent PT (Figs. 2, 3), OL14 caused PhAsO to induce imme-
diate triggering of PTP opening in both preparations (Fig. 4A, A′, trace e).
The response to Cu(OP)2 gave results superimposable to those obtained
with PhAsO, as PTP openingwas stimulated byNRB inmitochondria but
not in mitoplasts, while OL14 was equally effective (Fig. 4B, B′, trace
labeling is identical to panels A, A′).
Fig. 2. Effects of NRB and OL14 on the Ca2+ retention capacity of rat liver mitochondria
and mitoplasts. One milligram per milliliter of rat liver mitochondria (A) or mitoplasts
(A′) was suspended in the standard incubation medium in the presence of 0.5 μM Cal-
cium Green-5N, then loaded with a train of 10 (A) or 5 (A′) μM Ca2+ pulses at 1-min
intervals (trace a). In traces b,c the organelles were preincubated for 5 min with
40 nmol/mg of NRB (b) or OL14 (c). Extramitochondrial Ca2+ was monitored as the
fluorescence emission of Calcium Green-5N (λexcitation=480 nm; λemission=530 nm).
Fig. 4. Effects of NRB and OL14 on PT-dependent Ca2+ release in rat liver mitochondria
and mitoplasts. One milligram per milliliter of rat liver mitochondria (A) or mitoplasts
(A′) was incubated in the standard medium containing 0.5 μM Calcium Green-5N and
allowed to accumulate a Ca2+ load (30 and 15 nmol/mg of protein, respectively) that
was not sufficient for spontaneous PTP opening (trace a). PTP opening was then trig-
gered by 5 μM PhAsO (traces b–e). In the experiments of trace c 1 μM CsA was also pre-
sent, and in those of traces d and e the organelles were supplemented with 40 nmol/
mg of NRB and OL14, respectively, and incubated for 5 min prior to the addition of
Ca2+. Where indicated, Ca2+ was added followed by 0.1 μM ruthenium red (RR) and
by PhAsO. B, B′, the experimental conditions were the same as those described in A,
A′, except that 3 μM Cu(OP)2 was used as PT inducer.
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ence of high affinity TSPO-ligands
It has been previously demonstrated that the OMM regulates the
PT and that PTP regulatory sites are contributed by TSPO [19]. To
test whether NRB transport could occur through TSPO we studied
the effects of NRB on the PT induced by PhAsO and Cu(OP)2 in the
presence or absence of hematoporphyrin IX (HP), a dicarboxylic por-
phyrin with high affinity for TSPO that at the concentration used here
(3 μM) does not affect the PTP per se [19,21,24]. Mitochondria were
incubated with NRB for 5 or 2 min depending on whether PhAsO or
Cu(OP)2 was used as PT inducer because at these incubation times
NRB displayed the maximal effect with each thiol reagent (data not
shown). To evaluate the extent of stimulation by NRB, the permeabi-
lization rates of NRB-treated mitochondria were normalized to those
of NRB-untreated mitochondria. In the case of PhAsO HP suppressed
the stimulatory effect of NRB up to 25–30 nmol/mg (Fig. 5A). The
effect was even larger in the case of PTP induction by Cu(OP)2,
where HP caused a marked inhibition of the PT up to 20–30 nmol/mg
NRB (Fig. 5B). Consistent with competition for TSPO binding, NRB
above 20–30 nmol/mg regained its potentiating ability on the PTP.
Similar effects have been observed in the presence of other proto-
porphyrin IX-like dicarboxylic porphyrins, such as deuteroporphyrin
IX and protoporphyrin IX itself, which display even higher affinity
than HP in binding TSPO [24]. However, in this study no effect onFig. 3. CRC of rat liver mitochondria andmitoplasts loaded with NRB and OL14. The CRC
was calculated according to the experimental procedure described in the legend to
Fig. 2 after the addition of NRB (A) or OL14 (B) to rat liver mitochondria (closed sym-
bols) or mitoplasts (open symbols). PTP opening was determined as the Ca2+ retention
capacity (CRC, expressed as the % of the CRC of organelles not treated with NRB or
OL14). Values are mean±S.D. of three experiments.the NRB-stimulated PT was observed with PP-unrelated porphyrins,
such as the tetracarboxylic coproporphyrin III, whose binding to
TSPO is very weak, or etioporphyrin I, which lacks carboxylic groups
(data not shown). These results suggest that, at low NRB concentra-
tions, interference between NRB and TSPO-porphyrin binding sites
causes (i) a drop of reactivity of the external thiols, and (ii) blockade
of drug translocation into internal PTP-regulating sites. Other selec-
tive TSPO-ligands, such as Ro5-4864 and FGIN1-27 [18,25,26], at con-
centrations (≤10 μM) not sufficient to induce the PT per se (data notFig. 5. Effects of NRB and their inhibition by HP, on the PT induced by PhAsO and Cu
(OP)2 in rat liver mitochondria. Mitochondria (0.5 mg/ml) were incubated with the in-
dicated concentrations of NRB for 5 min (panel A) or 2 min (panel B) in standard me-
dium at 25 °C, both in the absence (no HP) or presence (HP) of 3 μM HP; then 10 μM
Ca2+ (a Ca2+ pulse not sufficient to induce the PT per se) was added followed by
5 μM PhAsO (A) or 3 μM Cu(OP)2 (B). Spreading of the PT was followed as the decrease
in light scattering intensity at 540 nm. The data are expressed as the ratio between the
permeabilization rates of NRB-treated (Pr) and -untreated (Pr0) mitochondria. Values
are mean±S.D. of three experiments.
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effects of NRB on the PT induced by both PhAsO and Cu(OP)2
(Fig. 6). In summary, these results suggest that in the presence of spe-
cific TSPO-ligands NRB accumulates in the contact regions between
IMM and OMM, and perturbation of these regions does not allow
NRB to reach its sites of action at the IMM/matrix.
The experiments described above were performed also in mouse
and guinea pig liver mitochondria. Irrespective of whether PhAsO or
Cu(OP)2 was used, or whether TSPO ligands were present, no effect
of NRB was observed, while the PT could be induced by the positively
charged OL14 (results not shown). These data confirm that in animal
species different from the rat the drug-sensitive sites of the mito-
chondrial PTP are not accessible to NRB [12,13].
4. Discussion
In this paper we have demonstrated that rat-selective opening of
the PTP by NRB in liver mitochondria requires an intact OMM, and
obtained compelling evidence that the effect of NRB is specifically
mediated by the OMM protein, TSPO.
The regulatory role of the OMM is demonstrated by the lack of PT-
promoting effect of NRB in mitoplasts, i.e. in the absence of an intact
OMM irrespective of whether PTP opening is induced by Ca2+ plus Pi,
or by reaction with internal (PhAsO-sensitive) or external (Cu(OP)2-
sensitive) sulfhydryls. We deduce that in rat mitochondria NRB is
transferred from the OMM to the IMM through a transport system
that is lost in mitoplasts. OMM TSPO appears to be the key element
mediating mitochondrial internalization of NRB, as suggested by the
findings that, at NRB concentrations up to 30 μM (i) high-affinity li-
gands of TSPO, such as protoporphyrin IX-like dicarboxylic porphy-
rins, Ro5-4864 and FGIN1-27, are able to abolish the effects of NRB
at the internal, PhAsO-reactive sites; and (ii) co-administration of
porphyrins and NRB to mitochondria drastically reduces the reactivi-
ty of the external, Cu(OP)2-sensitive sites, which we know to be in
close contact with the binding site of porphyrins on TSPO [19].
These effects are likely a consequence of competition between NRB
and TSPO-ligands for specific sites on TSPO, which both alters the ex-
ternal, Cu(OP)2-sensitive PTP domains and prevents NRB transfer to
the matrix. These findings suggest that NRB interacts with TSPO
sites adjacent to or overlapping with those of porphyrins, Ro5-4864
and FGIN1-27.
The cationic OL14 is active on both mitochondria and mitoplasts of
all species and is more potent than NRB. These data suggest that both
agents act from the matrix and thus must cross both the OMM and
IMM. Indeed, NRB cationic derivatives transiently depolarize the mi-
tochondrial inner membrane and then activate the PT also in mouseFig. 6. Effects of NRB, and their inhibition by Ro5-4864 and FGIN1-27, on the PT in-
duced by PhAsO and Cu(OP)2 in rat liver mitochondria. Mitochondria (1 mg/ml) sus-
pended in the standard medium at 25 °C were loaded with a small Ca2+ load
(10 μM) that was not sufficient for spontaneous PTP opening (trace a) followed by
5 μM PhAsO (A, traces b–e) or 3 μM Cu(OP)2 (B, traces b–e). In traces c–e, mitochondria
were supplemented with 10 (A) or 30 (B) nmol/mg NRB, and with the TSPO ligand
Ro5-4864 (10 μM, trace d only) or FGIN1-27 (10 μM, trace e only). The PT was followed
as the decrease in light scattering intensity at 540 nm.and guinea pig, consistent with transport to the matrix [13]. It is
also noteworthy that cationic NRB derivatives that do not bear the ac-
tive core still depolarize the inner membrane but are not able to acti-
vate the PT [13]. But why should NRB require TSPO to get to the IMM
and not OL14? We think that the amount of (neutral) NRB taken up
by mitochondria via passive diffusion may not be sufficient to stimu-
late the PT unless the drug first binds the OMM (via TSPO) and then is
transferred to the IMM. It is not inconceivable that the cationic OL14
can instead be attracted by the huge driving force provided by the
IMM proton electrochemical gradient (predicted equilibrium accu-
mulation of 1000 if the membrane potential is −180 mV, negative
inside).
When administered to mitochondria at 30 nmol/mg protein or
more, NRB regains its ability to potentiate the PT irrespective of the
presence of selective TSPO-ligands. TSPO is still required, because
these concentrations of NRB do not affect the PT in mitoplasts. A likely
explanation is that NRB at high concentrations is able to bind to lower
affinity secondary sites on TSPO, overcoming the inhibition produced
by TSPO ligands occupying the primary binding site. The presence of
two populations of (high and low affinity) drug-binding sites is com-
mon to other TSPO-ligands, and this observation has been used to ex-
plain the dose-dependent pro-apoptotic and anti-apoptotic effects,
and modulation of muscle contractility of many TSPO-ligands
[27–31]. Although in our interpretation TSPO allows NRB to be trans-
ported to its internal matrix site(s) of action (see also Ref. [13]), we
cannot exclude that, after interaction with NRB, TSPO per se might
mediate PTP opening.
In conclusion, the present data support previous results demon-
strating a key role of TSPO in PT regulation [19,32]. The absence of de-
monstrable effects of NRB on the PTP of mouse and guinea pig
mitochondria suggests that selectivity may depend on one or more
residues of TSPO that are unique to the rat. Of note, and in spite of
the high degree of TSPO sequence homology, changes in only 3
amino acid residues cause remarkable differences in the binding po-
tency of the archetypal TSPO-ligand Ro5-4864 in different species
[33–36], and mutation of only one critical residue at the interface be-
tween OMM and cytoplasm results in complete loss of ligand binding
activity [37].
Alignment of the rat and mouse primary sequences revealed that
the proteins have a high level of identity, with only 8 amino acid sub-
stitutions (Fig. 7). Since mouse and guinea pig are both resistant to
NRB, amino acids that have changed during evolution between
these species should not be critical. If this hypothesis is correct, the
only relevant difference between the NRB-sensitive rat and NRB-
insensitive mouse and guinea pig would be at position 113, where
in the rat a methionine interrupts a stretch of 3 leucine residues with-
in a highly conserved DLLLVSG motif (Fig. 7A). We analyzed all NRB-
insensitive species [3] and found that, as well as mouse and guinea
pig, the LLL sequence is conserved in ox, cat, chicken, dog, horse,
monkey, rabbit, and sheep. Based on the predicted protein membrane
topology [38] the DLLLVSG motif is located at the interface between
the OMM and the cytosol (Fig. 7B), where it could serve as a selectiv-
ity filter for the transported species. This issue can be addressed by
proper receptor swap and mutagenesis experiments that are under
way in our laboratories.Acknowledgements
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Fig. 7. Comparison of the primary sequence of rat, mouse and guinea pig TSPO and schematic membrane topology of the rat protein. Panel A, alignment of the rat, mouse and guinea
pig TSPO sequences. Panel B, schematic view of rat TSPO [38] where the methionine at position 113 is highlighted. For explanation see text.
1604 A. Zulian et al. / Biochimica et Biophysica Acta 1807 (2011) 1600–1605References
[1] A.P. Roszkowski, G.I. Poos, R.J. Mohrbacher, Selective rat toxicant, Science 144
(1964) 412–413.
[2] S. Bova, L. Trevisi, L. Cima, S. Luciani, V. Golovina, G. Cargnelli, Signaling mecha-
nisms for the selective vasoconstrictor effect of norbormide on the rat small ar-
teries, J. Pharmacol. Exp. Ther. 296 (2001) 458–463.
[3] A.P. Roszkowski, The pharmacological properties of norbormide, a selective rat
toxicant, J. Pharmacol. Exp. Ther. 149 (1965) 288–299.
[4] S. Bova, L. Trevisi, P. Debetto, L. Cima, M. Furnari, S. Luciani, R. Padrini, G. Cargnelli,
Vasorelaxant properties of norbormide, a selective vasoconstrictor agent for the
rat microvasculature, Br. J. Pharmacol. 117 (1996) 1041–1046.
[5] S. Bova, G. Cargnelli, E. D'Amato, S. Forti, Q. Yang, L. Trevisi, P. Debetto, L. Cima, S.
Luciani, R. Padrini, Calcium-antagonist effects of norbormide on isolated perfused
heart and cardiac myocytes of guinea-pig: a comparison with verapamil, Br. J.
Pharmacol. 120 (1997) 19–24.
[6] F. Fusi, S. Saponara, G. Sgaragli, G. Cargnelli, S. Bova, Ca2+ entry blocking and con-
tractility promoting actions of norbormide in single rat caudal artery myocytes,
Br. J. Pharmacol. 137 (2002) 323–328.
[7] S. Bova, M. Cavalli, L. Cima, S. Luciani, S. Saponara, G. Sgaragli, G. Cargnelli, F. Fusi,
Relaxant and Ca2+ channel blocking properties of norbormide on rat non-
vascular smooth muscles, Eur. J. Pharmacol. 470 (2003) 185–191.
[8] G.I. Poos, R.J. Mohrbacher, E.L. Carson, V. Paragamian, B.M. Puma, C.R. Rasmussen,
A.P. Roszkowski, Structure-activity studies with the selective rat toxicant norbor-
mide, J. Med. Chem. 9 (1966) 537–540.
[9] M.A. Brimble, V.J.Muir, B. Hopkins, S. Bova, Synthesis and evaluation of vasoconstric-
tor and vasorelaxant activity of norbormide isomers, ARKIVOC (i) (2004) 1–11.
[10] P.J. Steel, M.A. Brimble, B. Hopkins, D. Rennison, Two stereoisomers of the rat tox-
icant norbormide, Acta Crystallogr. C 60 (2004) o374–o376.
[11] D. Rennison, S. Bova, M. Cavalli, F. Ricchelli, A. Zulian, B. Hopkins, M.A. Brimble,
Synthesis and activity studies of analogues of the rat selective toxicant norbor-
mide, Bioorg. Med. Chem. 15 (2007) 2963–2974.
[12] F. Ricchelli, F. Dabbeni-Sala, V. Petronilli, P. Bernardi, B. Hopkins, S. Bova, Species-
specific modulation of the mitochondrial permeability transition by norbormide,
Biochim. Biophys. Acta 1708 (2005) 178–186.
[13] A. Zulian, V. Petronilli, S. Bova, F. Dabbeni-Sala, G. Cargnelli, M. Cavalli, D. Renni-
son, J. Stäb, O. Laita, D.J. Lee, M.A. Brimble, B. Hopkins, P. Bernardi, F. Ricchelli,Assessing the molecular basis for rat-selective induction of the mitochondrial
permeability transition by norbormide, Biochim. Biophys. Acta 1767 (2007)
980–988.
[14] P. Bernardi, A. Krauskopf, E. Basso, V. Petronilli, E. Blachly-Dyson, F. Di Lisa, M.A.
Forte, The mitochondrial permeability transition from in vitro artifact to disease
target, FEBS J. 273 (2006) 2077–2099.
[15] A. Rasola, P. Bernardi, The mitochondrial permeability transition pore and its in-
volvement in cell death and in disease pathogenesis, Apoptosis 12 (2007)
815–833.
[16] J.J. Lemasters, T. Qian, C.A. Bradham, D.A. Brenner, W.E. Cascio, L.C. Trost, Y. Nishi-
mura, A.L. Nieminen, B. Herman, Mitochondrial dysfunction in the pathogenesis
of necrotic and apoptotic cell death, J. Bioenerg. Biomembr. 31 (1999) 305–319.
[17] M. Crompton, The mitochondrial permeability transition pore and its role in cell
death, Biochem. J. 341 (1999) 233–249.
[18] V. Papadopoulos, M. Baraldi, T.R. Guilarte, T.B. Knudsen, J.J. Lacapere, P. Lindemann,
M.D. Norenberg, D. Nutt, A. Weizman, M.R. Zhang, M. Gavish, Translocator protein
(18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor
based on its structure and molecular function, Trends Pharmacol. Sci. 27 (2006)
402–409.
[19] J. Sileikyte, V. Petronilli, A. Zulian, F. Dabbeni-Sala, G. Tognon, P. Nikolov, P. Bernardi,
F. Ricchelli, Regulation of the inner membrane mitochondrial permeability transi-
tion by the outer membrane translocator protein (peripheral benzodiazepine re-
ceptor), J. Biol. Chem. 286 (2011) 1046–1053.
[20] E. Fontaine, F. Ichas, P. Bernardi, A ubiquinone-binding site regulates the mito-
chondrial permeability transition pore, J. Biol. Chem. 273 (1998) 25734–25740.
[21] V. Petronilli, J. Šileikyte, A. Zulian, F. Dabbeni-Sala, G. Jori, S. Gobbo, G. Tognon, P.
Nikolov, P. Bernardi, F. Ricchelli, Switch from inhibition to activation of the mito-
chondrial permeability transition during hematoporphyrin-mediated photooxi-
dative stress. Unmasking pore-regulating external thiols, Biochim. Biophys. Acta
1787 (2009) 897–904.
[22] V. Petronilli, P. Costantini, L. Scorrano, R. Colonna, S. Passamonti, P. Bernardi, The
voltage sensor of the mitochondrial permeability transition pore is tuned by the
oxidation-reduction state of vicinal thiols. Increase of the gating potential by ox-
idants and its reversal by reducing agents, J. Biol. Chem. 269 (1994)
16638–16642.
[23] P. Costantini, R. Colonna, P. Bernardi, Induction of the mitochondrial permeability
transition pore by N-ethylmaleimide depends on secondary oxidation of critical
thiol groups. Potentiation by copper-ortho-phenanthroline without dimerization
1605A. Zulian et al. / Biochimica et Biophysica Acta 1807 (2011) 1600–1605of the adenine nucleotide translocase, Biochim. Biophys. Acta 1365 (1998)
385–392.
[24] A. Verma, J.S. Nye, S.H. Snyder, Porphyrins are endogenous ligands for the mito-
chondrial (peripheral-type) benzodiazepine receptor, Proc. Natl. Acad. Sci. U. S.
A. 84 (1987) 2256–2260.
[25] G. Le Fur, N. Vaucher, M.L. Perrier, A. Flamier, J. Benavides, C. Renault, M.C.
Dubroeucq, C. Gueremy, A. Uzan, Differentiation between two ligands for periph-
eral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermo-
dynamic studies, Life Sci. 33 (1983) 449–457.
[26] E. Romeo, J. Auta, A.P. Kozikowski, D. Ma, V. Papadopoulos, G. Puia, E. Costa, A.
Guidotti, 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific
ligands for the mitochondrial DBI receptor (MDR), J. Pharmacol. Exp. Ther. 262
(1992) 971–978.
[27] L. Veenman, M. Gavish, The peripheral-type benzodiazepine receptor and the car-
diovascular system. Implications for drug development, Pharmacol. Ther. 110
(2006) 503–524.
[28] J.P. Hullihan, S. Spector, T. Taniguchi, J.K. Wang, The binding of [
3
H]-diazepam to
guinea-pig ileal longitudinal muscle and the in vitro inhibition of contraction by
benzodiazepines, Br. J. Pharmacol. 78 (1983) 321–327.
[29] P. Erne, M. Chiesi, S. Longoni, J. Fulbright, K. Hermsmeyer, Relaxation of rat vascu-
lar muscle by peripheral benzodiazepine modulators, J. Clin. Invest. 84 (1989)
493–498.
[30] D. Raeburn, L.G. Miller, W.R. Summer, Peripheral type benzodiazepine receptor
and airway smooth muscle relaxation, J. Pharmacol. Exp. Ther. 245 (1988)
557–562.[31] M. Holck, W. Osterrieder, The peripheral, high affinity benzodiazepine binding
site is not coupled to the cardiac Ca2+ channel, Eur. J. Pharmacol. 118 (1985)
293–301.
[32] F. Ricchelli, J. Sileikyte, P. Bernardi, Shedding light on the mitochondrial perme-
ability transition, Biochim. Biophys. Acta 1807 (2011) 482–490.
[33] A. Verma, S.H. Snyder, Characterization of porphyrin interactions with peripheral
type benzodiazepine receptors, Mol. Pharmacol. 34 (1988) 800–805.
[34] M. Awad, M. Gavish, Binding of [
3
H]Ro 5–4864 and [
3
H]PK 11195 to cerebral cor-
tex and peripheral tissues of various species: species differences and heterogene-
ity in peripheral benzodiazepine binding sites, J. Neurochem. 49 (1987)
1407–1414.
[35] M. Awad, M. Gavish, Species differences and heterogeneity of solubilized
peripheral-type benzodiazepine binding sites, Biochem. Pharmacol. 38 (1989)
3843–3849.
[36] R. Sprengel, P. Werner, P.H. Seeburg, A.G. Mukhin, M.R. Santi, D.R. Grayson, A.
Guidotti, K.E. Krueger, Molecular cloning and expression of cDNA encoding a
peripheral-type benzodiazepine receptor, J. Biol. Chem. 264 (1989)
20415–20421.
[37] R. Farges, E. Joseph-Liauzun, D. Shire, D. Caput, G. Le Fur, P. Ferrara, Site-directed
mutagenesis of the peripheral benzodiazepine receptor: identification of amino
acids implicated in the binding site of Ro5-4864, Mol. Pharmacol. 46 (1994)
1160–1167.
[38] M.B. Rone, J. Liu, J. Blonder, X. Ye, T.D. Veenstra, J.C. Young, V. Papadopoulos, Tar-
geting and insertion of the cholesterol-binding translocator protein into the outer
mitochondrial membrane, Biochemistry 48 (2009) 6909–6920.
